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Résumé
Les assistances cardio-respiratoires extracorporelles, souvent désignées par l’abréviation
anglophone ECLS (ExtraCorporeal Life Support), sont déjà largement utilisées dans de
nombreux hôpitaux. Ces assistances permettent de subvenir aux besoins vitaux de pa-
tients souffrant de maladies respiratoires et/ou cardio-vasculaires sévères. Cependant,
les cliniciens restent encore confrontés à plusieurs problèmes liés à l’utilisation de ces ap-
pareils médicaux et certaines améliorations des approches thérapeutiques associées seraient
souhaitables.
Dans cette thèse, nous développons des modèles mathématiques simplifiés des systèmes
respiratoire et cardiovasculaire couplés à un modèle d’ECLS. La plupart des paramètres
qui apparaissent dans la description sont déterminés à partir de données cliniques et les
modèles proposés sont donc patient-spécifiques. Ces modèles permettent de tester in
silico diverses options thérapeutiques et devraient donc permettre au clinicien d’optimiser
l’utilisation de l’ECLS.
Dans notre travail, une première validation des modèles mathématiques a été réalisée
à l’aide de données expérimentales obtenues à partir de modèles animals sur le cochon.
Ensuite, une seconde validation a été réalisée en utilisant des données cliniques. Les
résultats obtenus sont très prometteurs et constituent une perspective encourageante dans
le développement d’un outil qui permettra une utilisation des ECLS plus efficace et adaptée
à chaque patient.
Abstract
Extracorporeal life support (ECLS) is already widely used for helping patients suffering
from acute heart and/or lung pathologies. However, clinicians still face several issues with
the use of ECLS and improvements of the associated therapeutic approaches in ICU would
be beneficial.
In this thesis, mathematical models of the respiratory and cardiovascular systems cou-
pled with a model of the ECLS are developed. Most parameters of the description are
determined from clinical data and the models are thus patient-specific. Such models allow
one to test in silico different therapeutic options and should thus help the clinicians to
optimize the use of ECLS.
In our work, a first validation of our mathematical models has been performed using
experimental data obtained on animal models with pigs. Then a second validation was
carried out using clinical data. The obtained results are promising and provide an encour-
aging first step towards the development of a medical tool that will allow a more efficient
and personalized use of ECLS in ICU.
Copyright ©2018 Simon Habran
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Chapter 1
Introduction
1.1 Extracorporeal life support
Extracorporeal life support (ECLS) is used to help patients suffering from acute heart
failure and/or acute lung pathologies. When the heart and/or the lungs of such patients
are not capable of ensuring the vital functions (O2 and CO2 gas exchanges in the blood
and the circulation of blood), ECLS is used to support the main tasks of these organs until
patient recovery. Such devices are now commonly used already been used many times all
around the world since the first ECLS therapy was performed in 1971 [99]. However, even
if new technologies have contributed to several improvements of the different components
of the ECLS (components size reduction, efficacy and hemocompatibility improvements),
the side effects and the complications related to the use of an ECLS remain high [99].
Therefore, a better understanding of ECLS is necessary to develop new therapeutic ap-
proaches, and at the end increase the patient safety.
The ECLS can be set up in different configurations according to the pathology of the
patient. If the patient has a severe heart pathology, or a severe cardiopulmonary pathol-
ogy, the clinicians use the ECLS in the venoarterial configuration whereas if the patient
has a pulmonary disorder without heart failure, such as an acute respiratory distress syn-
drome (ARDS), the ECLS is rather used in the venovenous configuration. These two
main configurations have numerous distinct properties and the therapeutic approaches are
thus different. Therefore, the venoarterial ECLS (va-ECLS) and the venovenous ECLS
(vv-ECLS) are studied separately in this dissertation.
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1.1.1 Venoarterial ECLS (va-ECLS)
The standard configuration of a va-ECLS for an adult is the following: the cannula extract-
ing the venous blood is inserted into the femoral vein and placed just below the junction
of the right atrium and the inferior vena cava, while the cannula reinjecting the extracor-
poreal blood flow is inserted into the femoral artery and placed in the aortic arch. One
of the main issues that clinicians have to deal with is the weaning of va-ECLS. Indeed,
since this configuration takes a fraction of the systemic blood flow in the veins and rejects
it in the arteries, the va-ECLS "hides" the true hemodynamics of the heart by decreasing
the preload and increasing the afterload. Consequently, the medical team has to perform
weaning tests by decreasing the extracorporeal blood flow to approximately 0.5 l/min.
With this small extracorporeal blood flow, the interaction of the va-ECLS with the heart
is much smaller and the real hemodynamics of the heart can be evaluated by measuring
the mean arterial pressure, the ejection fraction in the left ventricle and the velocity time
integral [4]. However, small blood flows in the ECLS increase the risk of coagulation and
the concentration of heparin must be increased during the weaning tests. The drawback
of heparin is the risk of hemorrhages, one of the main complications of ECLS.
1.1.2 Venovenous ECLS (vv-ECLS)
The standard configuration of a vv-ECLS for an adult is the following: the cannula ex-
tracting the venous blood is inserted into the femoral vein and placed just below the
junction of the right atrium and the inferior vena cava, while the cannula reinjecting the
extracorporeal blood flow is inserted into the right internal jugular vein and placed in the
superior vena cava. This configuration does not directly influence the hemodynamics of
the heart since the vv-ECLS extracts and reinjects the blood almost at the same location
of the cardiovascular system. The important features of the vv-ECLS are thus an adequate
O2 supply and an adequate CO2 removal. Nowadays, the ECLS settings to achieve these
goals are empirically chosen by the clinicians after the ECLS is switched on. A different
approach would consist in estimating the optimal settings of the vv-ECLS before inserting
the cannulae, which could be useful to improve the therapeutic strategy. In particular, a
new kind of vv-ECLS has recently been developed: the extracorporeal CO2 removal de-
vice (ECCO2RD). ECCO2RD has already been used for patients suffering from moderate
ARDS (PaO2/FI,O2 > 100 mmHg [31], where PaO2 is the arterial partial pressure in O2 and
FI,O2 is the inspired oxygen fraction) or chronic obstructive pulmonary disease (COPD)
[75, 11, 30, 110, 1, 104]. This device is characterized by a small extracorporeal blood flow
and it could be helpful to estimate the quantity of CO2 removal. With this information,
the medical team could decide if this new technology can be used for a specific patient.
Chapter 1. Introduction 3
1.2 Approach
The study developed in this thesis aims to predict the physiological response of patients
assisted by ECLS. To achieve this goal, this dissertation develops a mathematical model
of the cardiovascular system connected to a va-ECLS and a mathematical model of the
respiratory system connected to a vv-ECLS. Then, the parameters of the mathematical
models are estimated with the measurements available in the intensive care unit (ICU).
This parameter identification thus turns clinical data into patient-specific parameters.
1.2.1 Mathematical models
Mathematical models are used to represent complex systems in order to improve the
knowledge of such systems in different situations. The models also try to predict the
behavior of the system for a specific situation. The cardiovascular and the respiratory
systems are very complex, but the models developed in this study are quite simplified with
the aim to be identifiable with the available measurements in the ICU and to obtain small
computation times. Therefore, lumped models of the cardiovascular system connected
to a va-ECLS and of the respiratory system connected to a vv-ECLS are used in this
study. These models consist in gathering different components of a system together in
several "boxes". The use of such mathematical models to improve health care in the
ICU becomes increasingly demanded and many similar models are currently developed to
provide personalised model-based cares (a review on these questions is proposed in [22]).
Cardiovascular model connected to a va-ECLS Many cardiovascular models have
already been developed in literature [18, 107, 86, 105, 67, 21, 47, 95, 97, 17] but only
a few have studied the interaction between a va-ECLS and the cardiovascular system.
Broomé et al. [17] have built such a mathematical model but their model is very complex
(32 compartments for the cardiovascular system and 1 ECLS compartment) and many
parameters cannot be identified with the data available in the ICU. Their model is thus very
hard to be made patient-specific. On the other hand, a minimal model of the cardiovascular
system was proposed by Pironet et al. [89] and shown identifiable in ICU. The purpose of
our work is to complement this latter model by an additional compartment describing the
va-ECLS [44].
Respiratory model connected to a vv-ECLS Scientists have already developed sev-
eral mathematical models of the respiratory system to describe lung and tissues gas ex-
changes [37, 113, 9] but these models rarely take into account pulmonary gas exchange ab-
normalities like ARDS and COPD. Some authors have proposed to model these pathologies
4 1.3. Goals
by including a perfusion/ventilation mismatch [54] or by decreasing the diffusion across
the alveolar capillary membrane [93]. On top of this, very few authors have developed
models of the respiratory system connected to an ECLS [14, 116, 74, 72]. The models of
Walter et al. [116] and Brendel et al. [14] describe lung, tissues and ECLS gas exchanges
but to account for gas exchange abnormalities in the lung, these authors introduce two
purely empirical parameters. An appropriate description of gas exchange abnormalities is
of paramount importance in this work and parameters with a clear physiological interpre-
tation are introduced to describe these abnormalities. Moreover, the goal of the authors
cited above is different from ours since they use their models in a control algorithm de-
signed to maintain appropriate long-term gas contents of the blood, while our approach
will help clinicians determining the best settings of an ELCS before it is used [42, 43, 45].
1.2.2 Parameter identifications
To obtained a patient-specific model, parameters have be identified from measurements
commonly available in the ICU. The word patient-specific means that the mathematical
models can be adapted to each patient and these models provide different results accord-
ing to the specific clinical conditions of the patient. However, clinical data are extremely
limited and several parameters cannot be identified even if the mathematical models are
simplified. Moreover, the model parameters should be uniquely identified from the mea-
surements to turn clinical data into patient-specific parameters [89]. Consequently, the
parameter identification is a delicate but essential procedure in order to develop person-
alised model-based care.
1.3 Goals
This study has several objectives and 5 mains goals can be enumerated:
1. Developing a simple model of the cardiovascular system connected to a va-ECLS and
a simple model of the respiratory system connected to a vv-ECLS.
2. Estimating the parameters of the models with the aim of being as much patient-
specific as possible.
3. Testing and validating the 2 models with animal experiments. For the cardiovascular
model connected to a va-ECLS, the tests are performed during the weaning tests
from this device. For the respiratory model connected to a vv-ECLS, the tests are
performed during the first hours of an extracorporeal life support therapy (ECLST).
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4. Testing and validating the 2 models with clinical retrospective data. For the cardio-
vascular model connected to a va-ECLS the tests are performed during the weaning
of this device. For the respiratory model connected to a vv-ECLS the tests are
performed during the first hours of an ECLST.
5. Developing medical tools in order to help clinicians to improve their therapeutic
approach. These tools will provide a personalised therapy.
The goals 1, 2, 3, and 4 are respectively developed in Part II, Part III, Part IV and
Part V of this thesis. The last goal is in fact a long-term follow-up of our study and a first
approach is introduced in Chapter 12.
1.4 Thesis organization
This thesis is divided into 5 main parts, each of them briefly introduced below.
Part I describes the cardiovascular and respiratory systems and introduces the use-
fulness and the key features of ECLS. The understanding of this medical background is
useful for the next parts of the thesis. This part is divided into 2 chapters: Chapter 2 and
Chapter 3 for, respectively, the description of the cardiopulmonary system and the ECLS.
Part II describes the modeling of the cardiovascular and respiratory systems and the
ECLS. This part is divided into 2 chapters. Chapter 4 introduces the different compart-
ments of the cardiovascular model connected to a va-ECLS, which are the arteries, the
veins, the heart and the ECLS. Chapter 5 introduces the different compartments of the
respiratory model connected to a vv-ECLS, which are the tissues, the lungs and the ECLS.
Part III presents the parameter identification for both models and is divided into 2
chapters: Chapter 6 for the cardiovascular model and Chapter 7 for the respiratory model.
Part IV describes the use of the models to simulate the cardiovascular system connected
to a va-ECLS and the respiratory system connected to a vv-ECLS. This part compares
the mathematical simulations with data obtained from pig experiments, with the aim to
validate the mathematical model. Chapter 8 describes the validation of the cardiovascular
model during the weaning tests from a va-ECLS while Chapter 9 describes the validation
of the respiratory model during the first hours of an ECLST.
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Part V is similar to Part IV except that the simulations are compared to clinical data
obtained in the ICU. Chapter 10 describes the validation of the cardiovascular model dur-
ing the weaning tests from a va-ECLS in the ICU while Chapter 11 describes the validation
of the respiratory model during the first hours of an ECLST in the ICU. The last chapter
presents conclusions and discusses a future approach to improve the use of ECLS in the
ICU.
Part I
Medical background
7

9The first part of this thesis introduces the elementary concepts in the medical field
which are essential to understand our study. This part is composed of two chapters;
Chapter 2 and Chapter 3. Chapter 2 describes the physiology of the cardiopulmonary
system. The basic functionnings of the heart, the vessels and the lungs are explicated.
Chapter 3 discusses the usefulness of extracorporeal circulations in intensive care unit.
The main components and the different applications of these devices are also described in
this chapter.

Chapter 2
Physiological background
Before modeling complex physiological systems such as the cardiovascular system, a good
understanding of these systems is necessary. Therefore, this chapter gives a brief intro-
duction of the cardiovascular and respiratory physiologies. Since the cardiovascular model
and the respiratory model described in the following chapters are macroscopic models, the
physiological descriptions will be limited to a macroscopic study; a molecular or a cellular
study is not necessary. In addition, a macroscopic description of the blood chemistry is
also provided in this chapter.
2.1 Cardiovascular system
The cardiovascular system is composed of two main systems: the heart and the vascular
system. The heart can be considered as a pump and the vascular system can be considered
as the pipes transporting blood. The description of these two systems is given in this
section.
2.1.1 Physiology of the heart
The heart is a complex pump which draws blood in and rejects it following a cardiac cycle.
The different components and the mechanisms of this pump are described below.
Anatomy
The heart has four cardiac chambers: the left and right ventricles and the left and right
atria (Figure 2.1). All cardiac chambers are subject to contraction and the corresponding
work is delivered by the cardiac muscle also called myocardium. The left and right ventri-
cles are separated by the intraventricular septum. Therefore, the two ventricles actually
work like two independent pumps. The left and right atria are located just before the left
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and right ventricles respectively and, when they contract, they fill the ventricles actively.
The atria thus act like a weak primer pump. These two cardiac chambers are separated
from the ventricles by tricuspid valve and mitral valve for the right side and the left side
of the heart respectively. In addition to these two valves, the heart has a pulmonary valve
at the entrance of the pulmonary artery and an aortic valve at the entrance of the aorta.
These four valves force blood to circulate in one direction. Indeed, when the blood flow
crosses a valve in the right direction (see the arrows in Figure 2.1) this valve is opened,
otherwise, it is closed. Figure 2.1 also illustrates the veins and the arteries which are
directly connected to the heart. While blood enters the right atrium from the inferior and
superior vena cava and goes out from the right ventricle towards the pulmonary artery,
blood enters the left atrium from pulmonary vein and goes out from the left ventricle
towards the aorta.
!
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At each intercalated disc the cell membranes fuse
with one another in such a way that they form perme-
able “communicating” junctions (gap junctions) that
allow almost totally free diffusion of ions. Therefore,
from a functional point of view, ions move with ease
in the intracellular fluid along the longitudinal axes of
the cardiac muscle fibers, so that action potentials
travel easily from one cardiac muscle cell to the next,
past the intercalated discs. Thus, cardiac muscle is a
syncytium of many heart muscle cells in which the
cardiac cells are so interconnected that when one 
of these cells becomes excited, the action potential
spreads to all of them, spreading from cell to cell
throughout the latticework interconnections.
The heart actually is composed of two syncytiums:
the atrial syncytium that constitutes the walls of the
two atria, and the ventricular syncytium that consti-
tutes the walls of the two ventricles.The atria are sepa-
rated from the ventricles by fibrous tissue that
surrounds the atrioventricular (A-V) valvular open-
ings between the atria and ventricles. Normally, poten-
tials are not conducted from the atrial syncytium into
the ventricular syncytium directly through this fibrous
tissue. Instead, they are conducted only by way of a
specialized conductive system called the A-V bundle,
a bundle of conductive fibers several millimeters in
diameter that is discussed in detail in Chapter 10.
This division of the muscle of the heart into two
functional syncytiums allows the atria to contract a
short time ahead of ventricular contraction, which is
important for effectiveness of heart pumping.
Action Potentials in Cardiac Muscle
The action potential recorded in a ventricular muscle
fiber, shown in Figure 9–3, averages about 105 milli-
volts, which means that the intracellular potential rises
from a very negative value, about -85 millivolts,
between beats to a slightly positive value, about +20
millivolts, during each beat. After the initial spike, the
membrane remains depolarized for about 0.2 second,
exhibiting a plateau as shown in the figure, followed at
the end of the plateau by abrupt repolarization. The
presence of this plateau in the action potential causes
ventricular contraction to last as much as 15 times as
long in cardiac muscle as in skeletal muscle.
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Figure 9–1
Structure of the heart, and course of blood flow through the heart
chambers and heart valves.
Figure 9–2
“Syncytial,” interconnecting nature of cardiac muscle fibers.
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Figure 9–3
Rhythmical action potentials (in millivolts) from a Purkinje fiber 
and from a ventricular muscle fiber, recorded by means of 
microelectrodes.
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Figure 2.1 – Anatomy of the heart and the blood circulation through the heart chambers and
the heart valves [46].
Cardiac cycle
For every cardiac beat, the heart follows a cycle which can be divided into 6 main steps
[46] (Figure 2.2):
1. Isovolumic contraction of the ventricles: for this step, all cardiac valves are closed
while the myocardium is contracting. Consequently, the pressure in the ventricular
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the electrocardiogram, and the sixth a phonocardio-
gram, which is a recording of the sounds produced by
the heart—mainly by the heart valves—as it pumps. It
is especially important that the reader study in detail
this figure and understand the causes of all the events
shown.
Relationship of the Electrocardiogram
to the Cardiac Cycle
The electrocardiogram in Figure 9–5 shows the P, Q,
R, S, and T waves, which are discussed in Chapters 11,
12, and 13. They are electrical voltages generated by
the heart and recorded by the electrocardiograph from
the surface of the body.
The P wave is caused by spread of depolarization
through the atria, and this is followed by atrial con-
traction, which causes a slight rise in the atrial pres-
sure curve immediately after the electrocardiographic
P wave.
About 0.16 second after the onset of the P wave, the
QRS waves appear as a result of electrical depolariza-
tion of the ventricles, which initiates contraction of the
ventricles and causes the ventricular pressure to begin
rising, as also shown in the figure. Therefore, the QRS
complex begins slightly before the onset of ventricu-
lar systole.
Finally, one observes the ventricular T wave in the
electrocardiogram. This represents the stage of repo-
larization of the ventricles when the ventricular muscle
fibers begin to relax. Therefore, the T wave occurs
slightly before the end of ventricular contraction.
Function of the Atria as Primer Pumps
Blood normally flows continually from the great veins
into the atria; about 80 per cent of the blood flows
directly through the atria into the ventricles even
before the atria contract. Then, atrial contraction
usually causes an additional 20 per cent filling of the
ventricles. Therefore, the atria simply function as
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Figure 9–5
Events of the cardiac cycle for left ventricular function, showing changes in left atrial pressure, left ventricular pressure, aortic pressure,
ventricular volume, the electrocardiogram, and the phonocardiogram.
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Figure 2.2 – Cardiac cycle for left ventricle. The figure depict changes in left arterial pres-
sure, left ventricular pressure, aortic pressure, ventricular volume, the electrocardiogram and the
phonocardiogram [46].
chambers increases.
2. Ejection of blood from the ventricles: the contraction continues and the pressure in
the ventricl s becom larger than in he aorta f r l ft ventricle and than in the
pulmonary artery for the right ventricle. So, the aortic valve and the pulmonary
valve open and blood goes out of the ventricles. As a result, the volume in the
ventricles decreases during this step.
3. Isovolumic relaxation of the ventricles: all cardiac valves are closed and the my-
ocardium relaxes. Consequently, the pressure in the ve tricular chambers d creases.
4. Rapid inflow in the ventricles: the pressure in the ventricles becomes lower than
in the atria and blood enters the ventricles. Hence, the volume in the ventricles
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increases during this step.
5. Diastasis of the ventricles: the blood flow in the ventricles decreases, the heart is
subject to very small changes during this step.
6. Atrial systole: the atria contract and the ventricles are filled actively. After that, the
isovolumic contraction of the ventricles occurs and the cardiac cycle starts again.
The aortic pressure, the left ventricular pressure and volume for the 6 steps are depicted
in Figure 2.2. These values correspond to an adult in a physiological situation. The two
panels at the bottom of Figure 2.2 describe the electric cardiac activity (electrocardiogram)
and the sounds made by the heart (phonocardiogram). This information will not be
discussed in this work.
2.1.2 Important physiological parameters of the heart
Stroke volume, heart rate and cardiac output
The value of the cardiac output (CO) is of paramount importance and is often estimated
in the ICU. The CO stands for the quantity of blood which is ejected by the heart during
one minute and it is thus equal to [60]:
CO = SV ·HR , (2.1)
where SV is the stroke volume and HR is the heart rate (the number of cardiac cycle
during one minute). The stroke volume stands for the volume ejected from the ventricle
during one single beat. This volume is equal to the difference between the end-diastolic
volume (corresponding to the volume at the end of step 6 in Figure 2.2) and the end-
systolic volume (corresponding to the volume at step 3 in Figure 2.2). For a human of 70
kg at rest, the standard values of the end-diastolic volume, the end-systolic volume and the
heartbeat are equal to 120 ml, 50 ml and 80 beats/min respectively [46]. Therefore, the
standard stroke volume and cardiac output are equal to 70 ml and 5.6 l/min respectively.
Pressure-volume loop
The pressure-volume loop (PV loop) is certainly one of the most important data to char-
acterizing the behavior of the heart. Figure 2.3 represents the different steps of the cardiac
cycle on the PV loop: first, the vertical line when the ventricle volume is the largest corre-
sponds to the isovolumic contraction of the ventricles, second, the PV loop shows a large
decrease in the ventricular volume corresponding to the ejection of blood, third, the verti-
cal line when the ventricle volume is the smallest corresponds to the isovolumic relaxation
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and, finally, the PV loop shows a large increase in the ventricular volume corresponding to
the filling of the ventricle. Therefore, the preload, the afterload and the ventricle contrac-
tility can be analyzed using the PV loop [61] and these concepts are briefly described below.
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Figure 2.3 – Pressure-volume loop [106]
Preload is the ability of the heart to fill up and is characterized by the compliance of
the heart. The compliance is an intrinsic property of the heart. However, the preload
also depends on extrinsic property of the heart such as the venous return. If the venous
return increases, more blood enters the ventricles and the preload is increased. Graph A in
Figure 2.4 shows how the PV loop changes when the preload increases or d creases. When
the preload increases, whereas the end-systolic volume is unchanged, the end-diastolic
volume increases and, therefore, the stroke volume increases. The relationship between
end-diastolic pressure and end-diastolic volume is of paramount importance and the ab-
breviation EDPVR, which stands for End-Diastolic Pressure Volume Relationship, is used
(Figure 2.3 and Figure 2.4).
Afterload describes the resistance to blood ejection. Afterload is an extrinsic property
of the heart and is influenced by several vascular properties such as the systemic resistances.
For example, if the systemic resistances increase, the afterload increases since it is harder
to eject blood out of ventricles. Graph B in Figure 2.4 shows how the PV loop changes
when afterload increases or decreases. When afterload increases, whereas the end-diastolic
volume is unchanged, the end-systolic volume increases and, therefore, the stroke volume
decreases. The end-systolic pressure also increases when afterload increases.
16 2.1. Cardiovascular system
Ventricle contractility is the ability of ventricles to contract and is an intrinsic prop-
erty of the heart. Therefore, the ventricle contractility does not change with the preload
or with the afterload. This contractility can be estimated with several PV loops: it is
equal to the slope of the straight line named ESPVR (Figure 2.3 and Figure 2.4). ESPVR
is the abbreviation of End-Systolic Pressure Volume Relationship and this straight line is
tangent to the PV loop corresponding to the end of the ventricle contraction (Figure 2.3).
For different afterloads, the ventricle contractility is unchanged and Figure 2.4 shows that
the different PV loops are tangent to the ESPVR. If the ventricle contractility increases,
the slope of the ESPVR increases and, for a same afterload and preload, whereas the end-
diastolic volume is unchanged, the end-systolic volume decreases and the stroke volume
thus increases.
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Figure 2.4 – Effect of preload (graph A) and afterload (graph B) on the pressure-volume loops
[61].
However, these 3 properties of the heart are not independent effects [61] since the
cardiovascular system is a closed loop. Hence, the different PV loops in Figure 2.4 are
rarely observed in real life. For example, if preload decreases, the ventricles eject less
blood and the blood flow in the arteries decreases. Consequently, the blood pressure in
the arteries decreases and afterload is thus diminished.
Elastance and compliance of the ventricles
The ability of the ventricles to expand when blood enters these cardiac cavities is really
important for the preload of the heart. This feature of the heart can be estimated with
the diastolic compliance or the diastolic elastance of the ventricles. These two parameters
describe a passive behavior of the ventricles. The diastolic compliance Cdiastole of a ventricle
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is the measure of its aptitude to expand under an increase in an external pressure [62] and
the following relation is written:
Cdiastole =
(
∂V
∂P
)
diastole
. (2.2)
This compliance is not constant during all the diastolic period, it is larger for small pressure
and smaller for larger pressure. The diastolic elastance Ediastole is the inverse of the
compliance and the following relation can be written:
Ediastole =
(
∂P
∂V
)
diastole
. (2.3)
Like the compliance, the elastance is not constant during all the diastolic period; it is
smaller for small pressure and larger for larger pressure. The EDPVR curve in Figure 2.3
represents the evolution of the ventricle pressure as a function of its volume during the
diastolic period. The slope of this curve increases and thus confirms the evolution of the
elastance values.
The preload influences directly the end-diastolic volume and therefore the stroke vol-
ume. The larger the preload, the larger the volume ejected by the ventricles. However,
the relation between the stroke volume and the preload is not linear. When the ventricles
are overfilled, the muscular fibres are too stretched and the myocardium cannot contract
efficiently [33]. This effect is well known under the name of Frank-Starling curve. Fig-
ure 2.5 represents this curve and highlights two different zones: one at low preload where
the stroke volume increases linearly with the preload and one at high preload where the
stroke volume is nearly constant with the preload.
Figure 2.5 – Frank-Starling curve [33].
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2.1.3 Physiology of the vascular system
The blood circulation
Thanks to the cardiac cycle, blood is transported across blood vessels toward the body tis-
sues. This circulation ensures the adequate supplies of various molecules to the organism.
A particularly important molecule is oxygen (O2) and Figure 2.6 represents blood vessels
in red when blood is rich in oxygen and in blue when blood is poor in oxygen. Indeed,
blood is oxygenated in the lungs and the oxygenated blood releases the O2 molecules in all
tissues which are used for their metabolism. The circulation of blood in the whole body is
quite complex but after some simplifications, this transport can be divided into 11 main
processes [119] (Figure 2.6):
Figure 2.6 – The blood circulation in the circulatory system [119]
1. Blood enters the right ventricle and gets out of this chamber through the pulmonary
artery.
2. The pulmonary artery is divided into 2 arteries: the left pulmonary artery, which
goes to the left lung, and the right pulmonary artery, which goes to the right lung.
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3. In the lungs, gas exchanges take place in the pulmonary capillaries: O2 is delivered
to blood and carbon dioxide (CO2) is released.
4. In the right and left pulmonary veins, the oxygen enriched blood is transported back
to left atrium.
5. Blood enters the left ventricle and then is ejected through the ascending aorta.
6. After the ascending aorta, one part of blood goes to the head and upper limbs and
the other part goes to the abdominal organs and lower limbs.
7. Oxygen is released and carbon dioxide is extracted in the capillaries of head and
lower limbs.
8. Oxygen is released and carbon dioxide is extracted in the capillaries of abdominal
organs and upper limbs.
9. Blood crosses the superior vena cava to go to the right atrium.
10. Blood crosses the inferior vena cava to go to the right atrium.
11. Blood enters the right atrium and, then, goes into the right ventricle (the cycle starts
again).
Steps 1 to 4 are commonly named the pulmonary circulation while steps 5 to 11 define the
systemic circulation.
The blood vessels
The blood circulation is carried out by blood vessels. These vessels have different shapes
and macro-molecular structures according to their locations and functions in the vascular
system. In the systemic circulation, 7 main types of blood vessels can be distinguished
[60, 46] (Figure 2.7 and Table 2.1):
• The aorta: is located just after the left ventricle and this large artery dampens the
pulsatile pressure thanks to its elastic membrane. The main function of the aorta is
of course to distribute blood toward the different arterial systems.
• Arteries: transport blood to the different tissues of the body. As in the aorta, blood
is under high pressure in the arteries and, consequently, they have a strong vascular
wall. Small arteries are able to constrict but it is mainly the arterioles which play
this function.
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• Arterioles: are small vessels (Table 2.1) which are able to constrict. Thanks to these
vessels, the arterial blood pressure is controled and the blood flow is regulated in
response to the tissue needs. For example, if the activity of one organ increases,
the arterioles located near this organ will dilate and the other arterioles will con-
strict. Consequently, these vessels need strong muscular walls and are innervated by
autonomic nerves.
• Capillaries: are microscopic vessels. However the total cross section is large (Ta-
ble 2.1) since the number of capillaries is huge. Their membrane is very thin and
it is permeable to water and other small molecules such as CO2 and O2. Therefore,
the function of these vessels is to participate in gas exchanges.
• Venules: collect blood from the capillaries. Like the arterioles, venules are able to
constrict and their membrane contains muscular cells. These vessels can thus control
the capillary blood pressure and the venous blood volume.
• Veins: collect blood from the venules. Their major roles are to store and to regulate
blood volume by decreasing or increasing their diameter. A large fraction of the
blood volume is stored in the systemic veins (≈ 60% [23]).
• Venae cavae: are the 2 final venous vessels (inferior vena cava and superior vena
cava). These vessels collect blood from the venules and transport it back to the right
atrium.
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ANATOMY AND FUNCTION
Vascular Network
The left ventricle ejects blood into the aorta,
which then distributes the blood flow
throughout the body using a network of arter-
ial vessels. These vessels are illustrated in
Figure 5-1. Table 5-1 summarizes the relative
sizes and functions of different blood vessels.
The aorta, besides being the main vessel
to distribute blood from the heart to the arte-
rial system, dampens the pulsatile pressure
that results from the intermittent ejection of
blood from the left ventricle. The dampening
is a function of the aortic compliance, which is
discussed in more detail later in this chapter.
Large arteries branching off the aorta (e.g.,
carotid, mesenteric, and renal arteries) dis-
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FIGURE 5-1 Major types of blood vessels found within the circulation.
TABLE 5-1 SIZE AND FUNCTION OF DIFFERENT TYPES OF BLOOD VESSELS IN
THE SYSTEMIC CIRCULATION
VESSEL TYPE DIAMETER (MM) FUNCTION
Aorta 25 Pulse dampening and distribution
Large arteries 1.0–4.0 Distribution
Small arteries 0.2–1.0 Distribution and resistance
Arterioles 0.01–0.20 Resistance (pressure/flow regulation)
Capillaries 0.006–0.010 Exchange
Venules 0.01–0.20 Exchange, collection, and capacitance
Veins 0.2–5.0 Capacitance function (blood volume)
Vena cava 35 Collection
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Figure 2.7 – Major types of blood vessels in the systemic circulation [60].
The pulmonary circulation is analogous to the systemic circulation; there are also
arterioles, capillaries and venules. The pulmonary arteries are analogous to the aorta in
the pulmonary circulation and the pulmonary veins re analog us to the venae cavae in
the pulmonary circulation.
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Table 2.1 – Characteristics (diameter, total cross-sectional area and function) of the different
types of the blood vessels in the systemic circulation [60, 46].
Vessel type Diameter
(mm)
Cross-sectional
area (cm2)
Function
Aorta 25 2.5 Pulse dampening and distribution
Arteries 0.2− 4.0 20 Distribution and resistance
Arterioles 0.01− 0.20 40 Resistance (pressure/flow regulation)
Capillaries 0.006− 0.010 2500 Exchange
Venules 0.01− 0.20 250 Exchange, collection and capacitance
Veins 0.2− 5.0 80 Capacitance (blood volume)
Venae Cavae 35 8 Collection
2.1.4 Important physiological parameters of the vascular system
Pressures and volumes
Pressures and volumes are not only important parameters for the heart (see section 2.1.2)
but also for the whole cardiovascular system. Figure 2.8 represents the normal blood pres-
sures in the different vascular vessels. In the aorta and in the large arteries, the blood
pressure is pulsatile because of the contraction of the left ventricle; the maximum pressure
is around 120 mmHg and the minimum pressure is around 80 mmHg. In small arteries,
their membrane is less elastic and the blood pressure becomes less pulsatile. In the arte-
rioles, the blood pressure decreases drastically since these vessels have a small diameter.
From the capillaries to the venae cavae, the blood pressure decreases progressively and
reaches a blood pressure near 0 mmHg in the venae cavae [46]. For the pulmonary circu-
lation, the same blood pressure evolution is observed but with much lower values in the
pulmonary arteries. However, the blood pressure in the pulmonary veins is larger than
in the systemic veins. Indeed, the pulmonary circulation has a much smaller vascular
network than the systemic circulation and the pressure drop is thus much smaller in the
pulmonary circulation.
Figure 2.9 represents the percentage of the total blood volume in the different parts
of the circulatory system. The vessels under low pressures (veins and venules) in the
systemic circulation have the largest percentage (around 64%). This result corresponds to
the vascular function of these vessels: storing the blood volume. The other vessels of the
systemic circulation (arteries, arterioles and capillaries) have a percentage around 10%.
Since the pulmonary circulation has a much smaller vascular network, the percentage in
this circulation is small (less than 10%).
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pulmonary capillaries to oxygen and other gases in the
pulmonary alveoli.
Basic Theory of Circulatory
Function
Although the details of circulatory function are
complex, there are three basic principles that underlie
all functions of the system.
1. The rate of blood flow to each tissue of the body
is almost always precisely controlled in relation to
the tissue need. When tissues are active, they need
greatly increased supply of nutrients and
therefore much more blood flow than when at
rest—occasionally as much as 20 to 30 times 
the resting level. Yet the heart normally cannot
increase its cardiac output more than four to
seven times greater than resting levels. Therefore,
it is not possible simply to increase blood flow
everywhere in the body when a particular tissue
demands increased flow. Instead, the microvessels
of each tissue continuously monitor tissue needs,
such as the availability of oxygen and other
nutrients and the accumulation of carbon dioxide
and other tissue waste products, and these in turn
act directly on the local blood vessels, dilating or
constricting them, to control local blood flow
precisely to that level required for the tissue
activity. Also, nervous control of the circulation
from the central nervous system provides
additional help in controlling tissue blood 
flow.
2. The cardiac output is controlled mainly by the
sum of all the local tissue flows. When blood flows
through a tissue, it immediately returns by way of
the veins to the heart. The heart responds
automatically to this increased inflow of blood by
pumping it immediately into the arteries from
whence it had originally come. Thus, the heart acts
as an automaton, responding to the demands of
the tissues. The heart, however, often needs help
in the form of special nerve signals to make it
pump the required amounts of blood flow.
3. In general the arterial pressure is controlled
independently of either local blood flow control
or cardiac output control. The circulatory 
system is provided with an extensive system for
controlling the arterial blood pressure.
For instance, if at any time the pressure falls
significantly below the normal level of about 
100 mm Hg, within seconds a barrage of nervous
reflexes elicits a series of circulatory changes to
raise the pressure back toward normal. The
nervous signals especially (a) increase the force of
heart pumping, (b) cause contraction of the large
venous reservoirs to provide more blood to the
heart, and (c) cause generalized constriction of
most of the arterioles throughout the body so that
more blood accumulates in the large arteries to
increase the arterial pressure. Then, over more
prolonged periods, hours and days, the kidneys
play an additional major role in pressure control
both by secreting pressure-controlling hormones
and by regulating the blood volume.
Thus, in summary, the needs of the individual tissues
are served specifically by the circulation. In the
remainder of this chapter, we begin to discuss the basic
details of the management of tissue blood flow and
control of cardiac output and arterial pressure.
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Figure 14–2
Normal blood pressures in the different portions of the circulatory system when a person is lying in the horizontal position.
Figure 2.8 – Normal blood pressure in the different vascular vessels [46].
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in major segments of the circulation. For instance,
about 84 per cent of the entire blood volume of the
body is in the systemic circulation, and 16 per cent in
heart and lungs. Of the 84 per cent in the systemic cir-
culation, 64 per cent is in the veins, 13 per cent in the
arteries, and 7 per cent in the systemic arterioles and
capillaries. The heart contains 7 per cent of the blood,
and the pulmonary vessels, 9 per cent.
Most surprising is the low blood volume in the cap-
illaries. It is here, however, that the most important
function of the circulation occurs, diffusion of sub-
stances back and forth between the blood and the
tissues. This function is discussed in detail in Chapter
16.
Cross-Sectional Areas and Velocities of Blood Flow. If all the
systemic vessels of each type were put side by side,
their approximate total cross-sectional areas for the
average human being would be as follows:
Note particularly the much larger cross-sectional
areas of the veins than of the arteries, averaging about
four times those of the corresponding arteries. This
explains the large storage of blood in the venous
system in comparison with the arterial system.
Because the same volume of blood must flow
through each segment of the circulation each minute,
the velocity of blood flow is inversely proportional to
vascular cross-sectional area. Thus, under resting con-
ditions, the velocity averages about 33 cm/sec in the
aorta but only 1/1000 as rapidly in the capillaries, about
0.3 mm/sec. However, because the capillaries have a
typical length of only 0.3 to 1 millimeter, the blood
remains in the capillaries for only 1 to 3 seconds. This
short time is surprising because all diffusion of 
nutrient food substances and electrolytes that occurs
through the capillary walls must do so in this exceed-
ingly short time.
Pressures in the Various Portions of the Circulation. Because
the heart pumps blood continually into the aorta,
the mean pressure in the aorta is high, averaging about
100 mm Hg. Also, because heart pumping is pulsatile,
the arterial pressure alternates between a systolic pres-
sure level of 120 mm Hg and a diastolic pressure level
of 80 mm Hg, as shown on the left side of Figure 14–2.
As the blood flows through the systemic circulation,
its mean pressure falls progressively to about 0 mm Hg
by the time it reaches the termination of the venae
cavae where they empty into the right atrium of the
heart.
The pressure in the systemic capillaries varies from
as high as 35 mm Hg near the arteriolar ends to as low
as 10 mm Hg near the venous ends, but their average
“functional” pressure in most vascular beds is about 
17 mm Hg, a pressure low enough that little of the
plasma leaks through the minute pores of the capillary
walls, even though nutrients can diffuse easily through
these same pores to the outlying tissue cells.
Note at the far right side of Figure 14–2 the respec-
tive pressures in the different parts of the pulmonary
circulation. In the pulmonary arteries, the pressure is 
pulsatile, just as in the aorta, but the pressure level is
far less: pulmonary artery systolic pressure averages
about 25 mm Hg and diastolic pressure 8 mm Hg, with
a mean pulmonary arterial pressure of only 16 mm Hg.
The mean pulmonary capillary pressure averages only
7 mm Hg. Yet the total blood flow through the lungs
each minute is the same as through the systemic cir-
culation. The low pressures of the pulmonary system
are in accord with the needs of the lungs, because 
all that is required is to expose the blood in the 
Systemic
vessels Arteries–13%
Arterioles
and
capillaries–7%
Heart–7%
Aorta
Pulmonary circulation–9%
Veins, venules,
and venous
sinuses–64%
Inferior
vena cava
Superior
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Figure 14–1
Distribution of blood (in percentage of total blood) in the different
parts of the circulatory system.
Vessel Cross-Sectional Area (cm2)
Aorta 2.5
Small arteries 20
Arterioles 40
Capillaries 2500
Venules 250
Small veins 80
Venae cavae 8
Figure 2.9 – Distribution of blood (in percentage of the total blood volume) in the different
parts of the circulatory system [46].
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Elastance and compliance
Elastance and compliance are also important parameters of the vascular system (the elas-
tance and compliance have been already discussed for the ventricles in section 2.1.2). The
relation between pressures and volumes is simpler for the vascular system since they are
passive elements and the pressure and volume variations are smaller. The approximation
of a constant elastance or a constant compliance is often used for the vascular vessels.
Therefore, the following equation can be written [60]:
∆V = C ·∆P (2.4a)
=
1
E
·∆P . (2.4b)
The compliance is much larger in the veins than in the arteries. Indeed, the veins must
dilate easily (the volume in the veins increases for a small increase in blood pressure in the
veins) in order to store the venous blood. For example, standard compliance values for an
adult are equal to about 100 ml/mmHg for the systemic veins and about 1 ml/mmHg for
the arteries [105].
Blood flow and resistance
Thanks to pressure gradients between the different vessels (Figure 2.8), blood can flow
from one vessel to another vessel having a lower blood pressure. If the inertial flows are
neglected, the blood flow Q between two locations is equal to [60, 57]:
Q =
∆P
R
, (2.5)
where ∆P is the difference between the blood pressure in the upstream part and the blood
pressure in the downstream part and R is the resistance in the section limited by the
two considered parts. The resistance increases very much (to the power 4, see Poiseuille’s
equation [118]) when the diameter of the vessels decreases. Therefore, the resistance is
very high for the small vessels. For example, the global resistance of the vascular system
surrounded the tissues is around 0.95 mmHg · s ·ml−1 for a healthy adult whereas the
resistance in the aorta is around 0.03 mmHg · s ·ml−1 [105].
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2.2 Blood chemistry
The blood chemistry is very complex; a large number of different molecules are present in
this fluid and a lot of chemical reactions are involved [94]. However, since this research
focuses on respiration, we will describe mainly the oxygen and carbon dioxide reactions.
2.2.1 Oxygen
O2 can be dissolved in blood plasma but this quantity alone would not be sufficient for
the metabolism of all cells [46]. In fact, the majority (≈ 97% [46]) of O2 in blood is
complexed with hemoglobin, a protein present in abundance in the erythrocytes (there
are several millions of hemoglobin molecules in each erythrocyte). The hemoglobin has 4
domains (2 α and 2 β) and each domain can bind a molecule of O2 [46]. The oxidation
of the hemoglobin occurs using an iron molecule which is localized on the heme of each
domain. An erythrocyte, the four domains of the protein and the heme are illustrated in
Figure 2.10.
!!
1!
2!3!
Figure 2.10 – Hemoglobin structure [26]. 1) View of an erythrocyte. 2) The four domains of
the hemoglobin. 3) Molecular structure of the heme.
IfHb represents one binding domain of hemoglobin, the following complexation reaction
of O2 with hemoglobin can be written [57]:
O2 + Hb −−⇀↽− Hb(O2) . (2.6)
However, the complexation reaction is more complex in reality because it can be influenced
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by many factors such as temperature, pH and CO2 partial pressure (PCO2). In addition,
the four domains of the hemoglobin are not independent and the kinetic of reaction 2.6
changes if one or several neighboring domains are already complexed with O2. Therefore, a
more realistic description of the hemoglobin complexation with O2 is given by the following
equations [35, 57]:
Hb4(O2)i−1 + O2
k2,i−−−⇀↽−−−
k−2,i
Hb4(O2)i ∀ i = 1, 2, 3, 4 , (2.7)
The kinetics of reaction 2.7 are slow when there is little oxygen in blood (there are few
oxygen molecules linked to the hemoglobin). The rate of the reaction increases when the
O2 concentration increases and when the hemoglobin is incompletely saturated. However,
if the concentration increases again, the hemoglobin gets saturated and the rate of the
reaction becomes very slow. In this way, the hemoglobin saturation curve with O2 in
terms of O2 partial pressure (directly related to the O2 concentration dissolved in blood
plasma) has an "S" shape (sigmoid curve). Figure 2.11 represents the saturation curve of
hemoglobin and also shows the influence of pH, PCO2 and temperature on this saturation.
Indeed, CO2 and H
+ can be linked to the hemoglobin (the binding sites are different
from the binding site of O2) and they thus change the hemoglobin configuration. If the
temperature, the PCO2 or the H
+ concentration increases, the saturation curve is shifted
to the right (the influence of pH on the saturation of hemoglobin is commonly named the
Bohr effect) [46]. In these conditions, the hemoglobin affinity with O2 is weaker. Since the
tissue cells produce heat and CO2 (and the CO2 in blood produces H
+), these hemoglobin
properties can be used by the body. Indeed, the cells need O2 for their metabolism and the
affinity of hemoglobin with O2 decreases when temperature and PCO2 increase. On the
contrary, if the temperature, the PCO2 or the H
+ concentration decreases, the saturation
curve is shifted to the left and the hemoglobin affinity with O2 is stronger.
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Figure 2.11 – The saturation curve of hemoglobin with O2 and the influences of pH, PCO2 and
temperature on this curve.
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2.2.2 Carbon dioxide
Like O2, CO2 is also dissolved in blood plasma (≈ 10% in venous blood [7]) and complexed
to the hemoglobin (≈ 30% in venous blood [7]). However, CO2 is also subject to the
hydration/dehydration reaction [57]:
CO2 + H2O −−⇀↽− HCO −3 + H+ , (2.8)
and the largest proportion of CO2 in blood is under the form of HCO
–
3 (≈ 60% in venous
blood [7]). Since this reaction produces H+, it influences directly the pH. As mentioned
before, PCO2 and pH influence the saturation of hemoglobin with O2. In addition, the
saturation of hemoglobin with O2 decreases the saturation of hemoglobin with CO2 (the
Haldane effect) [46]. All the different chemical components in blood are thus related to
one another.
2.3 Respiratory system
Coupled with the cardiovascular system, the respiratory system is fundamental for the
activity of every part of the body. Indeed, the respiration supplies the tissues with O2 and
rejects in the atmosphere the CO2 produced by the tissues. The anatomy, the mechanisms
and the properties of the respiratory system are described in the next subsections.
2.3.1 The anatomy of the respiratory system
Thanks to the thoracic muscles, the lungs can relax and contract leading to volume vari-
ations. When the lung volume changes, the pressure in the lungs changes and the atmo-
spheric air enters the lungs and gets out of the lungs through the respiratory tract.
The lungs
The thorax has 3 main cavities, two for the lungs and one for the heart. The right lung and
the left lung are located to the right and to the left of the heart respectively (Figure 2.12).
It is mainly the left lung which covers the heart and, consequently, this lung is smaller
than the right lung (the right lung has 3 lobes while the left lung has only 2 lobes).
Thoracic muscles
It is mainly the diaphragm, located at the bottom of the lungs, which generates lungs vol-
ume variations [46]. The other muscles taking part in the respiration are the external and
internal intercostal muscles and the abdominal muscles (Figure 2.13). During inspiration,
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Figure 2.12 – Simplified anatomy of the respiratory system [51].
the diaphragm and the external intercostal muscles contract resulting in an expansion of
the chest wall and the lungs. For expiration, there are differences between quiet breathing
and active breathing. During quiet breathing, the reduction of the chest wall and the lung
volume results from passive recoil of lungs; the diaphragm and the external intercostal
muscles relax. During active breathing, in addition to the relaxation of the diaphragm
and the external intercostal muscles, the abdominal and the internal intercostal muscles
contract.
Respiratory tract
The air goes from the mouth to the alveoli through the respiratory tract. First, the airflow
goes in the trachea. Then, the trachea is divided into several bronchi which are divided
into bronchioles. Finally, the bronchioles are divided into several alveoli (Figure 2.12).
Whereas the bronchi and bronchioles are rigid, the alveoli are elastic and participate in
lungs volume variations. The alveoli are in great abundance, their number is approximately
equal to 300 million [46], are in very close proximity with the pulmonary capillaries and
their membrane is very thin. Consequently, the gas exchanges occur in the alveoli: O2
goes from the alveoli to the blood in the pulmonary capillaries while CO2 goes from the
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Figure 2.13 – Respiratory muscles [28].
blood contained in the pulmonary capillaries to the alveoli.
2.3.2 The pulmonary ventilation
The pulmonary ventilation consists in cycles of inspiration and expiration [46]. During the
inspiration, the air enters the lungs and during the expiration, the air gets out. Thanks
to the ventilation, gas exchanges occur between the air in the alveoli and the blood in the
pulmonary capillaries. As a result, the blood flow in the pulmonary circulation and the
ventilation must be highly correlated and the ratio between the alveolar ventilation and the
capillary perfusion (V˙A/Qc) is an essential parameter [57]. This ratio is not constant for the
different parts of the lungs (Figure 2.14); it can be equal to infinity and the corresponding
area is named the dead space of the lungs, it can also be equal to 0 and this corresponds
to a pulmonary shunt or it can vary between these two extremes because of local perfusion
variations (West zones) or local ventilation variations (shunt effect).
Shunt and shunt effect
The pulmonary shunt corresponds to pulmonary capillaries which are not ventilated [13, 2].
The causes could be because the alveolus is obstructed (Chronic Obstructive Pulmonary
Disease), collapsed (emphysema) or full with water (pulmonary infection). The pulmonary
shunt is illustrated in Figure 2.14 in alveolus C. These specific alveoli can be partially ob-
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structed or collapse and the ventilation is thus not always equal to 0. The ventilation is
weaker in these alveoli than in normal alveoli and this phenomenon is called the shunt
effect.
The pulmonary shunt is also the fraction of blood that does not participate in gas
exchanges because blood goes directly from the pulmonary artery to the pulmonary veins
without reaching any alveolus. This shunt is called the anatomical shunt.
Dead space and West zones
The dead space refers to the alveoli which are not perfused [2]. The causes could be
because of vascular obstructions (pulmonary embolism) or damages of the pulmonary
vascular system (pulmonary arteritis or loss of capillary bed). The perfusion can also
decrease because of a lack of blood pressure in the pulmonary vessels. For example, if the
patient stands up, the blood pressure is weaker in the upper areas and larger in the lower
areas because of the gravity [41]. In physiological conditions, 3 zones are distinguished
and they are called the West Zones (Figure 2.15):
1. Zone 1 corresponds to the upper area of the lungs. In this region, pulmonary blood
pressures in the arteries (Ppa in Figure 2.15) and in the veins (Ppv in Figure 2.15)
are low and both blood pressures are smaller than the alveolar pressure (PA in
Figure 2.15). Since the pressure outside the vessels is larger than the pressures
inside, the pulmonary capillaries collapse in this region of the lungs. Therefore,
there is no blood flow in these vessels.
2. Further down in the lungs, Ppa and Ppv become larger and Zone 2 corresponds to
the area of the lungs where Ppa is greater than PA but Ppv is still smaller than PA.
The vessel diameter is reduced in this zone but the blood can flow in these vessels.
3. Still lower in the lungs, Ppa and Ppv still increase and Zone 3 corresponds to the area
of the lungs where Ppa and Ppv are larger than PA. In this last region of the lungs,
the capillary system is entirely open and the blood flow is the highest.
The dead space includes also the gas inhaled which does not reach any alveoli and
therefore does not contribute to gas exchanges. This dead space is called the anatomical
dead space.
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Figure 2.14 – The different ventilation/perfusion ratio [2]. V˙A is the alveolar ventilation and Q˙
is the capillary perfusion. In the text, Q˙ is replaced by Qc.
Figure 2.15 – West zones [117]. Ppa is the blood pressure in the pulmonary artery, Pva is the
blood pressure in the pulmonary vein and PA is the alveolar pressure.
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2.3.3 Cellular respiration
Whereas the external respiration or the pulmonary ventilation refers to the gas exchanges
in the lungs which reject CO2 in the atmosphere and deliver O2 to blood, the internal
respiration or the cellular respiration refers to the gas exchanges in the tissues which de-
liver O2 to the tissues and reject CO2 from the tissues into the blood [35]. Therefore, the
internal respiration supplies the molecules which are required for the cell activity and a
brief description is provided below.
All the body cells need O2 and carbonate substrates (CxHyOz) for their activity [36,
85]. The energy is produced from these substrates and using several reactions called
metabolism. These reactions produce CO2 and H2O. The ratio of the CO2 produced to
the O2 consumed, known as the respiratory quotient
RQ =
CO2,eliminated
O2,consumed
, (2.9)
depends on which substrate is consumed. For carbohydrates (CnH2nOn) such as glucose
(C6H12O6), the respiratory quotient RQ is equal to 1. However, this quotient is smaller
for other substrates such as fats (RQ ≈ 0.7 [5, 85]) or proteins (RQ ≈ 0.8 [5, 36]).
2.3.4 Important physiological parameters of the respiratory system
Minute ventilation, lung volumes and respiratory frequency
The minute ventilation V˙E1 is the quantity of gas entering the lungs during one minute
and is equal to [9]:
V˙E = fr · VE , (2.10)
where fr is the respiratory frequency and VE is the respiratory volume. At rest, the respi-
ratory frequency is approximately equal to 16 breathings per minute [102]. When an adult
breaths normally, in other words a breath without extra efforts, the respiratory volume is
approximately equal to 500 ml and this volume is called the tidal volume (Figure 2.16).
The human body can inspire and expire more volume than the tidal volume and these
additional volumes are called the inspiratory reserve volume and the expiratory reserve
volume respectively. Figure 2.16 shows that the inspiratory reserve volume is approxi-
mately equal to 3100 ml and the expiratory reserve volume is approximately equal to 1200
1Symbol V˙E is used in the literature because, historically, this quantity was always measured during
expiration [102].
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ml for a healthy adult. Therefore, an adult can increase his breathing to 4800 ml. But this
volume is not equal to the total lung capacity. Indeed, even with a maximal expiration, the
lung volume is never equal to 0 ml. This remaining volume is called the residual volume
and is equal to approximately 1200 ml for a healthy adult.
Figure 2.16 – Lung volumes and capacities for an adult [92].
For mechanically ventilated patients admitted to intensive care units, the respiration is
often performed without extra volume and the respiratory volume is thus equivalent to the
tidal volume VT . In our study, equation 2.10 is thus replaced by the following equation:
V˙E = fr · VT . (2.11)
Alveolar ventilation and alveolar perfusion
As already mentioned in subsection 2.3.2, all the minute ventilation does not reach the
alveoli and therefore does not participate in the gas exchanges. The alveolar ventilation
V˙A is thus smaller than the minute ventilation and is equal to [9, 93, 54]:
V˙A = fr · (VT − VDead) = V˙E − V˙Dead , (2.12)
where VDead is the dead space and V˙Dead is the minute dead space. For a healthy adult, the
dead space is approximately equal to 150 ml (and thus V˙Dead ≈ 2.4 l/min, see Figure 2.17).
For perfusion, the same kind of phenomenon is observed; all the pulmonary blood flow Qp
does not participate in gas exchanges and the alveolar perfusion Qa is equal to [93, 54]:
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Qa = (1− fs) ·Qp , (2.13)
where fs is the pulmonary shunt fraction (the fraction of the pulmonary blood flow which
does not participate in gas exchanges).
CO2 and O2 partial pressure in the respiratory system
The quantities of O2 and CO2 in the different parts of the respiratory system are of
paramount importance since the main purpose of this system is to provide enough O2 and
to reject enough CO2.
If the inhaled gas is atmospheric air, the gas entering the respiratory system is com-
posed of approximately 21% of O2, approximately 79% of N2 and nearly 0 % of CO2 (≈
0.04 %). In the medical field, these quantities are often measured in partial pressures
and the mmHg unit is often used. Since the standard atmospheric pressure is equal to
760 mmHg, the O2 partial pressure PO2 is approximately equal to 160 mmHg and the
N2 partial pressure PN2 is approximately equal to 600 mmHg. When the air is in the
trachea and in the bronchi, its composition is almost unchanged except that the air is
humidified and warmed up. The total pressure is unchanged (760 mmHg) but the H2O
partial pressure PH2O must also be considered and it is approximately equal to 47 mmHg
[102]. Therefore, in this part of the respiratory system, PO2 ≈ 0.21 · (760 − 47) = 150
mmHg and PN2 ≈ 0.79 · (760− 47) = 563 mmHg.
In the alveoli, due to the gas exchanges with the blood in the pulmonary capillaries,
PO2 is weaker, and PCO2 is larger, than in the bronchi. Figure 2.17 shows that for a
healthy human, PO2 is equal to 100 mmHg and PCO2 is equal to 39 mmHg in the alveoli
[102]. Gas exchanges are very efficient across the alveolar-capillary membrane and PO2
and PCO2 in the pulmonary capillaries are equal to PO2 and PCO2 in the alveoli [9, 57].
However, PO2 is weaker (95 mmHg) and PCO2 is larger (41 mmHg) in the arteries than in
the pulmonary capillaries because of the pulmonary shunt [48]. In an analogous manner,
PO2 is larger (115 mmHg) and PCO2 is weaker (33 mmHg) in the exhaled air than in the
alveoli because of the dead space [102].
Finally, PO2 is weaker in the veins (40 mmHg) than in the arteries because of the
O2 consumption by metabolism and PCO2 is larger in the veins (45 mmHg) than in the
arteries because of the CO2 production by metabolism.
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Figure 2.17 – Different physiological values of gas transport for an adult at rest [102]. All the
symbols are defined in the text excepted that in the text, the symbols V˙CO2 and V˙O2 are replaced
by V˙L,CO2 and V˙L,O2
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In addition, it is important to note that the measures of PO2 and PCO2 in blood
are only proportional to the concentrations of O2 and CO2 dissolved in blood plasma.
To estimate the total O2 and CO2 blood concentration, the measures of HCO
–
3 , of the
hemoglobin saturations with O2 and CO2 and of the hemoglobin concentration must be
estimated in addition to the O2 and CO2 partial pressures [94].
CO2 production and O2 consumption by metabolism
In the tissues, the important parameters are the quantity of CO2 produced by metabolism
and the quantity of O2 consumed by metabolism. Our study will be only focused on
the global production of CO2, symbolised by MRCO2 , and the global consumption of O2,
symbolised byMRO2 . These quantities can be estimated by the following formulas [9, 102]:
MRO2 = CO · avDO2 (2.14)
MRCO2 = CO · (−avDCO2) (2.15)
where avDO2 is the arterial-venous O2 difference (the difference between O2 concentrations
in the arteries and veins) and avDCO2 is the arterial-venous CO2 difference. In a stabilized
situation, the O2 consumption by metabolism is equal to the O2 supply in the lungs (V˙L,O2)
and the CO2 production by metabolism is equal to the CO2 extraction in the lungs (V˙L,CO2).
Note that the concentration unit used in the present study (and in other similar studies
[116, 9, 12, 113, 37]) is the partial volume (li/l). The relation between molar concentration
Ci (moli/l) and partial volume Vi is written by using the ideal gas law:
Vi = Ci · R · T
P
, (2.16)
where R is the gas constant, T the temperature and P the pressure. For a healthy adult,
the avDO2 is approximately equal to 0.05 lO2/l and the MRO2 , which is equal to V˙L,O2 , is
thus approximatively equal to 0.3 lO2/min for a CO of 6 l/min [102] (Figure 2.17). Since
the respiratory quotient RQ (see equation 2.9) is equal or smaller than 1, MRCO2 is equal
or smaller than MRO2 (MRCO2 = V˙L,CO2 ≈ 0.25 lCO2/min in Figure 2.17).
2.4 Controls and regulations of the cardio-pulmonary
system
Even if the controls and the regulations of the cardio-pulmonary system are not considered
in the mathematical models described in the next chapters, it is important to know these
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physiological effects to understand the impacts of several simplifications on the models.
The controls and the regulations act on different parts of the body to satisfy the human
homeostasis which is essential for the proper functioning of the different organs.
2.4.1 Controls and regulations of the cardiovascular system
Two important parameters of the cardiovascular system are strictly controlled to ensure an
appropriate hemodynamics in all the cardiovascular vessels. These two parameters are the
blood pressure and the blood flow. The control mechanisms on these parameters are very
complex and 3 major types can be distinguished: local (intrinsic) control, humoral control
and neural (extrinsic) control [57]. These 3 controls are only short-term controls (seconds
to hours) but long term controls (days to weeks), such as renal mechanisms, also exist
and allow to regulate the partial pressure. However, there is no real interest in discussing
here the long-term control since the aim of our study is to stimulate the cardio-pulmonary
system during minutes to hours and not days to weeks.
Local (intrinsic) control
The blood flow in the different tissues must correspond to their activity. If the blood flow
is too low, not enough O2 is transported to the tissue and not enough CO2 is evacuated
from the tissues. Hence, local controls are able to adjust the flow through an arteriole
according to the activity of the tissue which is supplied by this arteriole. The complete
mechanism is not known yet but it is assumed that chemoreceptor estimates the activity
of the tissues by measuring the concentrations of O2, CO2 and H
+ in the veins [57]. If the
activity is not proportional to the blood flow, regulatory substances, called vasodilators,
are transported to the arterioles. For instance, when the blood flow is too low for the
activity of the tissues (concentration of O2 is too low and concentration of CO2 and H
+
are too high), the vasodilators induce an increase in the arteriole diameters.
Neural (extrinsic) control
The nervous system has several nerve fibres controlling the vascular vessels and the heart.
Contrary to the previous control, the nervous control has a more global effect. It regulates
the cardiac function (heart rate and contractility), the distribution of blood to the different
parts of the body and the systemic arterial pressure. The rapid control of the arterial
pressure by the neural control is called the baroreflex and it is the most important extrinsic
control of the cardiovascular system [57]. This control works thanks to the baroreceptors
located in the carotid sinus and the aortic arch. When the nervous system detects a drop
in the arterial pressure, it sends several signals which increase the sympathetic stimulation
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and decrease the parasympathetic stimulation in order to increase the heart activity (heart
rate and contractility) and in order to constrict the small arteries, the arterioles and the
veins. The baroreflex mechanism is illustrated in Figure 2.18.11.6: Cardiovascular Regulation 501
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Figure 11.12 Schematic diagram of the baroreceptor reflex pathway. Adapted from Ottesen
(1997), Fig. 2.
vessels,with the exception of the capillaries. The primary effects of sympathetic nervous
stimulation are
1. contraction of small arteries and arterioles (by stimulation of the surrounding
smooth muscle) to increase blood flow resistance and thereby decrease blood flow
in the tissues;
2. constriction of the veins, thereby decreasing the amount of blood in the peripheral
circulation;
3. stimulation of the heart muscle, thereby increasing both the heart rate and stroke
volume.
The parasympathetic or vagus nerves have the opposite effect on the heart, decreas-
ing the heart rate and strength of contractility. Strong sympathetic stimulation can
increase the heart rate in adult humans to 180–200 beats per minute, and even as high
as 220 beats perminute in young adults. Strong parasympathetic stimulation can lower
the heart rate to 20–40 beats per minute and can decrease the strength of contraction
by 20 to 30 percent.
The effect of the baroreceptors is to increase sympathetic stimulation and decrease
parasympathetic stimulation when there is a drop in arterial pressure. This increase
in sympathetic activity, in turn, increases the heart rate, the systemic resistance, and
the cardiac compliances, and decreases the venous compliance. Notice from Table 11.2
that in the unregulated circulation these changes effect an increase of arterial pressure.
Thus, the overall effect of the baroreceptor loop is to maintain the arterial pressure at
a desired level.
Figure 2.18 – Schematic diagram of the baroreflex pathway [57].
Humoral control
Humoral control is mediated by substances secreted or absorbed in blood such as hor-
mones and ions [46, 57] nd thes substances can interac with chemoreceptors. Some of
these substances have local effects but others are transported throughout different parts
of the body and are able to control the entire cardiovascular system [46]. For example,
hypercapnic acidosis (CO2 and H
+ concentrations increase) changes several cardiovascular
properties: the pulmonary vascular resistance increases, the systemic vascular resistance
decreases and the heart rate increases [108].
2.4.2 Controls and re ulati s of the respiratory syste
Unlike the heart which has its own rhythm thanks to specific cardiac cells (cells of the sinus
node), the lungs cannot move without the control of the nervous system. It is mainly the
dorsal respiratory group located in the dorsal portion of the medulla which controls the
respiration cycle; it is active for inspiration and inactive for expiration. Two other respira-
tory groups are stimulated for extra breathing; the ventral respiratory group for expiration
and the pneumotaxic center for the rate and depth of breathing [46]. The nervous system
is able to modulate the amplitude and the frequ ncy of respiratory ventilation. Chemical
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factors stimulate or inhibit the respiratory nerves located in the medulla but Figure 2.19
shows that several other factors interact with the respiratory nerves.
Figure 2.19 – Controls of the respiratory system [25].
Chemical factors
There are two groups of chemoreceptors: the central chemoreceptors located in the central
nervous system (in the pons) and the peripheral chemoreceptors located in the carotid and
in the aortic arch (Figure 2.19). Since the aim of the respiration is to maintain appropriate
CO2, O2 and H
+ concentrations, these 3 molecules have a direct effect over the respiratory
activity [64, 46].
For the central nervous system, it is mainly PCO2 in blood which regulates the breath-
ing. Indeed, PO2 has no direct effect on the respiratory center of the brain and H
+ ions
in blood cannot cross the blood-brain barrier. However, PCO2 has an indirect effect over
the central nervous system. The CO2 molecules in blood cross the blood-brain barrier and
the CO2 molecules react with water in the cerebrospinal fluid and in the interstitial fluid
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of the medulla to form H+ ions (see reaction 2.8, p. 26). The neural sensors in the brain
are especially excited by these H+ ions. Therefore, if PCO2 increases in blood, the PCO2
and the H+ ions in the interstitial fluid of the medulla increase and the H+ ions stimulate
the respiratory groups. The stimulation of the respiratory groups increases the respiratory
activity [64, 46].
For the peripheral chemoreceptor system, it detects and controls the PO2, the PCO2
and the H+ concentration in blood. For a small increase in PCO2 and H
+ concentra-
tions, the respiratory groups are stimulated and the ventilation is increased. For the O2
molecules, the respiratory groups are stimulated only if PO2 decreases below 60 mmHg
[64, 46].
Other factors
Stretch receptors (proprioceptors) in the lungs are used to inhibit the breathing when the
lung walls are too stretched. Some irritant factors, such as smoke, dust or pollen, also
trigger the inhibition of the respiration thanks to irritant receptors. Furthermore, human
being is of course able to control their breathing voluntary. Other information of the
brain can affect the respiration such as emotional or pain stimuli. The last stimulation
of the respiratory system is provoked by the proprioceptors located in the muscles and
joints. This stimulus is used to anticipate the increased oxygen requirement during exercise
[64, 25].
2.5 Summary
This chapter has introduced the major concepts of the cardiovascular and respiratory
systems. The anatomy and the physiological performance of both systems have been de-
scribed and the important parameters characterizing these systems have been developed
for each system (the cardiac parameters have been described in subsection 2.1.2, the vas-
cular parameters have been described in subsection 2.1.4 and the respiratory parameters
have been described in subsection 2.3.4). In addition, several blood chemistry properties
have also been introduced in this chapter (in section 2.2). The last section (section 2.4)
has introduced the cardiopulmonary controls and regulations.

Chapter 3
Extracorporeal life support
In the previous chapter, the vital functions of the lungs and of the cardiovascular system
have been described. If one or both of these systems are seriously damaged, the whole
human body is in real danger. Therefore, scientists, physician and engineer have devel-
oped several extracorporeal circulations such as the Extracorporeal Life Support (ECLS)
which is able to reproduce the vital functions of the lungs or/and the heart. The acronym
ECMO for Extracorporeal Membrane Oxygenation is also used for this device. However,
this designation is a bit misleading since this device also extracts the CO2. Therefore, the
acronym ECLS will be used in our study.
In this chapter, the history of extracorporeal circulations, the different components
of the ECLS device, its applications in the ICU and the important parameters of the
extracorporeal circulation will be discussed. In order to train the medical staff before real
interventions on patients, several ECLS simulators have been developed. The different
simulators available on the market are also discussed in this chapter.
3.1 History of ECLS
The first extracorporeal circulation was set up by surgeon John Gibbon in 1954 [8]. This
device is called a cardio-pulmonary bypass and it is used to accomplish cardiac surgeries.
Cardio-pulmonary bypass is rather different from the ECLS device; the latter is used for a
longer support (several days or weeks) than cardio-pulmonary bypass and this extracorpo-
real circulation takes only a fraction of the cardiac blood flow whereas, cardio-pulmonary
bypass diverts all the blood flow to the extracorporeal circulation. Therefore, the ECLS
device must have an excellent hemocompatibility and the first successful use of this device
was performed by physician J. Donald Hill in 1971.
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Even if several improvements have been made during the last decades (the size of the
different components have been reduced, the efficacy and the hemocompatibility of the
different components have been improved), the side effects of setting an ECLS remains
high and the use of this technology is thus only intended for patients with acute heart
or/and lungs failures.
3.2 The different components of ECLS
The ECLS has three main components: a permeable membrane carrying out the gas ex-
changes between blood and the injected gas (atmospheric air or O2 enriched air), a pump
carrying out the extracorporeal blood flow and tubing and cannulae transporting blood
from the patient to the membrane and back to the patient.
The synthetic membrane attempts to maximize the O2 and CO2 gas exchanges like the
alveolar capillary membrane. The first membranes were in polyethylene. Then, using the
development of new materials, silicone and finally polymethylpentene (PMP) hollow-fiber
have been used [101]. Manufacturers try to produce a surface area as small as possible with
a high effectiveness. Indeed, a larger surface area involves more hemocompatibility con-
straints. To increase the hemocompatibility an anticoagulant named heparin is used and
the risk of hemorrhage is consequently increased. Furthermore, to avoid a large decrease
in the blood volume in the vascular system when the ECLS is initialized, the membrane
and the extracorporeal circuit are filled with physiological liquid before the initialization
of the extracorporeal therapy. Smaller membranes thus involve smaller priming volumes
and the blood dilution is weaker.
For the extracorporeal circulation, a centrifugal pump is often preferred than a roller
pump. The tubing is in PVC and the cannulae are in wire-reinforced polyurethane [101].
In addition, surface coatings are applied to the different components to improve bio-
compatibility. Indeed, these substances are able to bond heparin molecules and thus
prevent the coagulation of blood in the synthetic components.
3.3 The different applications of ECLS in the ICU
The ECLS can be set up in different configurations according to the pathology of the
patient. If the patient has a heart disorder or a cardiopulmonary disorder, the clinicians
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set up the ECLS in the venoarterial configuration, whereas if the patient has only a
pulmonary disorder, the ECLS is in the venovenous configuration.
Venoarterial ECLS The main cardiovascular pathologies which are apt to venoarterial
ECLS (va-ECLS) are the cardiogenic shock [82] and the septic shock [3]. The cardiogenic
shock brings several heart damages together and this general pathology leads to insufficient
cardiac output and thus insufficient tissue perfusions [69]. The septic shock is a body
infection which leads to a low blood pressure because of a large decrease in the systemic
vascular resistance [70]. In addition, a va-ECLS is also used after cardiac surgeries such
as replacements of cardiac valves. In Figure 3.1, the left picture illustrates the standard
configuration of a va-ECLS for an adult. The cannula extracting the venous blood is
inserted into the femoral vein and placed just below the junction of the right atrium and
the inferior vena cava. The cannula reinjecting the extracorporeal blood flow is inserted
into the femoral artery and placed in the aortic arch (near the aortic valve). The placement
of the arterial cannula must be strictly controlled. Indeed, the blood flow in the carotid
is of paramount importance since it irrigates the brain and the arterial cannula must be
thus appropriately placed.
Venovenous ECLS Acute respiratory distress syndrome (ARDS) is a serious lung
pathology and a venovenous ECLS (vv-ECLS) is often used with this pathology [15, 63, 29].
ARDS is characterized by pulmonary inflammations and pulmonary edema which leads
to severe hypoxemia [31]. In Figure 3.1, the right picture illustrates the standard config-
uration of a vv-ECLS for an adult. The cannula extracting the venous blood is inserted
in the same way as for the venoarterial configuration. On the other hand, the cannula
reinjecting the extracorporeal blood flow is inserted into the right internal jugular vein
and placed towards the junction of the right atrium and the superior vena cava. The two
cannulae are very closed to each other and their placement must be checked carefully to
limit the recirculation of the extracorporeal blood flow. In addition, a new kind of vv-
ECLS has been developed recently: the extracorporeal CO2 removal device (ECCO2RD)
which is used for moderate ARDS [75, 11, 30, 110] and for chronic obstructive pulmonary
disease (COPD) [1, 104]. COPD is characterized by airflow limitation. This pathology
is progressive, treatable but not fully reversible [20]. More details about ECCO2RD are
described in the next paragraph.
ECCO2RD Despite several technical improvements for the different components of the
ECLS, the setting of this device still leads to severe complications such as hemorrhages.
Therefore, the ECLS is reserved for patients with serious cardio-pulmonary disorders.
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Figure 3.1 – Venoarterial ECLS (left picture) and venovenous ECLS (right picture) [90].
However, recent studies have shown that the setting of an ECLS could be beneficial for
patients with moderate pulmonary disorders [75, 11, 30, 110]. The explanation is that it
is worse to impose large inspired volume using a ventilator than to proceed to a super-
protective ventilation combined with an extracorporeal CO2 removal therapy (ECCO2RT)
[75]. Indeed, when the lungs are injured, large inspired volumes can increase pulmonary
disorders. A super protective ventilation, which consists in a ventilation with very small
tidal volume (≈ 3ml/kg) and high O2 concentration in inspired air, is thus recommended
for patients with pulmonary insufficiencies. However, with this kind of ventilation, the
CO2 extraction is too small and an additional respiratory support must be included: an
ECCO2RD. The difference between an ECCO2RD and a conventional vv-ECLS is that
the ECCO2RD is specialized in CO2 extraction. Since it is easier to extract CO2 than
to oxygenate blood, the membrane of the ECCO2RD and the extracorporeal blood flow
are thus smaller than in the vv-ECLS. This device is thus less invasive and has a smaller
synthetic membrane. Therefore, it has fewer complications than the vv-ECLS.
3.4 Important parameters of the ECLS
Since the ECLS is able to support the functions of the heart and lungs, the important
parameters concern both hemodynamic and gas exchanges properties.
The gas exchanges across the synthetic membrane are based on similar concepts than
the gas exchanges in the lungs. The important parameters are thus similar to those of the
lungs and are the following:
• PO2, PCO2, pH, HCO
–
3 concentration and saturation of hemoglobin at the inlet
and outlet cannulae.
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• O2 and CO2 volume fraction in the gas entering the ECLS and in the gas getting
out of the ECLS.
• Extracorporeal blood flow.
• Gas flow entering the extracorporeal device.
• O2 and CO2 diffusion coefficients across the synthetic membrane.
On the other hand, the extracorporeal pump is quite different from the cardiac pump.
The extracorporeal pump delivers a continuous blood flow thanks to a mechanical rota-
tion. For a given rotation speed, the extracorporeal blood flow varies according to the
preload and the afterload of the pump. Figure 3.2 illustrates these concepts by clamping
the pump inlet or the pump outlet for different rotations.
4 Perfusion 
rates, regardless of clamping the pump inlet or pump 
outlet (p<0.01).
Figure 3 shows the pump curves for the Rotaflow 32 
and the Rotassist 2.8 centrifugal pumps when increasing 
resistance at either the pump inlet or the pump outlet. 
The figure reveals a discrepancy in the pump head, 
which increases as the pump flow is decreased. The 
pressure discrepancy also increased with increasing 
pump speed and was maximal at shut-off head for all 
pump speeds. The maximum discrepancy amounted to 
44 mmHg at 4,000 rpm for the Rotaflow 32 and 28 
mmHg at 4,000 rpm for the Rotassist 2.8 centrifugal 
pump. With near-full closing of the Hoffman clamp at 
the pump inlet at 5,000 rpm, the pump flow proved not 
to be reliably measurable due to massive embolization in 
the low-flow range. This effect occured at flows below 2 
L/min for the Rotaflow 32 and below 0.5 L/min for the 
Rotassist 2.8 centrifugal pump.
Figure 4 shows an exponential association of 0.73 
(p>0.001) and 0.71 (p<0.001) between decreasing pump 
inlet pressure and GME volume for the Rotassist 2.8 and 
Rotaflow 32 centrifugal pumps, respectively. GME 
activity at the pump outlet was detectable at pump inlet 
pressures of −156 mmHg and less, with a corresponding 
flow of 0.2 L/min at 2,500 rpm for the Rotassist 2.8. For 
the Rotaflow 32, GME activity at the pump outlet was 
detectable when pressures at the pump inlet amounted 
to −224 mmHg and less, starting at a pump flow of 0.9 
Figure 3. Pump performance with increased closing of the Hoffman clamp at the pump inlet or outlet tubing of the Rotaflow 32 
centrifugal pump (left) or Rotassist 2.8 centrifugal pump (right). Note the decreased performance when clamping the inlet compared 
to clamping the pump outlet.
Rpm: rotations per minute.
 at Maastricht University on September 17, 2014prf.sagepub.comDownloaded from 
Figure 3.2 – Pump performance of the Rotassist 2.8 centrifugal pump® [103]. The preload of
the pump is decreased by clamping the inlet cannula while the afterload of the pump is increased
by clamping the outlet cannula.
F r the extracorporeal circuit, the blood flow resistances ar mainly located at the inlet
and outlet cannulae. Figure 3.3 represents the pressure drop in pediatric femoral venous
cannulae (left panel) and in adult femoral venous cannulae (right panel). However, the
values must be read with cautious since the experimental data are carried out with water
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instead of blood. The pressure drop curves are thus underestimated. Blood pressure and
pressure drop are important parameters to avoid blood damages. It is mainly the negative
pressure which must be limited [79]. The inlet pressure has to be superior than -50 mmHg
[84, 24]. The limitation of positive pressure is less severe; the outlet pressure has to be
inferior than 300 mmHg [73].
	
!
Figure 3.3 – Pressure drops in femoral venous cannulae with different diameter sizes [71]. The
left panel corresponds to pediatric cannulae and the right panel corresponds to adult cannulae.
Note that in the cardiovascular model that will be developed in Chapter 4, the blood
pressures and the blood volumes of the extracorporeal circuit will not be explicitly included.
Indeed, the goal of our study is to characterize the behavior of the patient according to
different ECLS functionings. The hemodynamic interactions of the ECLS with the patient
are only the extracorporeal blood flow. Since the extracorporeal blood flow is continuously
measured and can be controlled by the medical team, this blood flow is simply an input
of the cardiovascular model. Nevertheless, we must keep in mind that the extracorporeal
blood flow depends on several parameters.
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3.5 The ECLS simulators
The setting and the control of an ECLS are complex and some technical errors could lead
to the death of a patient. The medical staff thus has to be well trained before using this
device. Two types of ECLS simulators designed for training purposes can be distinguished:
computer based simulators and simulators with hands-on approach. Computer based
simulations are really easy to use since the medical staff only needs a computer and the
appropriate program. Several programs already exist on the internet like the ECMOjo
simulator developed by the Telehealth Research Institute in the University of Hawaii and
the ECMO simulator developed by the Modular Simulation Environment (MSE) company
located in Australia [27]. Simulations with hands-on approach need more equipments
but are closer to reality. Indeed, these simulations are carried on real ECLS circuits
and the computer programs are often integrated to a material system such as a black
box or a mannequin. The price of such simulator is thus higher and fewer hospitals
own this type of tools. Several training device with hands-on simulations are available
on the market. There are the Califia developed by BioMed Simulation from California,
ECMOsim developed at the Radboud University Medical Center in Nijmegen, ECMO
simulation training developed in the Hawaiian medical center and ECMO crisis training
developed in Minnesota’s Mayo Clinic [27]. Figure 3.4 illustrates two ECLS simulators:
picture A represents the computer based simulation of the Telehealth Research Institute
(the ECMOjo program) and picture B represents the hands-on simulation of the Radboud
University Medical Center (the ECMOsim device).
3.6 Summary
Chapter 3 has described the role of extracorporeal life support (ECLS) in the medical
field. The different components and the different application of this device have been
described. Then, the important parameters characterizing the proper functionning of the
extracoporeal device have been briefly discussed. Finally, ECLS simulators have already
been developed by several firms and these have been briefly presented in this chapter.
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ECMOjo
ECMOjo simulator has beendevelopedby theTelehealthResearch Institute (TRI), JohnA. Burns
School of Medicine (JABSOM) of the University of Hawaii. It is a computer application im-
plemented in programming language Java. ECMOjo is possible to use for all major operating
systems including Windows, Macintosh, Linux and Unix. The application has a graphical user
interface (figure 2.7) for training nurses, students and physicians in the basics of ECMO [As-
chwanden et al., 2009].
Figure 2.7: Graphical interface of simulator ECMOjo [Aschwanden et al., 2009]
It is possible to download this application online and for free as well as its Java source. EC-
MOjo simulator consists of a scenario and simulation part. In the scenario part, the developers
describe how ECMO in general works, how the simulator is controlled andwhat is an appropri-
ate solution for different problems in leading an ECMOdevice. In the simulation part, there are
different types of crisis scenarios. During each scenario, some problem arises and the user is
supposed to solve the problem by fixing an appropriate part of the circuit or changing certain
settings. At the beginning, the user can choose the type of circuit, oxygenator and pump. The
application also offers the possibility to have humans or pigs as patients. The program allows
users to choose how the patient’s lungs work, but only if the function is good or bad. If the user
fails during the simulation, the patient dies. If the user succeeds, the patient survives. ECMOjo
is suitable for learning how ECMOworks but also how to control the device.
The online application works satisfactorily even though sometimes it crashes and the user is
not able to run it until the computer is restarted. Themathematical model behind the applica-
tion has very complex and untransparent structure. Therefore, possible improvements can be
made by the programmer only.
MSE simulator
MSE online simulator was developed by a hard- and soft- ware company MSE (Australia) PL
in Australia, Sydney. It is a screen-based implementation of a high-fidelity, medical simulation
system - "The Modular Simulation Environment" (MSE) (figure 2.8). MSE was developed with
an intention to teach the principles of VV and VA ECMO to people working in the fields of
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controlled by a computer. An advantage of this kind of simulators compared to computer ap-
plications lies in a more realistic controlling of the device. During hands-on simulation, the
user controls ECMO by an actual button instead of clicking in the case of computer applica-
tion.
ECMOsim
This simulator is in the production prototype phase but it seems the result will be possibly very
interesting (figure 2.10). ECMOsim will be a model of a baby in real size as well as the ECMO
machine [Antonius and Peeters, 2011]. This is another possibility how to train the leading of
ECMO. Trainees can work with the circuit in real sizes andmanually try to control all necessary
features. Nomodel is ideal, but this is an interesting option for learning how an ECMOmachine
works.
Figure 2.10: The prototype of simulator ECMOsim [Antonius and Peeters, 2011]
ECMO imulation training
TheHawaiianmedical center created a video tutorial as an educational tool to showhowECMO
simulation can be easily performed using a simulation program, standard ICU equipment and
an actual ECMO circuit (figure 2.11). This simulation was created as part of the training pro-
gram for students. This kind of practice is very good imitation of a real situation of le ding
ECMO. The team has some pr pared scenarios a d students are able to try to solve the prob-
lem which arises ring the conduct of a ECMO. The medical center’s website includes also
ECMO simulation documentation in pdf which explain some sc narios [Vara, 2012].
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A) 
B) 
Figure 3.4 – Illustration of two simulators. Picture A represents an online simulator while
picture B represents a hands-on simulator [27].
Part II
Mathematical modeling
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The second part of the thesis describes the modeling of the cardiovascular system,
the respiratory system and the extracorporeal life support. Since these systems are very
complex, many simplifications are going to be introduced. The models must be simple
enough to be identifiable with the available measurements in the ICU and necessitate
a small computation time to satisfy the need of a rapid decision by clinicians at the
patient bedside. There is a large number of cardiovascular and respiratory models in
the literature with various complexity. The most complex models are the distributed
models, which are 3-D finite elements models with millions degrees of freedom [50, 58].
These models are used to understand local part of the cardiovascular system or of the
respiratory system with an excellent accuracy. On the other extreme of complexity lie
lumped parameter models, which gather different components of the system together in
several boxes [18, 107, 86, 105, 67, 93, 54, 9, 45]. Figure 3.5 illustrates these two extreme
methods for the modeling of the heart. In this example, the distributed method divides the
right ventricle, the right atrium, the left ventricle, the left atrium, the pulmonary artery
and the aorta in small pieces whereas the lumped method represents the heart with only
two boxes; one for the right ventricle and the other one for the left ventricle. To achieve
the goal of our study (rapid simulations which are identifiable in the ICU), the lumped
parameter method is chosen.
 
Distributed method 
Lumped method  
Right 
Ventricle Left Ventricle 
Figure 3.5 – Modeling of the heart with the distributed method (picture on the left [120]) and
with the lumped method (picture on the right).
This second part consists in two chapters. Chapter 4 describes our modeling of the
cardiovascular system connected to a va-ECLS. Even if the va-ECLS has gas exchange
functions, the mathematical model focuses only on the mechanical side of the system.
Chapter 5 describes our modeling of the respiratory system connected to a vv-ECLS. This
configuration assists only the lungs and the model thus focuses only on the gas exchanges
in the lungs, in the tissues and in the ECLS. Therefore, our cardiovascular model will not
be taken into account for the modeling of patients under vv-ECLS and the respiratory
model will not be taken into account for the modeling of patients under va-ECLS. In this
part, several parameters are introduced and their estimations will be described in Part III.

Chapter 4
Modeling of the cardiovascular system
connected to a va-ECLS
Most lumped parameter models of the cardiovascular system are derived from the Wind-
kessel model [18, 107, 86, 105, 67]. A certain amount of them are very complex and take
into account numerous compartments [67] while others try to be as simple as possible to
be identifiable in the ICU [89, 86]. However, all the models are composed with the same
elements: cardiac valves, cardiac chambers, vascular vessels with elastance and resistance
properties. Since the goal of our study is to build a tool that could help clinicians in their
therapeutic approach, the minimal cardiovascular model of Pironet et al. [89] is chosen.
Indeed, these authors have presented practical identifiability of the mathematical model
from limited clinical data. To obtain the mathematical model of the cardiovascular sys-
tem connected to a va-ECLS, this cardiovascular model is complemented by an additional
compartment describing the va-ECLS.
Several hypothesis are introduced to build this model:
• Blood is considered as incompressible
• The different compartments are elastic chambers linked together thanks to rigid
cylinders (the resistance and the compliance of blood vessels are uncoupled)
• Pressure is constant over the transversal section of the rigid cylinders and the pressure
gradient is constant along the rigid cylinders.
• Gravity is neglected
• Control systems are neglected
• Inertia of blood flows is neglected
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• The pulmonary circulation is not considered in this approach. The model is com-
posed of one ventricle which sucks blood in the vena cavae and rejects it in the
aorta.
This chapter is divided into 3 sections; section 4.1 describes the different elements
and concepts of the cardiovascular model, section 4.2 presents the ECLS compartment
and section 4.3 shows how the different elements are linked together and describes all the
differential equations of the cardiovascular model connected to a va-ECLS.
4.1 Cardiovascular model
The cardiovascular system is composed of active elements (the ventricles), passive elements
(the vascular system) and cardiac valves. The hemodynamics of this system derived from
the Windkessel model and this concept is described in subsection 4.1.1. The pressure
volume relationships are described by considering a new variable: the stressed volume,
and the concept of stressed and unstressed volumes is introduced in subsection 4.1.2.
Finally, the mathematical descriptions of the passive and active elements are explained in
subsection 4.1.3 and 4.1.4 respectively, while the mathematical description of the cardiac
vales is explained in subsection 4.1.5.
4.1.1 Windkessel model
In the 18th century, researchers realized that the cardiovascular system is similar to the
contemporary hydraulic system used by firemen (Figure 4.1). Indeed, the pump activity is
analogous to the ventricle contraction, the valves are analogous to the cardiac valves and
the accumulation chamber (VX in Figure 4.1) is analogous to the elastic properties of the
vascular system (arteries and veins, see subsection 2.1.3). In addition, the resistance in the
fire hose is also observed in the small vessels of the cardiovascular system (the arterioles,
see subsection 2.1.3).
This analogy leads to simple equations describing the cardiovascular system. The
volume variation in the accumulation chamber V˙X is equal to:
V˙X = QX = Qpump −QOUT , (4.1)
where QX is the water flow entering the accumulation chamber, Qpump is the water flow
ejected from the pump and QOUT is the water flow moving into the fire hose. The water
flow QOUT crossing the resistance R is equal to:
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Figure 4.1 – Origins of the Windkessel model (adapted from [83]). All the symbols are defined
in the text and in the list of symbols.
QOUT =
PX − Patm
R
, (4.2)
where PX is the hydraulic pressure measured before the fire hose and Patm is the atmo-
spheric pressure (the pressure measured after the fire hose). The volume VX is analogous
to the volume in the aorta where Qpump is the blood flow going out of the left heart, QOUT
is the blood flow crossing the small vessels (the arterioles and the capillaries) and PX is
the blood pressure in the aorta.
The cardiovascular system is composed of elastic chamber elements. Indeed, the ves-
sel walls are deformable and the vessel volumes follow the variations of blood pressures.
The pressure-volume relationship of the cardiac chambers are described in the following
subsections 4.1.3 and 4.1.4.
4.1.2 Stressed and unstressed volumes
The different equations written above describe the behavior of blood when it is stressed.
However, the whole amount of blood in the vascular system is not stressed; there is also a
quantity of blood which is not stressed. These two quantities are named the stressed blood
volume and the unstressed blood volume. Since the venous system hoards a large fraction
of blood, the unstressed volume is significant in the veins. In addition, the vein volumes
can vary according to patient needs and, thus, the unstressed volume is not constant for
different physiological conditions.
An hydraulic analogy of the unstressed and stressed volumes is depicted in the left
part of Figure 4.2. This drawing represents a large container which is supplied by one
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pipe located on the upper right of the picture. The container has also an outflow pipe
characterized by a resistance VenR. The unstressed volume (named Vu in the left picture
of Figure 4.2) is located at the bottom of the container, below the outflow pipe. This vol-
ume has thus no influence on the flow crossing the resistance VenR. On the contrary, the
stressed volume (named Vs in the left picture of Figure 4.2) is located above the outflow
pipe and this volume has a direct influence on the outflow. Indeed, if the stressed volume
increases, the pressure at the entrance of the outflow piper increases. Hence, this analogy
shows that the stressed volume contributes to the hemodynamics of the cardiovascular
system while the unstressed volume is responsible for the passive filling of the cardiovas-
cular system.
 
V s
V u
Figure 4.2 – Illustration of stressed and unstressed blood volumes [34, 68].
The right panel of Figure 4.2 represents the evolution of the Mean Circulatory Filling
Pressure (MSFP) in terms of the total blood volume in the cardiovascular system. The
MSFP is the blood pressure in the cardiovascular system when there is no hemodynamics.
In these conditions, there is no cardiac beat, no blood flow across the vessels and the blood
pressure is the same in all blood vessels. The MSFP is thus equal to zero when the total
blood volume is small since the vessels are not fully filled and the vessel walls undergo
no pressure. When the total blood volume reaches approximately 3 l for a healthy adult,
the MSFP becomes positive. First, the MSFP increases non-linearly with the total blood
volume. Then, when the total blood volume exceeds 4 l, the MSFP increases linearly with
the total blood volume. The equations written previously (equations 4.3 and 4.7) have
assumed this linear relationship.
4.1.3 Pressure-volume relationship for passive elements
As already mentioned in subsection 2.1.4 (see equations 2.4), the cardiac chamber volumes
and pressures are linked together with the elastance E or the compliance C of the cor-
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responding cardiac chamber. The approximation of constant elastance or compliance is
taken for granted for the passive elements and the following pressure-volume relationship
is written:
Pi(Vi) = Ei · (Vi − Vu,i) (4.3a)
=
1
Ci
· (Vi − Vu,i) , (4.3b)
where Pi and Vi are the pressure and the volume of the cardiac chamber i, Ei and Ci are
the elastance and the compliance of the cardiac chamber i and Vu,i is the volume of the
cardiac chamber i when the blood pressure Pi is equal to 0 (the cardiac chamber wall is
unstressed). This approximation is represented by the straight line in the left panel of
Figure 4.3.
For our cardiovascular model, the following change of variable is considered:
Vs,i = Vi − Vu,i , (4.4)
where Vs,i and Vu,i are the stressed and unstressed volumes of the cardiac chamber i. This
change of variable is illustrated on the right panel of Figure 4.3. If the change of variable
defined in equation 4.4 is used in equations 4.3, they become:
Pi(Vs,i) = Ei · Vs,i (4.5a)
=
1
Ci
· Vs,i , (4.5b)
4.1.4 Pressure-volume relationship for the active elements
The ventricles are active elements and, therefore, the pressure in these cardiac chambers
does not solely depend on the volume. Indeed, the ventricles are subject to contraction
and the pressure thus also depend on time. Consequently, the ventricles follow a cycle and
the pressure-volume relationship results in a pressure-volume loop (see subsection 2.1.1
and subsection 2.1.2). To describe these active elements with a mathematical model, the
time-varying elastance theory is commonly used in the literature [18, 107, 86, 105, 67] and
it is the most simple model to describe the ventricle activity. The time-varying elastance
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Chapter 4. Passive Elements: Resistances, Valves and Chambers
Equation 4.4 can also be adapted to take the blood’s inertia into account. Such
a valve model allows to reproduce the fact that the valves "open on pressure and
close on flow" [89,113]. However, adapting Equation 4.4 to include inertances is not
an easy task because the differential Equation 4.3 has to be solved a priori to know
when Q becomes negative, making simulation more computationally intensive.
4.4 Pressure-Volume Relationships of the Chambers
In lumped models of the CVS, passive elastic chamber elements are used to ac-
count for the deformable properties of the large vessels, namely the arteries and
veins. As its name indicates, the pressure-volume relationship of a chamber de-
scribes the relationship between the blood volume inside the chamber and the
pressure exerted by the chamber. The pressure-volume relationship is often de-
scribed using a convex function P(V) [109,114], an example of which is displayed
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Figure 4.4: Left: illustration of P(V) and its first-order Taylor approximation. Right:
illustration of the change of variables in Equation 4.11.
A first-order Taylor approximation of this function around a chosen working
point [109] V = V¯, yields
P(V) ⇡ P(V¯) + dP
dV
    
V=V¯
(V   V¯). (4.5)
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Figure 4.3 – The left panel illustrates the pressure volume relationship in the passive elements
and illustrates the linear approximation of this pressure volume relationship. The right panel
illustrates the change of variable Vs = V − Vu [86].
theory is based on 3 concepts: the EDPVR, the ESPVR and the cardiac driver function
e(t) (the EDPVR and the ESPVR have already been introduced in subsection 2.1.2). The
mathematical development of these 3 concepts are described in the following paragraphs.
EDPVR
The EDPVR describes the passive filling of the heart (Figure 4.4) and this curve can be
approached by an exponential [106, 18]:
Ped = Bh ·
(
eAh·(Vh−Vu,h) − 1) = Bh · (eAh·(Vs,h) − 1) , (4.6)
where Ped is the end-diastolic pressure in the heart, Vh is the heart volume, Vu,h and Vs,h
are the unstressed and stressed heart volumes. Like the passive elements, the change of
variable Vs = V − Vu is used. Ah and Bh are two parameters of the model.
ESPVR
The ESPVR can be determined by considering the PV loop of several physiological states
corresponding to different afterloads and different preloads (Figure 2.4 in subsection 2.1.2,
p. 16). The ESPVR corresponds to the top-left point of each of these loops and it has
been shown [109] that this line can be approximated by a straight line:
Pes = Eh · (Vh − Vu,h) = Eh · (Vs,h) , (4.7)
where Pes is the end-systolic pressure in the heart and Eh is the slope of the straight line.
Chapter 4. Modeling of the cardiovascular system connected to a va-ECLS 59
Eh is a parameter of paramount importance since it characterizes the contractility of the
heart. Like equation 4.6, the change of variable Vs = V − Vu is considered.
Figure 4.4 – Modeling of a cardiac cycle using the EDPVR and the ESPVR [105].
Cardiac driver function
The ESPVR and the EDPVR describe two extreme behaviors of the heart. To go from
one curve to the other one, a cardiac driver function e(t) is defined to have the following
pressure-volume relationship (Figure 4.5):
Ph = e(t) · Pes +(1− e(t)) · Ped
= e(t)Eh · Vs,h +(1− e(t)) ·Bh ·
(
eAh·Vs,h − 1) , (4.8)
where e(t) is defined to vary between 0 and 1; when e(t) = 1 the pressure volume rela-
tionship is defined by the ESPVR and when e(t) = 0 the pressure volume relationship
is defined by the EDPVR. Using the cardiac driver function, the entire PV loop can be
simulated. Several cardiac driver functions have been developed in literature. A common
one defines e(t) as an arithmetic series of exponential:
e(t) =
N∑
i=1
Ai · e−Bi·(t−Ci)2 , (4.9)
where the different parameters have the following values [107, 105]: N = 1, A1 = 1,
B1 = 80 s-2 and C1 = 0.27 s. However, these parameters do not depend on the heart
rate and are thus only valid for a human at rest in physiological conditions (heart rate
between 70 and 90 beats per minute). In our study, the model must be subject-specific
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and the heart rate can be high since the patient has cardiovascular pathologies. If the
parameters B1 and C1 are considered constant, the function e(t) defined by equation 4.9
presents non negligible discontinuities for high heart rates (the dashed lines presented in
Figure 4.6 illustrates this phenomena). Therefore, in our approach, e(t) is scaled according
to the cardiac period T and parameters B1 and C1 are replaced by B1,T and C1,T , which
are defined as follow:
{
B1,T (T ) = (β · T )−2
C1,T (T ) = γ · T
, (4.10)
where β and γ are constant parameters. For a heart rate of 80 beats per minute (a cardiac
period of 0.75 s), the following assumption can be taken
{
B1,T (0.75) = B1 = 80 s−2
C1,T (0.75) = C1 = 0.27 s
,
and the parameters β and γ can thus be estimated:
{
β = 0.149
γ = 0.36
.
In our cardiovascular model, the driver function e(t) is thus described with the following
equation:
e(t) = exp
[−B1,T · (t− C1,T )2] = exp [− 1
(0.149 · T )2 · (t− 0.36 · T )
2
]
. (4.11)
Figure 4.6 illustrates this function e(t) during two cardiac periods and for different heart
rates (80, 100, 120 and 150 beats per minute). The solid lines represent e(t) when the
parameters B1,T (T ) and C1,T (T ) are used while the dashed lines represents e(t) when the
parameters B1 and C1 are used. When the parameters of the e(t) function are constant,
Figure 4.6 shows that the function e(t) is not valid for heart rates larger than 120 beats per
minute. Indeed, for a heart rate of 150 beats per minute, the dash line shows a significant
discontinuity. Note that in order to represent the e(t) function for several cardiac periods,
the time t in equation 4.11 is replaced by t? and the relationship between these two times
is written as follow:
t? = mod( t , T ) (4.12)
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Figure 4.5 – Illustration of the e(t) function which allows to go from the EDPVR to the ESPVR
[107].
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Figure 4.6 – Illustration of the e(t) function during two cardiac cycles. The solid lines represent
the e(t) function defined by equation 4.11 while the dashed lines represent the e(t) function when
the constant parameter B1 = 80 s-2 and C1 = 0.27 s are used.
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4.1.5 Valve modeling
In the cardiovascular system, the cardiac valves allow the blood flow to circulate in only
one direction. If there is no cardiac valve, the blood flow can be written as equation 2.5
(see section 2.1.4, p. 21). However, when the blood flow crosses a cardiac valve, this
equation is not always right. For example, the water flow Qpump presented in Figure 4.1
has the following values:
Qpump =

0 si Ppump ≤ PX
Ppump − PX
Rvalve
si Ppump > PX
, (4.13)
where Ppump is the pressure in the pump of the hydraulic system presented in Figure 4.1
and Rvalve is the resistance of the valve located between the pump and the accumulation
chamber X. Using the Heaviside function H(x), equation 4.13 can be rewritten:
Qpump = H [Ppump − PX ] ·
Ppump − PX
Rvalve
. (4.14)
where:
H [Ppump − PX ] =
 0 si Ppump − PX ≤ 01 si Ppump − PX > 0 . (4.15)
4.2 va-ECLS
When the ECLS assists the heart, this device takes a fraction of the blood flow in the
veins and rejects it in the arteries (see section 3.3 for the details). The contribution of the
ECLS in the cardiovascular model is very simplified. The ECLS compartment is modeled
as a parameter input. This parameter is the extracorporeal blood flow beginning in the
vena cava and ending in the aorta.
4.3 Differential equations for the cardiovascular model
connected to a va-ECLS
The cardiovascular model is a minimal model to be identifiable in the ICU. This model has
only 3 compartments: one for the heart, one for the arteries and one for the veins. This
cardiovascular model is complemented by the ECLS compartment which takes a fraction
of blood in the vena cava and rejects it in the aorta.
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Figure 4.7 depicts a schematic representation of the 4 compartments model. The arter-
ies compartment is characterized by the two variables Pa and Vs,a for the blood pressures
and the stress blood volumes in the arteries and by one parameters Ea defining the elas-
tance of the arteries (see subsection 4.1.3). The veins compartment is characterized by
the two variables Pv and Vs,v for the blood pressure and the stress blood volume in the
veins and by one parameter Ev defining the elastance of the veins. The variables and the
parameters of the heart compartment have already be presented in subsection 4.1.4. The
blood flow ejected by the heart Qo is characterized by the resistance Ro (the resistance of
the output valve), the blood flow going from the arteries to the veins Qs is characterized
by the resistance Rs (systemic resistance) and the blood flow entering the heart Qi is char-
acterized by the resistance Ri (resistance of the input valve). The ECLS is characterized
by the extracorporeal blood flow Qd which takes blood in the vena cava (just before the
input valve) and rejects it in the aorta (just after the output valve).
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Figure 4.7 – Model of the respiratory system connected to a va-ECLS. All the symbols are
defined in the text of this chapter and in the list of symbols page xxiii.
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If equations 4.1 and 4.14 are applied to this model, the following differential equations
can be written:

V˙s,h = Qi −Qo = H(Pv − Ph) ·
Pv − Ph
Ri
− H(Ph − Pa) ·
Ph − Pa
Ro
V˙s,a = Qo −Qs +Qd = H(Ph − Pa) ·
Ph − Pa
Ro
− H(Pa − Pv) ·
Pa − Pv
Rs
+Qd
V˙s,v = Qs −Qi −Qd = H(Pa − Pv) ·
Pa − Pv
Rs
− H(Pv − Ph) ·
Pv − Ph
Ri
−Qd
,
(4.16)
where the pressures are related to the volumes by equation 4.8 for the heart compartment
and by equation 4.3 for the arteries and veins compartments.
If the 3 equations of system 4.16 are summed, the following equation is written:
V˙s,h + V˙s,a + V˙s,v = 0 . (4.17)
The right-hand side of equation 4.17 is equal to 0 and this confirms that the system is a
closed loop. The integration of both-hand side of equation 4.17 gives the following relation:
Vs,h + Vs,a + Vs,v = SBV , (4.18)
where SBV is the total stress blood volume and this parameter is constant in time.
4.4 Summary
This chapter has described the different components of the cardiovascular model assisted
by a va-ECLS. Like several cardiovascular models, this model is based on the Windkessel
model. The different components of the model are one active compartment (the heart),
two passive compartments (arteries and veins) and the va-ECLS compartment. For the
active and passive compartments, the pressure volume relationship has been described and
the blood flows going from one compartment to another have been modeled by taking into
account resistive elements and cardiac valves. In addition, the concept of unstressed and
stressed blood volume have also been introduced.
Chapter 5
Modeling of the respiratory system
connected to a vv-ECLS
Our model of the respiratory system connected to a vv-ECLS is a lumped parameter model
with 3 compartments: the lungs, the tissues and the vv-ECLS (the 3 compartments are
sketched in Figure 5.1 and this model has also been presented in the paper of Habran et
al. [45]). Every compartment is discussed in this chapter. In addition, a blood chemistry
model is needed and is discussed in section 5.4. Finally, the blood transport between the
compartments is also discussed in the last section of this chapter.
Several hypothesis are considered to build this model:
• The lungs are considered as one compartment. Hence, the right and left lungs behave
alike.
• Gas equilibrium are assumed between alveoli and pulmonary capillaries and between
tissues and systemic capillaries.
• Control systems are neglected.
• Temperature in the body, humidity in the body and ambiant pressure are assumed
constant and equal to 37°C, 47 mmHg and 760 mmHg respectively.
• Gravity is neglected.
• The mechanics of ventilation are not described in the model. The gas inflow and the
gas outflow are continuous and constant flows.
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Figure 5.1 – Model of the respiratory system connected to a vv-ECLS. All the symbols are
defined in the text of this chapter and in the list of symbols page xxiii.
5.1 Gas exchanges in the lungs
Our mathematical model of pulmonary gas exchanges is based on the work of Batzel et
al. [9]. This model considers that the diffusions of O2 and CO2 through the alveolar-
capillary membrane are fast so that equilibrium can be assumed between the alveoli and
the capillaries at the end of pulmonary capillaries. To include pulmonary gas exchanges
abnormalities, additional parameters and additional equations are required. Lungs failures
such as ARDS are complex phenomena and some authors describe this pathology by
dividing the lungs into 2 compartments to model ventilation/perfusion mismatch [93,
54]. Since the identification of the parameters of these 2 compartments is not easy (and
even impossible in our case with the available data in the ICU), a simpler description
will be used. A pulmonary shunt characterized by the fraction fs of the blood flow not
participating in the gas exchanges and an alveolar ventilation V˙A will be considered. The
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value of these 2 parameters will determine the global quality of gas exchanges which will
thus allow modeling lung pathologies in a simple way (Figure 5.1 and subsection 2.3.2,
p. 28, for more details). In this context, the material balances of O2 and CO2 in the lungs
can be written as:
VL,O2 · F˙L,O2 = (1− fs) ·Qp · (Cra,O2 − Cl,O2) + V˙A · (FI,O2 − FL,O2) , (5.1a)
VL,CO2 · F˙L,CO2 = (1− fs) ·Qp · (Cra,CO2 − Cl,CO2) + V˙A · (FI,CO2 − FL,CO2) , (5.1b)
where:
• VL,O2 (ml) and VL,CO2 (ml) are the effective volumes of O2 and CO2 in the lungs
(these two quantities are not equal because CO2 passes easier into solution and an
additional storage into lung tissues and fluid is observed for CO2 [9]),
• FL,O2 and FL,CO2 are the O2 and the CO2 volume fractions in the lungs (alveoli),
• fs is the fraction of the pulmonary blood flow crossing the pulmonary shunt,
• Qp (ml/s) is the pulmonary blood flow,
• Cra,O2 (mlO2/ml) and Cra,CO2 (mlCO2/ml) are the O2 and the CO2 blood concentra-
tions in the right atrium,
• Cl,O2 (mlO2/ml) and Cl,CO2 (mlCO2/ml) are the O2 and the CO2 blood concentrations
in the lungs (pulmonary capillaries),
• FI,O2 and FI,CO2 are the inspired fractions of O2 and CO2,
• V˙A (ml/s) = fr · (VT − VDead) is the alveolar ventilation. fr (s−1) is the respiratory
frequency, VT (ml) is the tidal volume and VDead (ml) is the dead space. Here V˙A
will be identified because the value of VDead cannot be measured in our experiments.
On the other hand, parameters VT and fr are settings of the ventilator.
The concentrations in blood are measured in STPD whereas the partial pressures in the
lungs are measured in BTPS. The acronym STPD stands for Standard Temperature and
ambient Pressure, water Dry and has the following features: the temperature is equal
to 0°C or 273°K and the pressure is equal to the standard atmospheric pressure without
water vapor (= 760 mmHg). The other acronym BTPS stands for Body Temperature
and ambient Pressure, water Satured and has the following features: the temperature is
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equal to 37°C or 310°K, the total pressure is equal to the atmospheric pressure Patm and
water vapor pressure is equal to 47 mmHg. Therefore, the concentration units have to be
changed from BTPS to STPD and this conversion is written as follows:
PSTPD · VSTPD
PBTPS · VBTPS =
n ·R · TSTPD
n ·R · TBTPS ⇔
760 · VSTPD
273
=
(Patm − 47) · VBTPS
310
⇔ VBTPS = 863
(Patm − 47) · VSTPD . (5.2)
If the concentrations in equations 5.1 are in STPD instead of BTPS, the equations 5.1
become:
VL,O2 · P˙L,O2 = 863 · (1− fs) ·Qp · (Cra,O2 − Cl,O2) + V˙A · (PI,O2 − PL,O2) , (5.3a)
VL,CO2 · P˙L,CO2 = 863 · (1− fs) ·Qp · (Cra,CO2 − Cl,CO2) + V˙A · (PI,CO2 − PL,CO2) , (5.3b)
where:
• PL,O2 (mmHg) = FL,O2 · (Patm − 47) and PL,CO2 (mmHg) = FL,CO2 · (Patm − 47) are
the O2 and CO2 partial pressures in the air contained in the lungs (alveoli),
• PI,O2 (mmHg) = FI,O2 · (Patm − 47) and PI,CO2 (mmHg) = FI,CO2 · (Patm − 47) are
the inspired O2 and CO2 partial pressures.
After the oxygenation and the decarboxylation of blood in the lungs, the pulmonary
blood is mixed with the venous blood from the shunt and the O2 and CO2 concentrations
in the arteries, Ca,O2 and Ca,CO2 , are given by:
Ca,O2 = fs · Cra,O2 + (1− fs) · Cl,O2 , (5.4a)
Ca,CO2 = fs · Cra,CO2 + (1− fs) · Cl,CO2 . (5.4b)
5.2 Gas exchanges in the tissues
The tissue compartment includes all the tissues in the body. These tissues produce CO2
and consume O2 while the CO2 removal and the O2 delivery is performed by the systemic
blood flow in the systemic capillaries. The diffusion between capillaries and cells is rapid
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and the hypothesis of equilibrium between the tissues and venous blood can be accepted.
The material balance equations for O2 and CO2 in the tissues are the same as Batzel et
al. [9] and are given by:
VT,O2 · C˙v,O2 = Qs · (Ca,O2 − Cv,O2)−MRO2 , (5.5a)
VT,CO2 · C˙v,CO2 = Qs · (Ca,CO2 − Cv,CO2) +MRCO2 , (5.5b)
where:
• VT,O2 (ml) and VT,CO2 (ml) are the effective volume of O2 and CO2 in the tissues,
• Cv,O2 (mlO2/ml) and Cv,CO2 (mlCO2/ml) are the O2 and the CO2 concentrations in
the veins,
• MRO2 (mlO2/s) and MRCO2 (mlCO2/s) are the quantities of O2 used and CO2 pro-
duced by metabolism, which will be considered as parameters of our model,
• Qs (ml/s) is the systemic blood flow.
In our study, the equality Qs = Qp is considered and both values are equal to the cardiac
output CO. In equations 5.5, the O2 and CO2 concentrations and the two parameters
MRO2 and MRCO2 are estimated in STPD.
5.3 Gas exchanges in the ECLS
When a vv-ECLS is used to help a patient, the mathematical model of gas exchanges
must be complemented by appropriate equations describing the behavior of the respira-
tory assistance. This device can be considered as a second lung compartment which takes
a fraction fd of the systemic blood flow Qs in the inferior vena cava and which rejects the
corresponding treated blood in the right atrium (Figure 3.1 in section 3.3, p. 42). However,
for the extracorporeal device, the diffusion of O2 and CO2 across the synthetic membrane
is slower than across the lung membrane and the exchange surface is smaller than the
alveolar-capillary membrane. The hypothesis of equilibrium between the gas and blood in
the device cannot be taken for granted and the diffusion of O2 and CO2 across the syn-
thetic membrane should be modeled. Several membranes are available on the market and
their features can be very different (geometry, surface area, membrane thickness, ...). In
our study, the membranes of Maquet® are used and a sketch of one of their gas exchangers
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(the Quadrox PLS®) is shown in Figure 5.2 [91]. The geometry is quite complex (simi-
lar to a cross-flow plate heat exchanger) and several assumptions have to be considered
to model this device. In the present work, 3 different models of gas exchanges across the
ECLS are going to be presented and discussed. These 3 models are illustrated in Figure 5.2.
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For the first model (named Mod 1 in Figure 5.2), the geometry of the device is reduced
to one dimension, and the gas and blood flows are considered in opposite directions (see
for instance [14, 66]). The material balance equations for O2 and CO2 in the gas and in
the blood are thus given by:
Gas
VD
∂FM,O2
∂t
− V˙D
∂FM,O2
∂X
= Sm ·Ds,O2(Pm,O2 − PM,O2) , (5.6a)
VD
∂FM,CO2
∂t
− V˙D
∂FM,CO2
∂X
= Sm ·Ds,CO2(Pm,CO2 − PM,CO2) , (5.6b)
Blood
Vd
∂Cm,O2
∂t
+Qd
∂Cm,O2
∂X
= Sm ·Ds,O2(PM,O2 − Pm,O2) , (5.6c)
Vd
∂Cm,CO2
∂t
+Qd
∂Cm,CO2
∂X
= Sm ·Ds,CO2(PM,CO2 − Pm,CO2) , (5.6d)
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where:
• FM,O2 and FM,CO2 are the O2 and CO2 volume fractions in the gas along the synthetic
membrane,
• Cm,O2(mlO2/ml) and Cm,CO2(mlCO2/ml) are the O2 and CO2 concentrations in blood
along the synthetic membrane,
• PM,O2 (mmHg) and PM,CO2 (mmHg) are the O2 and CO2 partial pressures in the gas
along the synthetic membrane,
• Pm,O2 (mmHg) and Pm,CO2 (mmHg) are the O2 and CO2 partial pressures in blood
along the synthetic membrane,
• V˙D and Qd (ml/s) are the gas and blood flows crossing the extracorporeal device,
• VD and Vd (ml) are the gas and blood volumes in the extracorporeal device,
• Sm (cm2) is the exchange surface of the synthetic membrane between the blood and
the gas,
• Ds,O2 (mlO2/s/mmHg/cm
2) and Ds,CO2 (mlCO2/s/mmHg/cm
2) are the O2 and the
CO2 diffusion coefficients across the synthetic membrane,
• X = x/L is the nondimensional 1-D coordinate, where x is the distance along the
membrane and L is the length of the membrane (for example, X=0 (resp. 1) corre-
sponds to the entrance of blood (resp. air) in the device).
The real exchange surface of the device is provided by the manufacturer but does not cor-
respond to the exchange surface of this one dimension model. Therefore, the global factors
Sm×Ds,O2 and Sm×Ds,CO2 need to be estimated and they can be considered as global O2
and CO2 diffusion coefficients DO2 (mlO2/s/mmHg) and DCO2 (mlCO2/s/mmHg). These
global coefficients are often used in literature [12, 74]. In equations 5.6, the first terms
on the left-hand sides describe the accumulation rates of O2 and CO2 in volumes VD and
Vd. The 4 boundary conditions give the values of the O2 and CO2 concentrations at the
gas and blood inlets. Since these two inlets correspond to X=0 and X=1 respectively, the
system of differential equations and boundary conditions must be solved iteratively (note
that Cm,i(0, t) = Cin,i and FM,i(1, t) = FID,i ; where i = O2 or CO2, Cin,i is the concen-
tration of component i at the inlet cannula and FID,i is the volume fraction of component
i in the gas entering the extracorporeal device).
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The second simplified model of gas exchanges in the device (named Mod 2 in Figure 5.2)
can be obtained by considering the two compartments in contact perfectly mixed. Hence,
there is no spatial dimension and the mass balance equations for O2 and CO2 in the 2
compartments are written as follows [116]:
Gas
VD · F˙D,O2 = V˙D · (FID,O2 − FD,O2)−D′O2 · (PD,O2 − Pout,O2) , (5.7a)
VD · F˙D,CO2 = V˙D · (FID,CO2 − FD,CO2)−D′CO2 · (PD,CO2 − Pout,CO2) , (5.7b)
Blood
Vd · C˙out,O2 = Qd · (Cin,O2 − Cout,O2)−D′O2 · (Pout,O2 − PD,O2) , (5.7c)
Vd · C˙out,CO2 = Qd · (Cin,CO2 − Cout,CO2)−D′CO2 · (Pout,CO2 − PD,CO2) , (5.7d)
where:
• FD,O2 and FD,CO2 are the O2 and CO2 volume fractions in the gas leaving the extra-
corporeal device,
• FID,O2 and FID,CO2 are the O2 and CO2 volume fractions in the gas entering the
extracorporeal device,
• D′O2 (mlO2/s/mmHg) and D
′
CO2
(mlCO2/s/mmHg) are the global O2 and CO2 diffu-
sion coefficients across the membrane,
• Pout,O2 (mmHg) and Pout,CO2 (mmHg) are the O2 and CO2 partial pressures at the
outlet cannula,
• Cout,O2 (mlO2/ml) and Cout,CO2 (mlCO2/ml) are the O2 and CO2 concentrations at
the outlet cannula,
• Cin,O2 (mlO2/ml) and Cin,CO2 (mlCO2/ml) are the O2 and CO2 concentrations at the
inlet cannula,
• PD,O2 (mmHg) and PD,CO2 (mmHg) are the O2 and CO2 partial pressures in the gas
leaving the extracorporeal device (PD,CO2 = FD,CO2×Patm and PD,O2 = FD,O2×Patm).
The left-hand sides of equations 5.7 describe the accumulation rates of O2 and CO2 in
volumes VD and Vd.
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Finally, in the third model (named Mod 3 in Figure 5.2) the hypothesis of equilibrium
between blood and gas (PD,CO2 = Pout,CO2) is considered and the mass balance equa-
tions 5.7 can thus be reduced to a single relation for O2 and CO2 material balances:
(VD + Vd) · F˙D,O2 = Qd · (Cin,O2 − Cout,O2) + V˙D · (FID,O2 − FD,O2) , (5.8a)
(VD + Vd) · F˙D,CO2 = Qd · (Cin,CO2 − Cout,CO2) + V˙D · (FID,CO2 − FD,CO2) . (5.8b)
For the 3 mathematical models of the vv-ECLS, the terms describing accumulation
rates in the volumes VD and Vd are small compared to the CO2 and O2 gas transfer.
Therefore, these terms will be considered as negligible in our simulations.
5.3.1 Mixing of the treated blood and the venous blood without
recirculation
The recirculation of blood in the extracorporeal blood flow is the fraction of blood leaving
the outlet cannula which enters the inlet cannula (Figure 5.3 illustrates this phenomenon).
In this study, if the recirculation is smaller than 10%, the mathematical model neglects this
contribution (the recirculation is smaller than 10 % when the extracorporeal blood flow
is smaller than 1l/min [16, 72]). With this assumption, after crossing the device, all the
treated blood enters the right atrium and is mixed with venous blood. The concentrations
of O2 and CO2 entering the right atrium is thus given by:
Cra,O2 = fd · Cout,O2 + (1− fd) · Cv,O2 , (5.9a)
Cra,CO2 = fd · Cout,CO2 + (1− fd) · Cv,CO2 , (5.9b)
where fd is the fraction of the systemic blood flow entering the inlet cannula:
fd =
Qd
Qs
. (5.10)
Furthermore, when the recirculation is neglected, the O2 and CO2 concentrations at the
inlet cannula (Cin,O2 and Cin,CO2) are equal to the O2 and CO2 concentrations in the veins
(Cv,O2 and Cv,CO2)
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5.3.2 Mixing of the treated blood and the venous blood with re-
circulation
If the recirculation is larger than 10 %, the recirculation is taken into account in the
mathematical model. In these circumstances, all the treated blood does not reach the right
atrium; a fraction Rrecir of this blood returns at the inlet cannula. The extracorporeal
blood flow Qd is thus composed of a fraction of the systemic blood flow entering the inlet
cannula (this blood flow is referred as (1− Rrecir) ·Qd in Figure 5.3) and of a fraction of
the treated blood flow which returns at the inlet cannula (this blood flow is referred as
Rrecir · Qd in Figure 5.3). Hence, equation 5.10 is not valid with recirculation and this
equation becomes:
fd =
(1−Rrecir) ·Qd
Qs
. (5.11)
In addition, the O2 and CO2 concentrations at the inlet cannula are not equal to the
O2 and CO2 concentrations in the veins but are the mixing of the venous blood and the
treated blood with the following proportions:
Cin,O2 = Rrecir · Cout,O2 + (1−Rrecir) · Cv,O2 , (5.12a)
Cin,CO2 = Rrecir · Cout,CO2 + (1−Rrecir) · Cv,CO2 . (5.12b)
The value of Rrecir is not easy to estimate and can vary according to the different
cannulae available on the market or even according to the surgeon abilities to insert the
cannulae. Several authors have suggested that this recirculation depends linearly on the
extracorporeal blood flow [72, 16]. The following relation can thus be written:
Rrecir = krecir ·Qd , (5.13)
where krecir is the coefficient of recirculation. In our study, this parameter is assumed to
be unchanged and equal to 0.0833 min/l [72].
5.4 Blood chemistry
In previous equations, concentrations and partial pressures in blood have been introduced.
To estimate how these two quantities are connected, a chemical model is needed. In Chap-
ter 2 (section 2.2), the complexity of the blood chemistry has already been discussed. In-
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Figure 5.3 – Recirculation of the extracorporeal blood flow during vv-ECLS (adapted from [59]).
All the symbols are defined in the text (i = O2 or CO2) and in the list of symbols page xxiii.
deed, O2 and CO2 are not only dissolved in blood plasma since they can also be complexed
with hemoglobin. In addition, CO2 is also subject to the hydratation/dehydratation reac-
tion (see equation 2.8, p. 26) which influences pH. Therefore, the relations between partial
pressures and total concentrations of gases are really complex in blood. In the model, the
relation between the total O2 concentration CO2 and the O2 partial pressure PO2 follows
the equations of Grodins et al. [37]:
CO2 = 4 · CHb · SatO2(PO2) + αO2 · PO2 , (5.14a)
SatO2 =
(
1− exp(−S · PO2)
)2
, (5.14b)
S = 0.44921 · pH − 0.10098 · pH2 + 0.0066815 · pH3 − 0.454 , (5.14c)
where:
• CHb (mlHb/ml) is the hemoglobin concentration,
• SatO2 is the saturation of hemoglobin with O2,
• S (mmHg−1) is an empiric parameter which accounts for the Bohr effect,
• αO2 (mlO2/ml/mmHg) is the solubility coefficient of O2 in blood plasma.
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The first term on the right-hand side of equation 5.14a describes the concentration of O2
complexed with hemoglobin whereas the second term describes the concentration of O2
dissolved in blood plasma. The relations between the total CO2 concentration CCO2 , the
pH in blood plasma and the CO2 partial pressure PCO2 follow the equations of Trueb et
al. [113]:
CCO2 = (0.149− 0.014 · SatO2(PO2)) · PCO20.35 + kHCO3 , (5.15a)
CPl,CO2 = (1.19 + (4 · CHb − 0.2)) · CCO2 , (5.15b)
pH = − log10
(
KHCO3 ·
αCO2 · PCO2
CPl,CO2 − αCO2 · PCO2
)
, (5.15c)
where:
• kHCO3 (mlCO2/ml) is a correction term which is introduced to compensate for varia-
tions between individuals in standard HCO3 concentration [113],
• CPl,CO2 (mlCO2/ml) is the total CO2 concentration in blood plasma,
• KHCO3 is the equilibrium constant of chemical reaction 2.8 (see page 26),
• αCO2 (mlCO2/ml/mmHg) is the solubility coefficient of CO2 in blood plasma.
The first term on the right-hand side of equation 5.15a describes the CO2 concentration for
the three species (dissolved in blood plasma, complexed with hemoglobin and under the
form of HCO3). Figure 5.4 illustrates equation 5.15a for different SatO2 when kHCO3 = 0.
Note that the Haldane effect is taken into account by equation 5.15a since Figure 5.4 shows
an increase in the CO2 complexed with hemoglobin when SatO2 decreases.
This section shows that O2, CO2 and pH are linked to each other and have to be
estimated simultaneously (see equations 5.14 and 5.15).
5.5 Transport delays
The blood leaving the pulmonary capillaries does not reach the systemic capillaries instan-
taneously and transport delays must be taken into account. Delays are the durations of
the blood transport to reach the different parts of the body compartments. For example,
the CO2 and O2 concentrations at the entrance of the pulmonary capillaries at time t are
equal to the CO2 and O2 concentrations in the right atrium (Cra,CO2 and Cra,O2) at an
earlier time (t−τ). The time that blood needs to cross a part i of the body is proportional
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Figure 5.4 – Total CO2 concentration as a function of CO2 partial pressure for different
hemoglobin saturations with O2. These curves are obtained using equation 5.15a when kHCO3 = 0.
to the volume of blood contained in i and is inversely proportional to the cardiac blood
flow Qi which crosses this part i:
τi =
χi · VTB
Qi
, (5.16)
where VTB is the total blood volume and χi is the blood volume ratio of part i. In our ap-
proach, 3 vascular delays are necessary and the 3 following symbols are used: i = LT , TH,
HL (Figure 5.5). Symbol LT refers to the transport of blood from the lungs (pulmonary
capillaries) to the tissues symbol, TH refers to venous transport from the tissues to the
heart (right atrium) and symbol HL refers to transport from the heart (right atrium) to
the lungs (pulmonary capillaries). In this model, the different cardiac blood flowsQi can be
considered as equal to the cardiac output CO (note that the hypothesis of Qp = Qs = CO
has already been introduced in section 5.2).
The delays τ
IN
and τ
OUT
related to the transport to and from the vv-ECLS are deter-
mined by the priming volumes V
IN
and VOUT of the pipes connecting the device to the
body. These delays can be estimated as follows:
τ
i
=
Vi
Qd
, (5.17)
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Figure 5.5 – The delays in the respiratory system. All the symbols are defined in the text of
this section and in the list of symbols page xxiii.
where i = IN or OUT.
Taking the delays into account, the differential equations presented before become delay
differential equations and, for instance, equations 5.3, 5.4 and 5.5 become:
Lungs
VL,O2 · P˙L,O2(t) = 863 · (1− fs) ·Qp · (Cra,O2(t− τHL)− Cl,O2(t))
+ V˙A · (PI,O2 − PL,O2(t)) , (5.18a)
VL,CO2 · P˙L,CO2(t) = 863 · (1− fs) ·Qp · (Cra,CO2(t− τHL)− Cl,CO2(t))
+ V˙A · (PI,CO2 − PL,CO2(t)) , (5.18b)
Ca,O2(t) = fs · Cra,O2(t− τHL) + (1− fs) · Cl,O2(t) , (5.18c)
Ca,CO2(t) = fs · Cra,CO2(t− τHL) + (1− fs) · Cl,CO2(t) , (5.18d)
Tissues
VT,O2 · C˙v,O2(t) = Qs · (Ca,O2(t− τLT )− Cv,O2(t))−MRO2 , (5.18e)
VT,CO2 · C˙v,CO2(t) = Qs · (Ca,CO2(t− τLT )− Cv,CO2(t)) +MRCO2 . (5.18f)
5.6 Summary
Chapter 5 has described the different compartments of the respiratory model assisted by
a vv-ECLS. The different compartments are the lungs, the tissues and the ECLS. For the
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ECLS compartment, 3 mathematical models have been built and, when the extracorporeal
blood flow is equal or larger than 1 l/min, a recirculation of this blood flow is taken into
account. In addition, the blood chemistry model and the transport delays are included in
the model and have also been described in this chapter.

Part III
Identification
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After developing the differential equations of the mathematical model, several param-
eters have to be estimated in order to simulate our model. Most parameters are estimated
using experimental measurements and are thus subject-specific, but some parameters are
also taken from literature and are thus identical for different animals or for different pa-
tients. In our study, several retrospective experiments and several retrospective clinical
trials are analyzed. For the animal experiments, pigs have been chosen because their car-
diovascular and respiratory physiologies are similar to human.
In this third part of this thesis, two chapters are introduced. Chapter 6 describes the
parameter estimation for the model of the cardiovascular system connected to a va-ECLS
while Chapter 7 describes the parameter estimation for the model of the respiratory system
connected to a vv-ECLS.

Chapter 6
Identification of the cardiovascular
model connected to a va-ECLS
The identification of the cardiovascular model connected to a va-ECLS consists in estimat-
ing the parameters of the equations describing the model dynamics (equations 4.3, 4.8, 4.16
and 4.18). These parameters are estimated using experimental or clinical measurements.
Therefore, the first section of this chapter describes the experimental animal trials and the
clinical trials carried out in the CHU of Liège (CHU is the French abbreviation of Centre
Hospitalier Universitaire). However, the number of measurements is limited (mainly for
the clinical trials) and all the parameters cannot be identified; some of them are taken
from literature and are thus assumed to be identical for all subjects. Section 6.2 discusses
which parameters are identified and develops different methods to estimate them.
6.1 Experimental and clinical data
6.1.1 Animal experiments
Animal experiments, approved by the Ethics Committee of the Medical Faculty of the
University of Liège, are carried out on 8 Pietrain pigs.
At the beginning of the experiments, the pigs are anesthetized and intubated. The
ventilator is set to a tidal volume of 10 ml/kg, an FI,O2 of 0.5, a respiratory frequency of
20 respirations per minute and a PEEP (Positive End-Expiratory Pressure) of 5 mmHg.
Three catheters (Transonic®, USA) are placed in the cardiovascular system: an admit-
tance pressure-volume catheter is inserted in the left carotid artery and placed in the left
ventricle (the left picture of Figure 6.1), a pressure catheter with two sensors (the distance
between the two sensors is equal to 40 cm) is inserted in the right femoral artery and placed
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in the aortic arch and a pressure catheter with one sensor is inserted in the femoral venous
and placed in the inferior vena cava (the right picture of Figure 6.1). A Forgarty balloon
is also placed in the inferior vena cava in order to modify the preload of the ventricle.
Using the 3 catheters, the blood pressures in the left ventricle, in the aortic arch, in the
vessel located 40 cm below the aortic arch (in the iliac artery) and in the inferior vena
cava are continuously measured as well as the left ventricular volume. Using the Forgarty
balloon, the left ventricle PV loop can be shifted to the left when the balloon is inflated
and the contractility of the left ventricle can be estimated (see subsection 2.1.2 p. 14). In
addition, the stroke volume and the cardiac output are also evaluated by echocardiography
and can be compared to the stroke volume obtained with the pressure volume catheter.
Furthermore, two cannulae to be connected to the va-ECLS are placed in the cardiovas-
cular system: one is inserted in the left femoral artery and placed in the aorta and one is
inserted in the left jugular vein and placed in the superior vena cava (near the right atrium).
	 Pressure-Volume
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Figure 6.1 – Catheters inserted in the cardiovascular system. The left picture illustrates an
admittance pressure-volume catheter inserted in the left ventricle [111] while the right picture
illustrates a pressure catheter inserted in a cardiovascular vessel (adapted from [112]).
After the introduction of all the measurement instruments, the balloon and the cannu-
lae, all the data are recorded and this data defines the baseline situation. Then, a cardiac
arrest is induced by an electric current leading to a ventricular fibrillation. This current
is maintained during 5 min and the ventilation is stopped during this state. Then, the
ventilator is restarted with the same settings than before except for the FI,O2 which is
increased to 1. In addition, a va-ECLS (CARDIOHELP®, Getinge, Sweden) is connected
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to the cannulae and an extracorporeal blood flow is initiated with blood extracted in the
vena cava and reinjected in the aorta. The settings of this extracorporeal device are such
that the extracorporeal blood flow is as large as possible (the inlet pressure must be larger
than -60 mmHg), the gas flow is equal to 8 l/min and the fraction of O2 in the gas en-
tering the device is equal to 1. Furthermore, a defibrillator is used to restore a normal
sinus rythm. If the mean arterial blood pressure is smaller than 60 mmHg, a drug, called
noradrenaline, is injected to ensure a mean arterial blood pressure larger than 60 mmHg.
When the cardiovascular system connected to the va-ECLS is stabilized, weaning tests
are performed with a procedure relatively similar to the ones carried out on patients in the
ICU. To simulate these weaning tests, the extracorporeal blood flow is gradually decreased
by approximately 15 % every 5 min. At the end of each of these steps, the ventilator is
turned off during 1 min to remove the effects of breathing on the circulatory system.
During this phase, the experimental data are recorded. In the present study, the pressure
in the aortic arch will not be used and only the distal arterial pressure (the pressure in
the iliac artery) will be considered for the identification. Indeed, the sensor in the aorta
is close to the arterial cannula and the effect of the re-injected extracorporeal blood flow
is better taken into account if the pressure measurements are taken in the iliac artery.
In addition, this location is more appropriate to compare animal experiments with ICUs
since the arterial measurement taken in the ICU corresponds to the peripheral arterial
pressure and not to the aortic blood pressure. The end of the weaning test is defined when
the extracorporeal blood flow reaches approximately 0.3 l/min. Like the other steps, the
extracorporeal blood flow is maintained for 5 min, the ventilator is turn off during 1 min
and the experimental data are recorded. Then, the extracorporeal blood flow is increased
and fixed to its initial value (an extracorporeal blood flow as large as possible with the
constraint of an inlet pressure larger than -60 mmHg). After at least 30 min of stabilization,
this weaning test is restarted again once or twice according to the experimental conditions.
6.1.2 Application in the ICU
Since the final goal of our study is to improve the therapeutic approaches of va-ECLS in the
ICU, the validation of the mathematical model with pig experiments is not sufficient and
the mathematical model must also be validated with clinical data. These data are taken
from several patients suffering from various acute heart diseases and assisted by a va-ECLS.
Data available in the ICU are extracted from measurement instruments that are less
invasive than those used in the lab: the stroke volume and the diastolic volume are esti-
mated by echocardiography (pressure-volume catheter is not inserted in the left ventricle
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of a patient), the arterial pressure is estimated using the arterial line with a pressure trans-
ducer and the venous pressure is estimated using the central venous line with a pressure
transducer (Figure 6.2).
The different data are recorded during the weaning test from a va-ECLS with the fol-
lowing protocol. At the beginning of the test, all the hemodynamic data (the diastolic and
systolic pressures in the arteries, the mean venous pressure in the veins, the stroke volume
and the diastolic volume in the left ventricle) are recorded. Then, the extracorporeal blood
flow is gradually decreased by approximately 1 l/min every 5 min until reaching an extra-
corporeal blood flow of 0.5 l/min. For each extracorporeal blood flow, the hemodynamic
data are recorded.
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Figure 6.2 – Estimation of arterial and venous blood pressures in the ICU (adapted from
[52, 19]).
6.2 Identification of the parameters
6.2.1 Identification of the parameters for one given extracorporeal
blood flow
The cardiovascular model connected to a va-ECLS contains 9 parameters (Ri, Ro, Rs,
Bh, Ah, Eh, Ea, Ev, SBV , see section 4.3, p. 62) which have to be estimated from the
available data. These data are continuous blood pressures in the arteries and veins, the
stroke volume in the left ventricle and the diastolic volume in the left ventricle. For the
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blood pressure in the arteries, two essential values are extracted: the mean blood pressure
and the pulse blood pressure (or the amplitude blood pressure). For the blood pressure
in the veins only the value of the mean blood pressure can be extracted. Indeed, this
signal is not accurate enough to extract its amplitude. Consequently, the parameter Ev
cannot be estimated from clinical data since it depends strongly on this amplitude. In our
study, this parameter is thus considered constant and its value is taken from literature
(Table 6.1). Three of the 8 remaining parameters must also be extracted from literature
and considered constant since only 5 measurements are available (3 blood pressures and
2 blood volumes). These parameters are Ri, Ro and Bh and their values are presented in
Table 6.1. Indeed, Ri and Ro are non-identifiable with the available data since the blood
pressure in the heart is not estimated in the ICU. In addition, if the subject does not have
any valve pathology, the resistance of the valves should not vary much between different
subjects or between different hemodynamic situations. Note then, the two parameters of
the EDPVR equation, Bh and Ah, cannot be both identified with the available data. In
our study, we assume that parameter Ah is more likely to change since, in previous studies
[18, 105], Bh is identical for both ventricles while Ah is smaller for the right ventricle than
the left ventricle. Therefore, Ah is taken as a patient-specific parameter and Bh is taken
from literature (Table 6.1). To summarize, the remaining 5 parameters Rs, Ah, Eh, Ea
and SBV are estimated using the vector ydata containing the following 5 elements:
ydata =

P a
PPa
P v
maxT(Vh)
SV
 , (6.1)
where:
• P a is the mean blood pressure in the arteries. For the pig experiments and for the
clinical trials, this value is estimated with the following equation: P a = 13maxT(Pa)+
2
3
minT(Pa), where maxT(Pa) and minT(Pa) are respectively the maximum and the
minimum of the blood pressure in the arteries during one cardiac period [64].
• PPa is the pulse blood pressure in the arteries. For the pig experiments and for the
clinical trials, this value is estimated by subtracting the diastolic blood pressure in
the arteries (minT(Pa)) from the systolic blood pressure in the arteries (maxT(Pa)).
• P v is the mean blood pressure in the veins. For the pig experiments, this value is
estimated by calculating the mean venous pressure for one beat. On the other hand,
for the clinical trials, P v is directly displayed by the manometer (Figure 6.2).
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• maxT(Vh) is the maximum blood volume in the heart during one cardiac period. For
the pig experiments, this quantity is estimated using the pressure-volume catheter
in the left ventricle, and, for the clinical trials, it is estimated by echocardiography
of the left ventricle during the end-diastolic period.
• SV is the stroke volume. For the pig experiments, SV is estimated using the
pressure-volume catheter and by subtracting the minimum blood volume in the
left ventricle (minT(Vh)) from the maximum blood volume in the left ventricle
(maxT(Vh)). For the clinical trials, SV is estimated using Doppler echocardiog-
raphy. With this technique, the clinicians estimate the VTI (velocity time integral)
of flow through the left ventricular outflow tract (LVOT) and the diameter of the
LVOT φLV OT [32]. With these two values, the stroke volume is estimated as follows:
SV = pi
(
φLV OT
2
)2
V TI . (6.2)
Furthermore, the cardiovascular model connected to a va-ECLS contains 2 other parame-
ters, the heart rate HR (HR = T−1) and the extracorporeal blood Qd which are directly
measured in our lab and in the ICU. Remark that Table 6.1 summarizes all the parameters
of this mathematical model.
Note that for the animal experiments, data are recorded on several cardiac beats.
Therefore, the 5 values in vector ydata are the means of the different quantities for the
considered beats. For the clinical trials, only one measurement of P a, PPa, P v, maxT(Vh)
and SV is recorded in vector ydata.
If p is the vector containing the 5 parameters, the parameter identification is performed
by finding p = p∗ which minimizes the error function Ψ, defined as follows [89]:
Ψ(p) =
m∑
k=1
(
ydatak − ymodelk (p)
σk
)2
, (6.3)
where:
• m = 5 is the size of vector ydata,
• ymodel(p) is the same vector than ydata but the different hemodynamic values are
estimated with the mathematical model when the parameter values are defined by
the vector p and
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• σk are standard errors related to the different elements of vector ydata. These quan-
tities are defined more precisely below.
With the experimental data, the means of the different elements of vector ydata are esti-
mated for each extracorporeal blood flow of the different weaning tests carried out on the
8 pigs. For each extracorporeal blood flow, a standard error σk is associated to each ele-
ments. In the present study, the mean of these errors will be used for taking into account
the experimental errors in our lab and the different values of σk are given in Table 6.2.
Since these standard errors cannot be estimated with clinical data (only one measurement
is recorded), the standard errors of the clinical trials will be assumed the same as the pig
experiments. The quantitative values of these errors is certainly erroneous for the clinical
trials since the clinical environment is different than the lab environment but the quali-
tative values should be relatively similar. Indeed, the volume measurements such as the
stroke volume are always less accurate than the blood pressure measurements [87]. It is
thus preferable to put more importance on the errors between simulated and measured
blood pressures than on the errors between simulated and measured ventricular volumes.
This important consideration is taken into account by minimizing Ψ(p) defined in equation
6.3.
Table 6.1 – Parameters of the cardiovascular model connected to a va-ECLS
Parameters Descriptions Values
Identified parameters
Ah Exponential parameter of the EDPVR equation Subject-specific
Ea Elastance of the arteries Subject-specific
Eh Slope of the ESPVR equation Subject-specific
Rs Systemic resistance Subject-specific
SBV Stress blood volume Subject-specific
Measured parameters
HR Heart rate Subject-specific
Parameters taken from the literature
Bh Pre-exponential parameter of the EDPVR equation 0.35 mmHg [18]
Ev Elastance of the veins 0.014 mmHg/ml [18]
Ri Resistance of the input valve 0.015 mmHg · s/ml [18]
Ro Resistance of the output valve 0.03 mmHg · s/ml [18]
ECLS settings
Qd Extracorporeal blood flow Chosen by the clinicians
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Table 6.2 – The different measurement standard errors
Measurement σ
maxT(Vh) 2 ml
PPa 0.4 mmHg
P a 0.2 mmHg
P v 0.1 mmHg
SV 3 ml
6.2.2 Identification of the parameters corresponding to several
extracorporeal blood flows
One should remember that the goal of our mathematical model is to predict the behavior
of the cardiovascular system when the extracorporeal blood flow is decreased. However,
if the extracorporeal blood flow decreases, the cardiovascular system changes significantly
since the preload is decreased and the afterload is increased. It thus seems reasonable
to assume that all the parameters of the cardiovascular system are not constant if the
extracorporeal blood flow varies. The simplest way for taking into account the variation
of the parameters with Qd is to assumed a linear relationship. If this assumption is taken
for the 5 subject-specific parameters, the following equations can be written:

Ah = ASl,h ·Qd + A0,h
Eh = ESl,h ·Qd + E0,h
Ea = ESl,a ·Qd + E0,a
Rs = RSl,s ·Qd +R0,s
SBV = SBVSl ·Qd + SBV0
, (6.4)
where: ASl,h, A0,h, ESl,h, E0,h, ESl,a, E0,a, RSl,s, R0,s, SBVSl and SBV0 are the 10 pa-
rameters whose values must be determined from the available data. To estimate these
parameters, the identification procedure introduced before must be modified as follows.
The extracorporeal blood flow is an input of the cardiovascular system connected to
a va-ECLS and the medical team can control this quantity. The identification of the
parameters can thus be carried out with the same measurements as in the previous section
but the measurements related to different extracorporeal blood flows will be taken into
account and a new error function Ψ is introduced:
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Ψ(p) =
n∑
j=1
m∑
k=1
(
ydatak,j − ymodelk,j (p)
σk
)2
, (6.5)
where n is the number of the different extracorporeal blood flows, p is the vector of the
10 sought coefficients and m = 5 is the number of measurements for one extracorporeal
blood flow. With this method, the number of measurements is multiplied by the number of
extracorporeal blood flows used for the identification. Since 10 values must be identified,
m must be larger than or equal to 2.
6.3 Summary
This chapter has presented how the different parameters of the cardiovascular system
connected to a va-ECLS can be estimated. Section 6.1 has described the experimental
protocol and the clinical protocol that provide the experimental and clinical data and
section 6.2 has explained 2 different methods to estimate the parameters of the model with
experimental or clinical data. The first method identifies 5 parameters of the cardiovascular
model using the experimental or clinical data corresponding to one extracorporeal blood
flow while the second method identifies the 10 coefficients describing the same parameters
using the experimental or clinical data corresponding to at least 2 different extracorporeal
blood flows.

Chapter 7
Identification of the respiratory model
connected to a vv-ECLS
The identification of the respiratory model connected to a vv-ECLS consists in estimating
the parameters of the equations describing the model dynamics described previously in
Chapter 5 (equations 5.18 for the lungs and tissues, equations 5.6 to 5.13 for vv-ECLS,
equations 5.14 and 5.15 for blood chemistry and equations 5.16 and 5.17 for transport
delays). Most parameters are subject-specific and are thus evaluated using experimental
or clinical measurements. Therefore, the first section of this chapter describes the exper-
imental animal trials and the clinical trials carried out in the CHU of Liège. Afterwards,
the second section discusses how the different parameters are estimated from the measure-
ments and which parameters are taken from literature (these parameters are assumed to
be identical for the different subjects).
7.1 Experimental and clinical data
7.1.1 Animal experiments
A new technology of vv-ECLS is used in our animal trials: the extracorporeal CO2 re-
moval device (ECCO2RD, see section 3.3, p. 43). Two sets of retrospective experiments
(approved by the Ethics Committee of the Medical Faculty of the University of Liège)
including an ECCO2RD are used for testing the mathematical model. The first set of
experiments, that are referred to as experiments H in the text below, are carried out on
4 healthy pigs, named H1 to H4, subject to protective ventilation (ventilation with small
tidal volume, this concept has already been described in section 3.3, p. 42). For the second
set of experiments, that are referred to as experiments A, 6 animals (labelled A1 to A6)
are analyzed and ARDS is induced in addition to protective ventilation (for the detailed
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protocol of the induction of ARDS, see Morimont et al. [76]).
At the beginning of both sets of experiments, the pigs are anesthetized and intubated.
After a 30 min stabilization period, whose end defines the baseline situation, several ex-
perimental data (blood flow, CO2 and O2 concentrations in venous and arterial blood
samples) are measured and the settings of the ventilator are also recorded. Then, pro-
tective ventilation is started. In experiments A, ARDS is induced during this phase of
the protocol by the normal saline lavage method [76]. After approximately 45 minutes
of protective ventilation, the ECCO2RD (PALP®, Getinge, Sweden) is switched on to
remove the excess CO2. In all experiments, the gas flow through the device is set to 10
liters of atmospheric air per minute. The blood flow in the ECCO2RD is fixed to several
values between 0.2 and 0.8 l/min (the values of the extracorporeal blood flow are specified
in Chapter 9).
The cardiac output is measured with the thermodilution technique (PiCCO®, Pulsion,
Germany) and also with an admittance pressure-volume catheter (Transonic®, USA) in
the right ventricle. Tidal volume, FI,O2 , respiratory frequency and driving pressure are
fixed by the ventilator (Engström Carestation®, General Electric, USA) and note that
FI,CO2 is always equal to 0. Arterial and venous blood samples are analyzed during the
experimentation with a RapidPoint500® device (Siemens, Germany). In experiments H,
additional blood samples are analyzed at the inlet and outlet cannulae and the gas exiting
the ECCO2RD is also analyzed with a CARBOCAP® device (Vaisala, Finland).
Note that the two sets of experiments are important for the purpose of our work since
they complement one another. Experiments H are needed because more data are available
and the estimation of all the parameters of the model is feasible. However, the model must
also be validated in case of gas exchange abnormalities. Therefore, experiments A are also
needed since an ARDS is induced.
7.1.2 Application in the ICU
Clinical data are also used for the parameter estimations and the protocol should be similar
to the pig experiments. Actually, a European study has been launched recently to prove
the beneficial effects for the lungs of protective ventilation coupled with an extracorporeal
CO2 removal therapy (ECCO2RT) for patients suffering from moderate ARDS; this study
is called Supernova [81] and is referred to as clinical trial S in the text below. However,
only one patient (S1) was recruited in this study at the CHU of Liège and we did not
get access to the other patients’ data. Therefore, an additional retrospective clinical trial,
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that is referred to as clinical trial R, is analyzed even if the extracorporeal device used is
not an ECCO2RD but a traditional vv-ECLS (this device is also used to oxygenate blood).
For both sets of clinical trials, the baseline situation is defined as the situation just
before the initialization of the extracorporeal device. The baseline is thus different from
that of the animal trials since the patients have lung failures at that time. Then, the
extracorporeal device is switched on and the protective ventilation is induced after a few
minutes. The ventilator and the extracorporeal device settings are recorded at least every
hour and several blood samples are taken in the veins, in the arteries, at the inlet and
outlet cannulae. The cardiac output is estimated with an electrocardiograph manipulated
by an experienced physician.
Whereas clinical trial R have no rigorous protocol (the protective ventilation and the
extracorporeal device settings are chosen according to the patient and are specified in
Chapter 11), clinical trial S follow a strict protocol and the most important features
are following. The inclusion criteria of clinical trial S are a mechanical ventilation with
expected duration longer than 24 hours and a patient with moderate ARDS (Pa,O2/FI,O2 :
200-100 mmHg [31]). For the baseline situation, the tidal volume is set to 6 ml/kg and
is maintained constant during two hours. Then, the ECCO2RD is switched on and the
protective ventilation is progressively induced by decreasing the tidal volume from 6 ml/kg
to 5 ml/kg when the ECCO2RD is switched on, from 5 ml/kg to 4.5 ml/kg after 45 min
of ECCO2RT and from 4.5 ml/kg to 4 ml/kg after 90 min of ECCO2RT. The gas flow
through the device is set to 6 liters of atmospheric air per minute and the blood flow in the
ECCO2RD is set to 1 l/min. The membrane of the ECCO2RD used in the CHU of Liège is
an HLS Set Advanced 5.0® (Maquet, Getinge, Sweden). For each step (baseline situation,
VT = 5 ml/kg, VT = 4.5 ml/kg and VT = 4 ml/kg), blood samples are taken in the veins,
in the arteries, at the inlet and outlet cannulae. The ventilator and extracorporeal device
settings are also recorded for each step.
7.2 Identification of the parameters
As already mentioned, several parameters describe the patient’s status and must be esti-
mated with several measurements. These parameters are thus subject-specific and their
estimation, which is described below, is of paramount importance. Other parameters are
simply the settings of the devices or are considered constant and identical for all subjects.
All the parameters of the respiratory system connected to a vv-ECLS are summarized in
Table 7.1.
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The parameters related to the blood chemistry and transport delays are described in
subsections 7.2.1 and 7.2.2 respectively while those related to the tissues and the lungs
are discussed in subsections 7.2.3 and 7.2.4 respectively. In addition, the value of the
diffusion coefficients characterizing the membrane of the vv-ECLS is not provided by the
manufacturer and this quantity must also be considered as a parameter. Its value is
determined by a procedure which is explained in the last subsection below.
7.2.1 Blood chemistry
Quantity kHCO3 in equations 5.15 (see section 5.4, p. 74) is a subject-specific parameter
and it must be evaluated for each pig or each patient. Its value is assumed constant in time
and can be estimated using equations 5.15 and the values of pH, PCO2 and the hemoglobin
saturation with O2 in the arteries during baseline situation. Parameter CHb is directly
estimated from blood sample analysis. The other parameters, αO2 , αCO2 and KHCO3 , are
considered constant and their values are taken from the literature (Table 7.1). Even if
these chemical constants are derived from human studies, the same values are used for pig
experiments. This assumption is reasonable since the human blood is very similar to the
pig blood.
7.2.2 Transport delays
To estimate the delays in the respiratory system, the values of the blood volume ratio (χi)
are adapted from the work of Willem van Meurs [114] (Table 7.1) where the unstressed
volumes in the different compartments are proposed. The total blood volume VTB is as-
sumed proportional to the body weight and its value is adapted from [18] (where this
value is given for a man of 75 kg) and gives VTB = 73 · Weight (kg) ml. For example, the
transport delay of the whole cardiovascular system (τLT + τTH + τHL) for a man of 75 kg
with a cardiac output of 5.5 l/min is equal to approximately 1 minute (1× 73× 75/5500).
These values of χi and VTB are used for both the pig experiments and the clinical trials
even if the human morphology is quite different from that of pigs. However, the delays
only impact the unstationary behavior of the system and a rough approximation for these
parameters is thus enough for the goal of our analysis.
For the delays τ
IN
and τ
OUT
, which are the times to go from the inlet cannula to the
ECLS and to go from the ECLS to the outlet cannula, they depend on the ECLS used.
For the Maquet products, the PALP membrane has a priming volume of 250 ml [38]
and the other membranes (PLS, HLS advanced 5.0 and 7.0) have a priming volume of
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Table 7.1 – Parameters of the respiratory model connected to a vv-ECLS
Parameters Descriptions Values
Identified parameters
DCO2 CO2 diffusion coefficient across the synthetic mem-
brane
Membrane-specific
DO2 O2 diffusion coefficient across the synthetic mem-
brane
Membrane-specific
fs Pulmonary shunt Subject-specific
kHCO3 Correction term for variations between individuals
in standard HCO3 concentration
Subject-specific
MRCO2 Quantities of CO2 produced by metabolism Subject-specific
MRO2 Quantities of O2 used by metabolism Subject-specific
V˙A Alveolar ventilation Subject-specific
Measured parameters
CHb Hemoglobin concentration Subject-specific
CO Cardiac output (in this model CO = Qs = Qp) Subject-specific
Parameters taken from the literature
αCO2 Solubility coefficient of CO2 in blood plasma 6.9 · 10−4 lCO2/l/mmHg
[94]
αO2 Solubility coefficient of O2 in blood plasma 2.837·10−5 lO2/l/mmHg
[94]
KHCO3 Equilibrium constant of chemical equation 2.8 10
−6.1 [94]
VL,CO2 Effective volume of CO2 in the lungs 43 · Poids (kg) ml [9]
VL,O2 Effective volume of O2 in the lungs 33 · Poids (kg) ml [9]
VIN Volume that blood crosses to go from the inlet can-
nula to the ECLS
125 ml for PALP, 300 ml
for others [38, 40, 39]
VOUT Volume that blood crosses to go from the ECLS to
the outlet cannula
125 ml for PALP, 300 ml
for others [38, 40, 39]
VT,CO2 Effective volume of CO2 in the tissues 200 · Poids (kg) ml [9]
VT,O2 Effective volume of O2 in the tissues 80 · Poids (kg) ml [9]
VTB Total blood volume 73 · Poids (kg) ml [18]
χLT Blood volume ratio of pulmonary veins, left heart
and systemic arteries
30.2 % [114]
χTH Blood volume ratio of systemic veins 66.3 % [114]
χHL Blood volume ratio of right heart and pulmonary
arteries
3.5 % [114]
Ventilator settings
FI,CO2 Inspired fraction of CO2 0
FI,O2 Inspired fraction of O2 Chosen by the clinicians
ECLS settings
FID,CO2 Fraction of CO2 at the gas inlet 0
FID,O2 Fraction of O2 at the gas inlet Chosen by the clinicians
Qd Extracorporeal blood flow Chosen by the clinicians
V˙D Ventilation of the ECLS Chosen by the clinicians
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approximately 600 ml [40, 39]. The priming volume is the quantity of saline water one has
to fill in the extracorporeal circuit before switching on the ECLS. In our study, we consider
that half of this volume corresponds to the inlet circuit and the other half corresponds to
the outlet circuit. Therefore, V
IN
= VOUT = 125ml when the PALP membrane is used and
V
IN
= VOUT = 300 ml when other membranes are used.
7.2.3 Gas exchanges in the tissues
MRCO2 andMRO2 describe the CO2 production and O2 consumption by the tissue. These
parameters are assumed not to be affected by the ventilator settings or by the induction of
ARDS. These quantities are thus estimated only at baseline situation for each individual.
Parameter MRO2 can be determined using the values of cardiac output and O2 concen-
trations in arterial and venous blood samples in a time independent situation. For the
CO2 production in the tissues, the equalityMRCO2 = MRO2 is assumed. In clinical trials,
cardiac output and O2 concentrations in arterial and venous blood samples are rarely esti-
mated together in the ICU during baseline situation. Therefore,MRCO2 andMRO2 cannot
be identified before the ECLST and these two parameters could be assumed proportional
to the body weight. If this approximation is used, their values could be adapted from [9]
(where these parameters are given for a man weighting 75 kg) and give the following rela-
tion: MRCO2 = MRO2 = 3.6 · Weight (kg) ml/min. Another solution is to estimate these
two parameters with arterial and venous blood samples in a time independent situation
and with a weight based approximation of the cardiac output. An approximation of the
cardiac output can be obtained by using the cardiac index which is the cardiac output
divided by the body surface area (BSA, see for instance the Mosteller formula [115]). A
standard value of the cardiac index is 3 l/min/m2 when the patient is at rest [80, 96]. Note
also that the body temperature of the animals is not perfectly controlled in our pig exper-
iments and a significant decrease in the temperature is observed as soon as the ECCO2RT
is started (blood loses heat in the pipes and in the device). This temperature decrease
induces a change in metabolism and the values of MRCO2 and MRO2 have to be modified
accordingly (see Appendix A for the details). However, since the temperature of the body
is controlled in the ICU, this decrease is not observed in clinic. MRCO2 and MRO2 are
thus kept constant in our clinical trials.
The other two parameters in the tissues are VT,CO2 and VT,O2 . These effective volumes
are assumed proportional to the body weight and their values are adapted from [9] where
these parameters are given for a man weighting 75 kg (the values are given in Table 7.1).
These values are used for the pig experiments and for the clinical trials. The morphology
of humans and pigs is of course different and taking the values adapted from Batzel et
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al. for the pig experiments is thus a rather rough approximation. However, the effective
volumes influence just the unstationary terms of the system, which is not of paramount
importance for the goal of this paper.
7.2.4 Gas exchanges in the lungs
Parameters fs and V˙A are used to describe the global efficiency of gas exchanges in the
lungs and their estimation is crucial. To our knowledge, this approach is unique in the
literature since it is the first time that the pulmonary gas exchange abnormalities are de-
scribed with these two parameters when an ECLS is connected to the respiratory system.
The settings of the ventilator (tidal volume and respiratory frequency) and ARDS notably
influence the gas exchange. Parameters fs and V˙A must thus be re-evaluated each time
these settings are modified and after the induction of ARDS for experiments A. For ex-
ample, these quantities must be identified twice in pig experiments (once during baseline
situation and once during protective ventilation, combined with ARDS induction in exper-
iments A) and 4 times in the clinical trial Supernova (baseline situation, VT = 5 ml/kg,
VT = 4.5 ml/kg and VT = 4 ml/kg). The identification of these parameters is obtained
by fitting the measurements of arterial PCO2 and PO2 (the venous counterparts being
linked to the arterial values by the previously determined MRCO2 and MRO2) with the
corresponding simulated values. During baseline, the system is stabilized and the variables
are thus time independent. The identification of these parameters is more difficult for the
other situations. Indeed, for the pig experiments, the protective ventilation is usually too
short (less than 45 min) to reach a real steady state in the respiratory system. Therefore,
the fitting of fs and V˙A is based on the comparison of the measurements and the time
evolution obtained from the solution of the differential equations. Since the unstationary
evolution of PCO2 and PO2 obtained with the mathematical model is based on several
rather rough assumptions, only the last measurements are used to estimate fs and V˙A
during this period. For the clinical trials, the protective ventilation is induced during the
extracorporeal therapy. Since the final goal of the study is to predict the O2 and CO2 time
evolutions when the ECLS is switched on, fs and V˙A must be estimated before the ECLST.
Therefore, the only method to estimate these parameters is to predict their variations for
a given decrease in tidal volume. This method will be presented in Chapter 11.
The other 2 parameters in the lungs are VL,CO2 , VL,O2 . These effective volumes are
assumed proportional to the body weight and their values are adapted from [9] like in the
tissues (the values are given in Table 7.1 and they are used for pig experiments and clinical
trials).
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7.2.5 ECLS
The CO2 and O2 exchanges in the ECLS are characterized by the CO2 and O2 diffusion
coefficients across the synthetic membrane. Their values are independent of the patient’s
status and ventilator settings. For the first model (Mod 1, see Figure 5.2, p. 70), DCO2
and DO2 can be obtained by fitting the predictions of equations 5.6 (with VD = Vd = 0)
with the measures of PCO2 and PO2 at the inlet and outlet canulae and, for the pig
experiments, with the measures of PCO2 in the gas flowing out of the device. For the
second model (Mod 2, see Figure 5.2, p. 70), D′CO2 and D
′
O2
can be obtained by fitting the
predictions of equations 5.7 (with VD = Vd = 0) with the measures of PCO2 and PO2 at
the inlet and outlet canulae and, for the pig experiments, with the measures of PCO2 in
the gas flowing out of the device.
For the O2 diffusion coefficients across the synthetic membrane DO2 and D
′
O2
, the
measurements of the O2 fraction in the gas flowing out of the ECLS was not available.
In addition, the accuracy of O2 concentration measurements in blood is not high enough
to estimate DO2 and D
′
O2
in our pig experiments. For these reasons, DO2 and D
′
O2
are
assumed to be 40 times smaller than DCO2 and D
′
CO2
respectively for the pig experiments
as is the case of the heart-lung machine described in [74]. This estimation of DO2 and
D′O2 is a bit rough but it is still sufficient for the main purpose of this work. Indeed, this
quantity has only a minute influence on the time evolution of PCO2, which is the main
quantity of interest for the pig experiments.
7.3 Summary
This chapter has described the methods to estimate the parameters of the respiratory
model connected to a vv-ECLS with experimental data. The identification of the pa-
rameters is carried out in each compartment (tissues, lungs and ECLS) independently
(see subsection 7.2.3, 7.2.4 and 7.2.5) and several differences between pig experiments and
clinical trials have also been underlined in this chapter. In addition, some parameters
cannot be estimated with our animal experiments and clinical trials and their values are
taken from literature, especially for the parameters related to the blood chemistry (see
subsection 7.2.1) and related to the transport delays (see subsection 7.2.1).
Part IV
Animal experiments
103

105
After building the mathematical model, we used several experiments in order to vali-
date it. With these experiments, all the subject-specific parameters can be estimated (see
part III) and the mathematical model can then be used to start simulations. This part of
the thesis shows the results of the pig experiments and discusses the values of the different
parameters. It also analyzes the validity of the mathematical model by comparing the
experimental data with the simulations.
This fourth part includes two chapters. Chapter 8 describes, discusses and analyzes
the results of the pig experiments under va-ECLS while Chapter 9 describes, discusses and
analyzes the results of the pig experiments under vv-ECLS.

Chapter 8
Experiments with a va-ECLS
The protocol of the animal experiments has already been described in subsection 6.1.1,
p. 85. With the experimental data, all the subject-specific parameters can be estimated and
their values are presented in section 8.1. To identify all the parameters, the measurements
corresponding to the first 3 extracorporeal blood flows of a weaning test are considered.
After estimating all the parameters, the mathematical model of the cardiovascular system
connected to a va-ECLS can be used to predict the evolution of the system for other
extracorporeal blood flows. In order to validate the predictions of the mathematical model
describing the weaning of a va-ECLS, the simulations are compared to experimental data
and the results are presented in section 8.2. Afterwards, another approach, consisting in
identifying the parameters with the measurements related to all the extracorporeal blood
flows, is introduced in section 8.3. Then, all the results are discussed and analyzed in
section 8.4 and the limitations of our model are outlined in section 8.5. Finally, section
8.6 summarizes the results of this chapter.
8.1 Values of the parameters
8.1.1 During baseline situation
The values of the parameters are estimated during baseline situation (this phase corre-
spond to the data recorded before the cardiac arrest, see subsection 6.1.1). During this
phase, the parameter HR is directly measured and the 5 parameters of the mathemat-
ical model are estimated using the methods described in subsection 6.2.1 (minimize the
function Ψ(p) defined by equation 6.3) for Qd = 0 l/min. With this method and our ex-
perimental data, the errors between the simulated values and the measurements are very
small (Ψ(p∗) ≈ 0) and the values of the 5 parameters and HR for each pig are given in
Table 8.1. All the parameters are of the same order of magnitude for the different pigs
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and these baseline values will be used to compare the baseline situation with the ECLST
situation.
Table 8.1 – Values of the 5 parameters and of the heart rate during baseline situation.
Data Pig1 Pig2 Pig3 Pig4 Pig5 Pig6 Pig7 Pig8 Mean ± σ
Parameter identification
Eh (mmHg/ml) 1.17 1.15 1.24 1.74 1.75 1.25 2.37 1.58 1.53 ± 0.42
SBV (ml) 846 1046 1064 1764 691 1093 1085 961 1069 ± 314
Ah (ml−1) 0.025 0.052 0.046 0.035 0.035 0.032 0.054 0.031 0.039 ± 0.011
Ea (mmHg/ml) 0.82 1.47 1.72 0.83 1.70 1.40 2.03 1.59 1.44 ± 0.43
Rs (mmHg·s/ml) 0.93 1.58 1.62 0.91 2.05 1.63 2.21 1.83 1.59 ± 0.47
Heart rate measurement
HR (s−1) 1.26 1.18 1.35 1.69 1.17 1.23 1.31 1.33 1.32 ± 0.17
8.1.2 During ECLST
For the parameter identification during ECLST, HR and Qd are directly measured and
the values of HR in terms of Qd for each weaning test are presented in Figure 8.1. Except
for Pig1 and Pig3, two weaning tests (labeled T1 and T2) are carried out for each pig.
Whereas the first 4 panels in Figure 8.1, which refer to the weaning tests Pig1 T1 to Pig3
T1, depict only 3 crosses, the other panels, which refer to the weaning tests Pig4 T1 to
Pig8 T2, depict 3 crosses and several diamonds. The experimental data related to the 3
highest Qd (the crosses) are distinguished from the other Qd (the diamond) because the
measurements related to these two sets of Qd do not have the same function. Indeed, the
measurements related to the 3 highest Qd are used for the parameter identification while
the measurements corresponding to the others Qd are used for testing the predictions of
the mathematical model. When testing the prediction of the model, the values of HR
represented by the diamonds cannot thus be used as input data and an estimation of these
quantities must be evaluated. In the present study, a linear relationship between HR and
Qd will be assumed:
HR = HRSl ·Qd +HR0 , (8.1)
where HRSl and HR0 can be estimated for each weaning test, using only the HR values
described by the crosses in Figure 8.1.
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Figure 8.1 – Heart rate in terms of Qd for the different weaning tests. The crosses correspond
to the experimental data used for the parameter identification and the diamonds correspond to
the experimental data used for testing the predictions of the mathematical model.
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The values of HRSl and HR0 for each weaning test are given in Table 8.2. Except
for the weaning tests Pig2 T2 and Pig4 T1, Figure 8.1 shows that HR decreases with the
decrease in Qd. The values of HRSl, given in Table 8.2, show similar results (except for
2 weaning tests, HRSl is positive) except for the weaning test Pig8 T1 (for this weaning
test, the 3 first data do not have the same trend than all the 8 data).
The values of the 10 coefficients, ESl,a, E0,a, SBVSl, SBV0, ASl,h, A0,h, ESl,a, E0,a, RSl,s
and R0,s are determined by the method presented in section 6.2 using n = 3. Their values
are provided in Table 8.2 for each weaning test. Note that the values of the independent
terms in equation 6.4 are of the same order for the different weaning tests. However, the
values of the slopes in equation 6.4 are quite different for the different pigs and even for
different weaning tests of a given pig.
In the minimization process allowing the identification of the 10 coefficients, the mini-
mum value of Ψ(p), Ψ(p∗), is not equal to 0 (Table 8.3) and there is thus an error between
the experimental data and the corresponding values estimated by the mathematical model.
It is interesting to analyze separately the errors corresponding to the different components
of the vector defined in equation 6.1 and it is worth introducing the following quantities:
|∆PPa/PPa| = 1
n
n∑
j=1
1
n
|PP sima,j − PP expa,j |
PP expa,j
, (8.2)
|∆P a/P a| = 1
n
n∑
j=1
|P sima,j − P expa,j |
P
exp
a,j
, (8.3)
|∆P v/P v| = 1
n
n∑
j=1
1
n
|P simv,j − P expv,j |
P
exp
v,j
, (8.4)
|∆maxT(Vh)/maxT(Vh)| = 1
n
n∑
j=1
|maxT(Vh,j)sim −maxT(Vh,j) exp|
maxT(Vh,j)exp
, (8.5)
|∆SV/SV | = 1
n
n∑
j=1
|SV simj − SV expj |
SV expj
, (8.6)
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where |∆PPa/PPa| is the mean relative error between simulated and experimental PPa,
while index j corresponds to the different values of Qd. The other symbols defined in
equation 8.3 to 8.6 have similar meanings. In order to estimate if the model tends to
overestimate or to underestimate the experimental data, the mean relative errors are also
computed without the absolute values (and the corresponding symbols are written as
∆P a/P a, ∆PPa/PPa, ∆P v/P v, ∆maxT(Vh)/maxT(Vh) and ∆SV/SV ). Remember that
for the parameter identification, n = 3 in equations 8.2 to 8.6.
The different errors are given in Table 8.3. This table shows that the errors between
the measurements and the corresponding simulated value are in fact quite small: for all the
weaning tests, the means |∆PPa/PPa|, |∆P a/P a|, |∆P v/P v| and |∆maxT(Vh)/maxT(Vh)|
are all smaller than 2 % and the mean |∆SV/SV | is smaller than 3 %. Table 8.3 also
shows that the simulated venous pressure overestimates the measured venous pressure
(∆P v/P v = 1%) while there is no global overestimation or global underestimation for the
other quantities.
8.2 Predictions of the mathematical model
Once all the parameters of the mathematical model are estimated, the model can be used
to predict the evolution of the cardiovascular system during a weaning test. To estimate
the quality of these predictions, the simulated values are compared with the experimental
data. Figure 8.2 illustrates the evolution of simulated and experimental hemodynamic
variables of Pig8 for the two weaning tests T1 and T2. The simulated values are de-
picted by solid lines while experimental data are depicted by crosses and diamonds. As
already mentioned, the experimental data depicted by crosses are used for the parame-
ter identification while the experimental data depicted by diamonds are used to validate
the mathematical model. In this figure, the agreement between the simulations and the
crosses is very good and this fact has already been discussed for all the weaning tests
in the previous section. On the other hand, Figure 8.2 shows a rather small difference
between the simulations and the diamonds. The results for the weaning tests Pig4 T1 to
Pig7 T2 have similar features and are given in Figure B.1 and Figure B.2 of Appendix B.1.
To quantify the differences between the simulations and the experimental data (the
diamonds), the different values of ∆PPa/PPa, ∆P a/P a, ∆P v/P v, ∆maxT(Vh)/maxT(Vh)
and ∆SV/SV are calculated with and without the absolute values for each weaning test
(these symbols have already been defined by equations 8.2 to 8.6). Table 8.4 gives all these
values for the weaning tests Pig4 T1 to Pig8 T2. For the weaning tests Pig1 T1 to Pig3 T1,
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Figure 8.2 – Evolution of P a, PPa, P v, maxT(Vh) and SV in terms of different Qd for the
two weaning tests Pig8 T1 and Pig8 T2. The solid lines are the simulations and the crosses and
diamonds are the experimental data (the difference between diamonds and crosses has already
been explained in Figure 8.1).
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these values cannot be estimated since the hemodynamic data related to only 3 Qd were
recorded during the weaning tests. Table 8.4 provides also the number n of the different
Qd used to compare the predictions with the experimental data. This table shows that
the errors are small for PPa, P a, P v and maxT(Vh) (the mean of |∆P a/P a|, |∆PPa/PPa|,
|∆P v/P v|, |∆maxT(Vh)/maxT(Vh)| for all the tests are all smaller or equal to 5 %) but
it shows a more significant, but still acceptable, error for SV (|∆SV/SV | = 9.2%). This
table also shows that there is no global overestimation or global underestimation of the
different hemodynamic data simulated with the mathematical model.
8.3 Improving the parameter identification by using all
the Qd
Another approach to analyze the validity of the model is to identify the parameters using
measurements related to all the Qd. In this context, the predictions of the mathematical
model cannot, of course, be tested, but one can check that the mathematical model can
reproduce the general behavior of the cardiovascular system during a weaning test. The
parameter identification used here is similar to the previous one except that the measure-
ments related to all the Qd are used in equation 6.5 (with this method, the diamonds
depicted in Figure 8.1 and Figure 8.2 are replaced by crosses). The 10 values of the linear
coefficients estimated with this method are given in Table 8.5 and the relative differ-
ences between the simulated and experimental values for ∆PPa/PPa, ∆P a/P a, ∆P v/P v,
∆maxT(Vh)/maxT(Vh) are given in Table 8.6 (the values for Pig1 to Pig3 are not given
since they are the same as those in Table 8.2 and Table 8.3). Note that the corresponding
evolution of simulated and experimental hemodynamic variables for the weaning tests Pig4
T1 to Pig8 T2 are given in Figure B.3, Figure B.4 and Figure B.5 of Appendix B.1.
Except the values of Esl,a and Asl,h, the values provided in Table 8.5 are quite similar
to those given in Table 8.2. On the other hand, Table 8.6 shows larger errors with the
parameter identification using the measurements related to all the Qd than with the pre-
vious parameter identification (Table 8.3). Nevertheless, these errors are still acceptable
since the means |∆PPa/PPa|, |∆P a/P a|, |∆P v/P v| and |∆maxT(Vh)/maxT(Vh)| are all
smaller than 2.5 % and the mean |∆SV/SV | is smaller than 5 %. Finally, as expected,
Table 8.5 shows smaller errors with the parameter identification using the measurements
related to all the Qd than those obtained with the predictions (Table 8.4).
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8.4 Discussion
8.4.1 Values of the parameters for Qd = 0
Table 8.1 has shown the values of the 5 parameters during baseline situation and Table 8.2
has shown the coefficients of the linear development of the parameters in terms of Qd.
These developments can be used to calculate the values of the parameters corresponding
to Qd = 0 and these values can be compared with the corresponding quantities in Table 8.1.
Note however that, during ECLST, noradrenaline is injected to maintain a mean arterial
pressure larger than 60 mmHg. This drug influences the parameters of the cardiovascular
system since it is known to increase the contractility of the heart and to constrict the
blood vessels. To carefully compare these 2 sets of parameters values, Table 8.7 provides
all these quantities and also mentions the injection of noradrenaline. The mean SBV ,
Ah and Ea for all the pigs during baseline situation are relatively similar to, respectively,
the mean SBV0, A0,h and E0,a during ECLST. On the other hand, the mean Eh during
baseline situation is larger than the mean E0,h and the mean Rs during baseline situation
is a little bit larger than the mean Rs,0. A decrease in Eh after the baseline situation
corresponds to a reduction of the contractility of the heart. These results make sense
since the cardiovascular system has been perturbed and traumatized after the baseline
situation. Moreover, a septic shock was observed after the induction of the ventricular
fibrillation and this pathology reduces the systemic resistance Rs. Table 8.7 also shows
that the decrease in Eh,0 is even more significant when there is no noradrenaline injection
during the weaning test (see Pig1 T1, Pig5 T1, Pig7 T1, Pig7 T2, Pig8 T1 and Pig 8 T2).
This result confirms the influence of noradrenaline, which increases the heart contractility.
Therefore, the evolution of parameters E0,h and R0,s seems to be of paramount importance
to check the evolution of the cardiovascular system.
8.4.2 Variations of the parameters with Qd
Table 8.2 has also provided the slopes of the parameters with respect to Qd. These
quantities are of paramount importance since they describe the variation of the parameters
with the extracorporeal blood flow. With these values, the response of the cardiovascular
system to the decrease in Qd can be investigated. In order to analyze these variations
easier, one can calculate the following relative variations of the 5 parameters for a change
of Qd equal to 1l/min:
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∆1Eh/Eh =
Eh(Qd = 1 l/min)− Eh(Qd = 0 l/min)
Eh(Qd = 0 l/min)
, (8.7a)
∆1SBV/SBV =
SBV (Qd = 1 l/min)− SBV (Qd = 0 l/min)
SBV (Qd = 0 l/min)
, (8.7b)
∆1Ah/Ah =
Ah(Qd = 1 l/min)− Ah(Qd = 0 l/min)
Ah(Qd = 0 l/min)
, (8.7c)
∆1Ea/Ea =
Ea(Qd = 1 l/min)− Ea(Qd = 0 l/min)
Ea(Qd = 0 l/min)
, (8.7d)
∆1Rs/Rs =
Rs(Qd = 1 l/min)−Rs(Qd = 0 l/min)
Rs(Qd = 0 l/min)
. (8.7e)
It is worth remembering that the 5 slopes have been identified with the measurements
related to 3 different Qd. With the aim of analyzing the variations of the 5 parameters
with more reliability, the 10 coefficients of the linear expression of the 5 parameters can
also be identified using the measurements related to all the Qd (see section 8.3) and the
corresponding values of ∆1Eh/Eh, ∆1SBV/SBV , ∆1Ah/Ah, ∆1Ea/Ea and ∆1Rs/Rs can
also be estimated.
Figure 8.3 represents ∆1Eh/Eh for each weaning test for the 2 parameter identifications
(the parameter identification using only 3 Qd is represented by the full bars while the
parameter identification using all the Qd is represented by the empty bars). This figure
demonstrates that ∆1Eh/Eh is always positive for the parameter identification using all
the Qd. This implies that Eh always decreases when Qd decreases. Such a change of the
contractility with Qd is not surprising since the preload and the afterload change with Qd.
Indeed, the load independence of the ventricle contractility is only true for an instantaneous
variation of the PV loop [77, 65, 56]. In the situation analyzed in our work, the preload and
afterload are changed for a relative long time (approximately 5 min between 2 different Qd)
and the heart has time to adjust its activity. The results for the parameter identification
using 3 Qd is similar except for Pig5 T1 which has a much larger value of ∆1Eh/Eh and for
Pig4 T2 and Pig6 T2 for which a small negative value is found. Note that the 2 parameter
identifications are identical for Pig1 T1, Pig2 T1, Pig2 T2 and Pig3 T1 since there is only
3 Qd available for these weaning tests.
Figure 8.4 describes ∆1SBV/SBV . For both parameter identification, the values are
small in comparison with ∆1Eh/Eh and the signs vary between the different weaning tests.
Except for Pig8 T1 and Pig8 T2, the parameter identification using 3 Qd has the same
trend as the other parameter identification.
Figure 8.5 represents ∆1Ah/Ah. The signs vary between the different weaning tests
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Figure 8.3 – Values of ∆1Eh/Eh for each weaning test when only 3 Qd are used for the parameter
identification (full bars) and when all the Qd are used for the parameter identification (empty
bars).
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Figure 8.4 – Values of ∆1SBV/SBV for each weaning test when only 3 Qd are used for the
parameter identification (full bars) and when all the Qd are used for the parameter identification
(empty bars).
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Figure 8.5 – Values of ∆1Ah/Ah for each weaning test when only 3 Qd are used for the parameter
identification (full bars) and when all the Qd are used for the parameter identification (empty
bars).
Chapter 8. Experiments with a va-ECLS 123
and the parameter identification using 3 Qd does not have the same trend as the other pa-
rameter identification but, for both parameter identifications, the values are much smaller
than the values of ∆1Eh/Eh.
Figure 8.6 represents ∆1Ea/Ea. This figure demonstrates that parameter Ea varies
significantly and the sign of ∆1Ea/Ea changes between the different weaning tests. The
variations of Ea thus do not have a clear trend. In addition, there is a significant difference
between the values of ∆1Ea/Ea obtained with the 2 parameter identifications. A possible
explanation of this result is that coefficient Esl,a is very sensitive to experimental errors
and physiological interpretations of the variation of Ea are quite delicate.
Finally, Figure 8.7 describes ∆1Rs/Rs. This figure demonstrates that ∆1Rs/Rs is
almost always negative. Parameter Rs thus increases when Qd decreases. This result
could possibly be related to the baroreflex (see section 2.4, p. 35). Indeed, when Qd
decreases, the aortic pressure decreases and, in order to restore a higher blood pressure in
the arteries, the nervous system constricts small vessels, which increases Rs.
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Figure 8.6 – Values of ∆1Ea/Ea for each weaning test when only 3 Qd are used for the parameter
identification (full bars) and when all the Qd are used for the parameter identification (empty
bars).
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Figure 8.7 – Values of ∆1Rs/Rs for each weaning t when only 3 Qd are used for the parameter
identification (full bars) and when all the Qd are used for the parameter identification (empty
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8.4.3 Prediction of the mathematical model
Table 8.4 has shown small prediction errors for PPa, P a, P v and maxT(Vh) (relatives errors
smaller or equal to 5 %) and a relative error of approximately 9 % for SV . These errors
are acceptable and the larger error for SV makes sense since the measurements of SV are
not very accurate.
Another important information is to check that the model allows a better prediction of
the physiologically relevant quantities than a simple interpolation from previous measure-
ments. Indeed, the model, after the parameter identification using PPa, P a, P v, maxT(Vh)
and SV measurements related to 3 different Qd, allows to predict the evolution of these
quantities for lower values of Qd. Another approach could consist in linearly interpolating
the quantities corresponding to the 3 Qd. Figure 8.8 compares these two methods for
determining the evolutions of SV and P a during the weaning test Pig8 T1. This figure
illustrates that better predictions of SV and P a are obtained by using our mathematical
model. The quantitative errors for the predictions obtained with the interpolations can
also be estimated and compared with the previous errors obtained with the mathematical
model. Table 8.8 shows that the predicted values of P a, P v and SV are slighty better
with the model than with the interpolation but the predicted values of PPa is little worse
with the model than with the interpolation. However, the values of PPa are notably less
important for the patient monitoring than the other hemodynamic quantities.
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Figure 8.8 – Comparison of SV and P a evolutions obtained using the model (solid lines) with the
linear interpolations of SV and P a obtained with the first 3 Qd (dotted lines) for the weaning test
Pig8 T1. The crosses and diamonds are the experimental data (the difference between diamonds
and crosses has already been explained in Figure 8.1).
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Table 8.8 – Comparison between the prediction errors obtained with the mathematical model
and the prediction errors obtained with the interpolations of the measurements.
Global errors Mathematical model Interpolation
|∆PPa/PPa| 0.055 ± 0.053 0.049 ± 0.050
|∆P a/P a| 0.028 ± 0.029 0.034 ± 0.029
|∆P v/P v| 0.037 ± 0.033 0.043 ± 0.049∣∣∣∣∣∆maxT(Vh)maxT(Vh)
∣∣∣∣∣ 0.023 ± 0.023 0.020 ± 0.025
|∆SV/SV | 0.092 ± 0.065 0.102 ± 0.059
∆PPa/PPa 0.027 ± 0.073 0.024 ± 0.066
∆P a/P a 0.001 ± 0.040 0.008 ± 0.044
∆P v/P v 0.016 ± 0.048 0.015 ± 0.065
∆maxT(Vh)
maxT(Vh)
-0.013 ± 0.024 -0.012 ± 0.024
∆SV/SV -0.035 ± 0.099 -0.042 ± 0.106
To refine the comparison between the model and the linear interpolation, it is interest-
ing to consider the parameter identification using all the Qd (see section 8.3). Table 8.9
gives the global errors (averaged values for Pig4 T1 to Pig8 T2) for the values of PPa, P a,
P v, maxT(Vh) and SV simulated with the model and obtained with the interpolations of
the measurements related to all the Qd. This approach leads to similar results than the
previous one; the predicted values of P a and SV is slighty better with the model than
with the interpolation but the predicted values of P v is little worse with the model than
with the interpolation.
In conclusion, the errors between the simulated values obtained with the mathematical
model and the experimental data are small and these errors are a little bit smaller than
those obtained with linear interpolations. SV and P a are two quantities of paramount
importance to check the vital functions of the cardiovascular system and the mathematical
model improves by 10 % the prediction of SV and by 15 % the prediction of P a. Our
mathematical model thus provides a promising first step to predict the evolution of the
cardiovascular system for a decrease in Qd.
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Table 8.9 – Comparison between the identification errors obtained with the mathematical model
and the interpolation errors when the measurements related to all Qd are used.
Global errors Mathematical model Interpolation
|∆PPa/PPa| 0.015 ± 0.010 0.015 ± 0.019
|∆P a/P a| 0.009 ± 0.007 0.012 ± 0.015
|∆P v/P v| 0.014 ± 0.005 0.010 ± 0.006∣∣∣∣∣∆maxT(Vh)maxT(Vh)
∣∣∣∣∣ 0.009 ± 0.011 0.009 ± 0.012
|∆SV/SV | 0.040 ± 0.021 0.045 ± 0.042
∆PPa/PPa 0.004 ± 0.003 0.0004 ± 0.0008
∆P a/P a 0.002 ± 0.002 0.0003 ± 0.004
∆P v/P v 0.010 ± 0.006 0.0002 ± 0.0002
∆maxT(Vh)
maxT(Vh)
0.002 ± 0.002 0.0004 ± 0.0011
∆SV/SV -0.006 ± 0.011 0.0027 ± 0.0037
8.5 Limitations
Several assumptions were introduced to build the mathematical model of the cardiovascu-
lar system connected to a va-ECLS. Probably the most limiting hypothesis is the absence
of a description of the cardio-pulmonary controls since this model is used for different
values of Qd. However, our model takes into account the variations of the parameters Eh,
Ah, Ea, SBV and Rs with Qd. Therefore, the controls and the regulations of the cardio-
pulmonary system are implicitly described using the 5 slopes ESl,h, ASl,h, ESl,a, SBVSl
and RSl,s.
Volume measurements of the left ventricle are used for the parameter identification of
the mathematical model and these measurements are not quite accurate. The reliability
of the estimated parameters is thus impacted. A potential solution could be to take an
additional continuous measurement of the left ventricle volume, such as the estimation of
the cardiac output with an ultrasound flow probe surrounding the aorta [87].
The weaning tests performed on the 8 pigs are undertaken in different conditions than
those performed on humans. Indeed, for the pigs, the weaning tests began approximately
one hour after the cardiac arrest, while for ICU patients, weaning tests can be considered
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after at least 24 hours of stable hemodynamic status. Therefore, the pigs analyzed in this
chapter are less stable and still have heart failure symptoms during the weaning tests.
In addition, the vessels of the studied pigs are smaller than those of adult humans and
the range of extracorporeal blood flows is thus rather limited in the pig experiments. In
order to overcome this limitation, the experiments could be carried out on larger pigs and
these experiments could last longer than several hours. Of course, the optimal solution
is to validate the mathematical model with clinical data during weaning tests and this
approach will be developed in Chapter 10.
8.6 Summary
In this chapter, the model of the cardiovascular system connected to a va-ECLS has been
used to simulate weaning tests of a va-ECLS using experimental data.
First, the values of the different parameters have been estimated using the measure-
ments related to 3 different extracorporeal blood flows (Qd). These parameters are thus
subject-specific and their values have been discussed in subsection 8.4.1 and subsection
8.4.2. In addition, the parameters have also been estimated using the measurements re-
lated to all Qd.
After the parameter identification using the measurements related to 3 Qd, the model
was tested by comparing the values simulated by the mathematical model with the exper-
imental data related to different Qd (smaller than the Qd used for the parameter identi-
fication). Except for the stroke volume, the errors between the simulated values and the
experimental data are rather small (less or equal to 5 %). The slightly larger error on
the stroke volume (≈ 9%) remains acceptable and can also be related to the rather poor
quality of the corresponding measurement precision. In addition, subsection 8.4.3 provides
the errors between the predictions obtained with the linear interpolations using the same
measurements as the parameter identification and the clinical data. The prediction errors
of the mean arterial pressure and of the stroke volume obtained with the mathematical
model are smaller than those obtained with the linear interpolations.
The comparison between the mathematical model and the linear interpolations is also
analyzed when the estimated values are obtained with the parameter identification using
the measurements related to all Qd (and when the linear interpolations are obtained using
the measurements related to all Qd). Of course, this approach gives much smaller errors
between the simulated values and the experimental data. On the other hand, the errors
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obtained with the mathematical model are a little bit smaller than the errors obtained
with the linear interpolations.
Chapter 9
Experiments with a vv-ECLS
The protocol of the two set of experiments has already been described in subsection 7.1.1,
p. 95. With the experimental data, the parameters of the model are estimated and their
values are presented in section 9.1. Afterwards, the mathematical model of the respiratory
system connected to a vv-ECLS can be used to start simulations and the results are shown
in section 9.2. The main results consist in the time evolution of PCO2 estimated by the
mathematical model at several places in the body during the first hours of ECLST. Then,
the results are discussed and analyzed in section 9.3 and the limitations of our model are
drawn in section 9.4. Finally, the section 9.5 summarizes the results of this chapter.
9.1 Values of the parameters
To determine the diffusion coefficients across the membrane of the ECCO2RD, the data
of experiments H are used. Using the method presented in subsection 7.2.5, one finds
DCO2= 6.33 ×10−5 lCO2/s/mmHg, D′CO2= 3.97 ×10−4 lCO2/s/mmHg, DO2 = 1.58× 10−6
lO2/s/mmHg and D
′
O2
= 9.93 × 10−6 lO2/s/mmHg. As already mentioned, the settings
of the ECCO2RD are such that the atmospheric air flow is always equal to 10 liters per
minute, while parameter Qd is changed several times (200 ml/min, 400 ml/min and 600
ml/min) for experiments H and, except for pig A1, set to one value (around 700 ml/min)
for experiments A. For pig A1, parameter Qd is changed several times (200 ml/min, 400
ml/min, 600 ml/min and 800 ml/min). Since Qd is always smaller than 1 l/min, the recir-
culation of the extracorporeal blood flow is not taken into account for the pig experiments
(see subsection 5.3.1, p. 73).
The other parameters of the model are given in Table 9.1 for all animals. Parameter
FI,O2 , VT and fr are the ventilator settings. On the other hand, the values of MRCO2 ,
MRO2 , kHCO3 , fs and V˙A are determined by the procedures described in subsections 7.2.1,
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7.2.3 and 7.2.4. Note that in Table 9.1, parameter fs increases when protective ventilation
is induced and it increases even more when protective ventilation is coupled with ARDS.
On the other hand, the alveolar ventilation V˙A decreases when protective ventilation is
induced.
Cardiac blood flow values for the different animals during the experiments are also
parameters of the model and Figure 9.1 provides these values for all pigs. The hemoglobin
concentration CHb is estimated in arterial and venous blood samples for every pig and the
mean of all these values is used and is equal to 0.15 lHb/l. This value is smaller than other
values found in literature (0.2 lHb/l [9, 94]) since blood is diluted in our experiments.
Finally, parameters VL,CO2 , VL,O2 , VT,CO2 , VT,O2 and VTB are proportional to the body
weight (Table 7.1, p. 99) and are directly estimated from the weight specified in Table 9.1.
Table 9.1 – Measurements, settings of the ventilator and identified parameters for experiments
H (H1 − H4) and experiments A (A1 − A6)
Experiments H ("healthy" pigs) Experiments A (pigs with ARDS)
Data H1 H2 H3 H4 A1 A2 A3 A4 A5 A6
Baseline situation
Measurements
Weight (kg) 22 29 28 31 28 35 22 22.7 30 30
Ventilator settings
FI,O2 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 1 0.5
VT (l) 0.290 0.375 0.360 0.400 0.280 0.300 0.222 0.230 0.300 0.250
fr (min-1) 25 25 25 25 20 20 20 20 20 20
Identified parameters
MRO2
(lO2/min)
0.147 0.202 0.183 0.226 0.173 0.182 0.142 0.108 0.133 0.195
MRCO2
(lCO2/min)
0.147 0.202 0.183 0.226 0.173 0.182 0.142 0.108 0.133 0.195
kHCO3
(lCO2/l)
0.06 0.028 0.068 -0.001 0.042 0.05 -0.053 0.018 0.055 0.06
fs 0.044 0.066 0.047 0.029 0.037 0.08 0.133 0.08 0.059 0.050
V˙A (l/min) 3 5.85 4.325 6.875 3.24 3.9 2.76 2.2 3.92 4.58
Protective ventilation Protective ventilation and ARDS
Ventilator settings
FI,O2 1 1 1 1 0.5 0.5 1 1 1 1
VT (l) 0.135 0.170 0.175 0.185 0.200 0.200 0.132 0.120 0.180 0.180
fr (min-1) 15 15 15 15 20 20 20 20 20 20
Identified parameters
fs 0.105 0.092 0.069 0.128 0.304 0.436 0.49 0.57 0.409 0.532
V˙A (l/min) 0.93 1.73 1.38 2.1 1.42 1.92 1.44 1.2 2 2.7
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Figure 9.1 – Time evolution of the cardiac blood flows for experiments H (H1 − H4) and
experiments A (A1 − A6).
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9.2 Comparaison between simulations and experimen-
tal data
To validate the model, the simulations must be compared with experimental data. To test
the predictions of the model, the mean difference (|∆Pi| where i = CO2 or O2) between
the simulations and the experimental data is estimated with the following formula:
|∆Pi| = 1
m
m∑
j=1
|P simi,j − P expi,j | , (9.1)
where m is the number of PCO2 or PO2 measurements, P
exp
i,j is the PCO2 or PO2 mea-
surement j and P simi,j is the corresponding PCO2 or PO2 simulated with the model. The
mean relative difference (|∆Pi/Pi| where i = CO2 or O2) provides another way to estimate
the error :
|∆Pi/Pi| = 1
m
m∑
j=1
|P simi,j − P expi,j |
P expi,j
. (9.2)
In addition, to estimate whether the model tends to overestimate or to underestimate the
partial pressures, the mean differences and the mean relative differences are also com-
puted without the absolute value (and the corresponding symbols are written as ∆Pi and
∆Pi/Pi). Since the purpose of the ECCO2RD is to remove CO2, in this chapter, only the
simulated CO2 partial pressure are compared with the experimental data (i = CO2).
The ECLS compartment is of paramount importance and the 3 ECLS models pre-
sented previously (see section 5.3) are tested independently of the other compartments in
subsection 9.2.1. On the other hand, subsection 9.2.2 describes the results of the whole
model of the respiratory system connected to an ECLS.
9.2.1 Results for the ECLS models alone
To compare the 3 ECLS models presented in section 5.3 (Figure 5.2), the composition of
blood (PCO2, PO2, pH and HCO
–
3 ) entering the device is assumed given and the predic-
tions of the 3 models concerning the change of PCO2 across the device are compared. The
results are presented in Figure 9.2 and Figure 9.3, which show PCO2 of the blood exiting
the machine and PCO2 of the gas exiting the machine respectively. The experimental data
presented in these figures correspond to the data available for pigs H1-H4. Note that the
error on the measurements in blood is equal to 0.03×{value of the measurement}+0.17
mmHg according to the manufacturer of the RapidPoint500® device and the error on
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the measurements in gas is equal to 0.02× {value of the measurement} + 0.342 mmHg
according to the manufacturer of the CARBOCAP® device. As expected, the 3 models
agree rather well for small blood flow, but Mod 1 gets better and better as the blood flow
is increased in the ECCO2RD. Table 9.2 provides the mean errors |∆PCO2| and the mean
relative errors |∆PCO2/PCO2| for each ECLS model. |∆PCO2 | and |∆PCO2/PCO2| for Mod
1 are smaller than |∆PCO2| and |∆PCO2/PCO2| for Mod 2 and much smaller than |∆PCO2|
and |∆PCO2/PCO2| for Mod 3. For this reason, Mod 1 is preferred and it will be used in
the next simulations.
Table 9.2 – Errors between the simulations and the measurements of the CO2 partial pressure
exiting the ECCO2RD. m is the number of PCO2 or PO2 measurements
Models Mod 1 Mod 2 Mod 3
|∆PCO2| (mmHg) 0.78 ± 0.50 1.23 ± 1.32 2.70 ± 2.09
|∆PCO2/PCO2| 0.09 ± 0.01 0.13 ± 0.04 0.29 ± 0.06
m 26 26 27
9.2.2 Result of the respiratory model connected to a vv-ECLS
Using the values of the parameters given in section 9.1, the mathematical model is able to
describe the gas exchanges for experiments H and experiments A during the ECCO2RT.
The main results consist in the time evolution of PCO2 at several places in the body.
The right panel of Figure 9.4 illustrates the time evolution of PCO2 in the veins, in the
arteries and in the right ventricle for pig H2 and the left panel of Figure 9.4 illustrates
the time evolution of PCO2 in the veins and arteries for pig A6. The results for the other
pigs have similar features and are given in Figure B.6 and Figure B.7 of Appendix B.2.
In the two panels, the vertical lines indicate the beginning of the different phases of the
experiments. As expected, PCO2 in the body increases when protective ventilation and
ARDS are induced and decreases when the ECCO2RD is initialized.
Figure 9.4 shows a good agreement between the numerical simulations and the corre-
sponding experimental data. During baseline situation (the first 10 minutes in Figure 9.4),
the agreement is perfect for PCO2 in the arteries since parameters fs and V˙A are identi-
fied to fit PCO2 in the arteries. On the other hand, the agreement is not perfect for the
venous PCO2 because MRCO2 is not estimated with the measurements but with the ap-
proximation MRCO2 = MRO2 . After baseline situation, protective ventilation is induced
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Figure 9.2 – PCO2 in the blood exiting the ECCO2RD (Pout,CO2) as a function of PCO2 in
venous blood and for different blood flows entering the ECCO2RD.
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Figure 9.4 – Time evolution of calculated (lines) and measured (crosses, circles and diamonds)
CO2 partial pressures in the veins, in the right ventricle and in the arteries for pig H2 (the left
panel) and in the veins and arteries for pig A6 (the right panel). The labels PV, QD 200, QD
400, QD 600 and QD 800 mean respectively the start of protective ventilation and the blood flow
through the ECCO2RD set to 200, 400, 600 and 800 ml/min.
(combined with ARDS in experiments A) and the agreement is still good since parameters
fs and V˙A are re-evaluated. Now, the comparison between experimental and numerical
results during the ECCO2RT will be analyzed in detail. During this period, all parameters
are kept constant and the agreement between simulations and experimental data remains
quite good, for a relatively long period of time. Table 9.3 provides the mean errors ∆PCO2
and the mean relative errors ∆PCO2/PCO2 with and without absolute value for each pig
of the two sets of experiments. The number of PCO2 measurements (m) is also given.
Note that the standard deviation of the errors is not given for experiments A since the
number of measurements is small (less than 5 measurements). One can observe that the
errors for experiments H are larger than for experiments A. However, experiments H have
more experimental data in different parts of the body (experiments A have only arterial
measurements during the ECCO2RT). For experiments H, the model always underesti-
mates the PCO2 measurements (the value of ∆PCO2 and ∆PCO2/PCO2 is always negative)
whereas overestimations are almost always observed for experiments A (every pigs except
A1). Therefore, the mean error ∆PCO2 and the mean relative error ∆PCO2/PCO2 without
the absolute value for all pigs are close to 0. On the other hand, the mean relative error
|∆PCO2/PCO2| is equal to 11%.
136 9.2. Comparaison between simulations and experimental data
T
ab
le
9.
3
–
E
rr
or
s
be
tw
ee
n
th
e
si
m
ul
at
io
ns
an
d
th
e
m
ea
su
re
m
en
ts
du
ri
ng
th
e
E
C
C
O
2R
T
fo
r
ex
pe
ri
m
en
ts
H
an
d
ex
pe
ri
m
en
ts
A
.T
he
lin
e
m
in
di
ca
te
s
th
e
nu
m
be
r
of
P
C
O
2
m
ea
su
re
m
en
ts
av
ai
la
bl
e
du
ri
ng
th
e
E
C
C
O
2R
T
.
E
xp
er
im
en
ts
H
E
xp
er
im
en
ts
A
D
at
a
H
1
H
2
H
3
H
4
A
1
A
2
A
3
A
4
A
5
A
6
M
ea
n
±
σ
|∆
P
C
O
2
|(
m
m
H
g)
9.
82 ±
7.
40
7.
47 ±
6.
60
4.
24 ±
6.
02
7.
00 ±
5.
76
2.
93
9.
04
4.
51
5.
77
0.
08
4.
96
5.
58
±
2.
91
|∆
P
C
O
2
/P
C
O
2
|
0.
14 ±
0.
10
0.
12 ±
0.
06
0.
06 ±
0.
07
0.
11 ±
0.
05
0.
06
0.
21
0.
12
0.
14
0.
00
0.
15
0.
11
±
0.
06
∆
P
C
O
2
(m
m
H
g)
-9
.4
8
±
9.
97
-7
.3
7
±
4.
88
0.
91 ±
7.
33
-5
.2
8
±
6.
08
-2
.4
9
9.
04
4.
51
0.
39
0.
08
4.
96
-0
.4
7
±
5.
81
∆
P
C
O
2
/P
C
O
2
-0
.1
3
±
0.
12
-0
.1
1
±
0.
06
-0
.0
0
±
0.
09
-0
.0
9
±
0.
08
-0
.0
6
0.
21
0.
12
0.
00
0.
00
0.
15
0.
01
±
0.
12
m
23
23
24
16
4
2
1
2
1
3
Chapter 9. Experiments with a vv-ECLS 137
9.3 Discussion
This section discusses the physiological meaning of important parameters and discusses
the ability of our model to predict the decrease in PCO2 during the ECCO2RT. The
application of the mathematical model in the ICU is also discussed in this section.
9.3.1 Modeling of lung gas exchanges
Since the aim of our work is to find subject-specific parameters before ECCO2RT is initi-
ated, the description of the possible lung pathologies is quite crucial. For this reason, our
model uses two parameters with clear physiological meaning to describe the impairments
of gas exchange: fs which describes the importance of the pulmonary shunt and V˙A which
is the mean alveolar ventilation. In the literature, the mean alveolar ventilation V˙A is
often not identified as in our approach, but directly estimated [93, 55]. V˙A depends on the
tidal volume and the respiratory frequency, which are easily known since these are settings
of the ventilator. But V˙A also depends on the dead space VDead, which is much more
difficult to obtain. Some authors assume that this space is equal to 150 ml for an adult
patient [93], while others measure the dead space with a stand-alone respiratory monitor
[55]. In our experiments on pigs, the assumption of a human value equal to 150 ml can of
course not be made. It is not either possible to estimate VDead with a gas analyzer at the
outlet of the ventilator. Indeed, the experimental data related to the CO2 expired out of
the ventilator are not enough accurate to estimate the dead space with the small ventila-
tion used in our experiments. Consequently, V˙A is identified together with the pulmonary
shunt fs and these two parameters describe the global efficiency of gas exchanges in the
lungs. Note that, in physiology, the quality of gas exchanges in the lungs depends on sev-
eral factors, such as ventilation-perfusion mismatch or the quality of diffusion across the
alveolar-capillary membrane. In the present work, these effects are not explicitly modeled
and parameters fs and V˙A must thus be considered as lumped parameters that allow a
global description of all gas exchange abnormalities in the mathematical model.
During the animal experiments, the tidal volume is decreased drastically when the
protective ventilation starts. Of course, the alveolar ventilation changes with the tidal
volume but the pulmonary shunt can also change since the lung dynamics are modified.
The induction of ARDS has also an impact on the pulmonary shunt. Therefore, it is
necessary that the two parameters are estimated twice: first during the baseline situation
and then during protective ventilation (combined with ARDS induction in experiments
A). The changes of these two parameters between the two phases are discussed in the next
subsection.
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9.3.2 Values of the parameters
Table 9.1 shows that the two lumped parameters fs and V˙A behave as physiologically
expected. Indeed, during ARDS, a significant fraction of alveoli does not work properly
and an increase in the pulmonary shunt is expected in physiology [6, 100]. The value of
fs during ARDS (45.7±9.6%) is larger than in previous studies on human suffering from
ARDS (31±10% [54]) but note that the experiments are carried out on pigs and that the
ARDS is simulated by injecting water into the lungs. This ARDS model is thus different
from the respiratory pathology and could lead to different values of fs. The value of fs at
baseline (6.3±3%) is also larger than expected for a healthy human (2% [46]) but the pigs
are intubated and anesthetized and thus not in a truly physiologically healthy state. The
small increase in fs during protective ventilation for experiments H can be interpreted
by the collapse of some alveoli when the pressure in the lungs is lower. With regards to
parameter V˙A, its decrease during protective ventilation is clearly related to the drastic
decrease in the tidal volume.
MRCO2 and MRO2 values are in the same range as in previous studies. All pigs of
experiment H and pigs A1, A3 and A6 have MRO2 (and MRCO2) values very close to
the standard empirical relation used by Karagiannidis et al. [53]: MRO2 (= MRCO2 ) =
7 · 10−3 ·Weight(kg) lO2/min/kg.
9.3.3 Quality of the PCO2 predictions
Even if the CO2 removal therapies considered are rather complex for experiments H, since
the settings of the device are changed several times during the period of interest, the model
is able to describe the general behavior of the system throughout the whole experiment.
The global relative error |∆PCO2/PCO2| for all pigs of experiments H and experiments A is
larger than the accuracy of the blood analyser RapidPoint500 (11% compared to 3%) but
the simulation of the PCO2 prediction depends on several other measurements such as the
cardiac output, the inspired fraction of O2 and the PO2. In addition, for the simulations,
the extracorporeal blood flow is assumed perfectly controlled whereas in reality, it is dif-
ficult to achieve that goal. Recall also that the parameters fs and V˙A are kept constant
throughout the ECCO2RT and are estimated before the ECCO2RT. If this global relative
error (11%) is compared to the global relative error of the ECLS model alone (9%, see sub-
section 9.2.1), the global relative error of the respiratory model connected to a vv-ECLS is
slightly larger than the global relative error of the ECLS model alone. This result confirms
that the error of 11% is mainly due to experimental uncertainties and not due to an error
of the mathematical prediction. For these reasons, we can consider that our mathematical
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model of the respiratory system connected to an ECCO2RD can predict rather nicely the
decrease in PCO2 during the ECCO2RT, and our model can be considered as validated by
the pig experiments.
One main purpose of the mathematical model is to determine an appropriate extracor-
poreal blood flow for a specific patient. Therefore, it is interesting to know how the 11%
relative error on PCO2 impacts the prediction of the blood flow. To test the sensitivity
of the extracorporeal blood flow with respect to the PCO2 error, we have considered the
"mean pig" of all the experiments. This "mean pig" is obtained by considering the mean
of all the parameters given in Table 9.1 (MRCO2 = MRO2 = 0.17 l/min, V˙A = 1.7 l/min,
fs = 0.25% and kHCO3 = 0.03 lCO2/l, FI,O2 = 0.9 and a weight of 28 kg) and we have
used our mathematical model to determine the blood flow that allows to achieve a PCO2
equal to 50 mmHg in the arteries after 1 hour of the ECCO2RT. Then, the blood flows
corresponding to 50+11% mmHg and 50−11% mmHg are also determined. The situation
is illustrated in Figure 9.5 and the values of the three blood flows are 268 ml/min, 199
ml/min and 377 ml/min respectively. The positive and negative errors in PCO2 thus give
rise to 26% and 40% of imprecision in the calculated blood flows respectively, which is
not negligible but nevertheless acceptable in comparison with the global error of all our
experiments. In addition, in a clinical environment, the patients’ status is often quite
unstable like in our pig experiments and an uncertainty over the appropriated blood flow
is unavoidable.
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9.3.4 Application of the model in the ICU
Results show that the mathematical model is able to predict the decrease in PCO2 during
the ECCO2RT performed on pigs. This is a very encouraging step to extend the use of this
model to the ICU. It could improve patient-specific care under ECCO2RT. In the context
of this possible extension of the use of the model, 3 additional points need to be made.
Fast computation time
Delay differential equations need much more time to be solved than classical differential
equations. The time needed for a numerical simulation of PCO2 decrease during a one hour
of ECCO2RT is around 32 min (on a standard laptop computer and using MATLAB®)
for the mathematical model with delay differential equations while it takes only 3 min
for the mathematical model with classical differential equations. If the transport delays
are neglected, the values of the two parameters V˙A and fs are slightly different during
protective ventilation since they are identified in an unstationary state (their values are
given in Table B.1 of Appendix B.2). Figure 9.6 compares our simulations when delays
in blood circulation are or are not taken into account and one can observe that the two
simulations are slightly different when the system is in an unsteady state. However, the
long-term evolution does not require taking the delays into account, which is a conse-
quence of the smallness of the delays with respect to the duration of the ECCO2RT. The
delays of blood circulation can thus safely be disregarded in the description. In addition,
the mean relative errors ∆PCO2/PCO2 for all pigs is still equal to 11 % when the delays
are not taken into account (the values of the mean errors ∆PCO2 and the mean relative
errors ∆PCO2/PCO2 with and without absolute value for each pig are given in Table B.2
of Appendix B.2). The mathematical model with classical differential equations is thus
preferred since the computation time is sufficiently small to allow the model to participate
in the rapid decision-making that is required by clinicians at the patients bedside in the
ICU. Therefore, the differential equations without transport delays will be used in the next
simulations (end of this chapter and in Chapter 11).
Weight-based estimation of cardiac output
The cardiac blood flow, which is continuously measured in our experiments, is introduced
as a given function of time in the calculations. However, if the model is used in the ICU
before starting the ECCO2RT to determine the best settings of the device, the change of
cardiac output is of course unknown when the calculations are carried out. In addition,
cardiac blood flow is not often measured before the ECCO2RT. For these reasons, it is
important to check the validity of our model when approximate values of cardiac output
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Figure 9.6 – Time evolution of calculated (lines) and measured (crosses and diamonds) CO2
partial pressures in the veins and arteries for pig A6 when transport delays are considered (con-
tinuous lines) and when they are not (dotted lines).
are introduced in the calculations.
An approximation of the cardiac blood flow can be obtained by using the cardiac
index, which is the cardiac output divided by the BSA (subsection 7.2.3, p. 100). Various
formulae have been published to estimate the BSA and a commonly used expression is the
Mosteller formula [115]. This approximation is based on human morphology and can be
used in the ICU. However, it cannot be used in our experiments that were carried out on
pigs. To test the validity of our model when a precise value of cardiac output is not known,
the mean value obtained by considering all our available measurements (all pigs, baseline
situation and protective ventilation) will be used, which is equal to 3.21 l/min. This
value will be kept constant during all the simulations considered in the present section.
Table 9.4 gives the corresponding new estimations of parameters fs and V˙A (with all the
other parameters and measurements remaining the same as in Table 9.1). Let us mention
that as expected, the re-identified alveolar ventilation keeps the same value as before. On
the other hand, parameters fs describing the pulmonary shunt decreases (resp. increases)
when the approximate cardiac output is larger (resp. smaller) than the measured value.
To test the validity of our approach with approximate cardiac output, we consider the
mean errors ∆PCO2 and the mean relative errors ∆PCO2/PCO2 with and without absolute
value like in subsection 9.2.2. The results are similar than those with precise values of the
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cardiac output and the mean relative errors ∆PCO2/PCO2 for all pigs is still equal to 11 %
(the values of the mean errors ∆PCO2 and the mean relative errors ∆PCO2/PCO2 with and
without absolute value for each pig are given in Appendix B.2 in Table B.3). We can thus
conclude that the quality of the predictions of our model is almost not affected when only
approximate cardiac output is known. This is an important result for the use of our model
in the ICU.
Table 9.4 – Parameters for experiments H and experiments A when the cardiac output is equal
to 3.21 l/min and when transport delays are neglected.
Experiments H Experiments A
Data H1 H2 H3 H4 A1 A2 A3 A4 A5 A6
Baseline situation
fs 0.041 0.07 0.038 0.025 0.041 0.077 0.117 0.11 0.07 0.055
V˙A (l/min) 3 5.85 4.325 6.875 3.24 3.9 2.76 2.2 3.92 4.58
Protective ventilation Protective ventilation and ARDS
fs 0.105 0.098 0.069 0.114 0.326 0.425 0.516 0.62 0.47 0.495
V˙A (l/min) 0.93 1.8 1.695 2.1 1.58 1.92 1.44 1.2 2 2.66
Weight-based estimation of MRCO2 and MRO2
In ICU, venous blood samples are not always taken before starting the extracorporeal
circulation and, as previously mentioned, cardiac output is not often measured. In such
circumstances, the estimation of metabolism production and consumption cannot be done
as explained in subsection 7.2.3. For this reason, our model is also tested when these
production and consumption are simply estimated by using a weight-based estimation
MRO2 (=MRCO2 ) = 7×10−3lO2/min/kg [53]. Table 9.5 provides the corresponding values
of metabolism production and consumption for the pigs of our two sets of experiments.
The associated values of parameter fs and V˙A are also given. For most pigs (7 out of
10), the values given in Table 9.5 are quite similar to the values of Table 9.1. However,
for pigs A2, A4 and A5, the two estimations give significantly different values for the
parameters. In particular, in the baseline situation, parameter V˙A has a larger value than
the tidal minute ventilation (fr × VT ) for pig A5, which is physiologically unacceptable
and thus makes the weight-based estimation unusable for pig A5. For the other pigs, the
mean errors ∆PCO2 and the mean relative errors ∆PCO2/PCO2 with and without absolute
value are estimated (all the values are given in Table B.4 of Appendix B.2) and the mean
relative error for all pigs is equal to 14 %. This error is larger than the previous one
(Table 9.3) because pig A4 shows much larger errors when the weight-base approximation
is used to estimate metabolism (the mean relative error is equal to 27%). We can thus
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conclude that estimating the metabolism production and consumption from measured
data always provides good results and this method must thus be preferred. However,
when experimental data are not available, the weight-based estimation of MRCO2 and
MRO2 can also provide acceptable results in most cases.
Table 9.5 – Parameters for experiments H and experiments A when metabolism is estimated
with the weight-based approximation and when transport delays are neglected.
Experiments H Experiments A
Data H1 H2 H3 H4 A1 A2 A3 A4 A5 A6
Baseline situation
MRO2
(lO2/min)
0.154 0.203 0.196 0.217 0.196 0.245 0.154 0.159 0.210 0.210
MRCO2
(lCO2/min)
0.154 0.203 0.196 0.217 0.196 0.245 0.154 0.159 0.210 0.210
fs 0.043 0.065 0.040 0.030 0.033 0.060 0.124 0.056 0.038 0.047
V˙A (l/min) 3.15 5.875 4.65 6.6 3.68 5.24 3 3.24 6.18 4.9
Protective ventilation Protective ventilation and ARDS
fs 0.085 0.085 0.080 0.090 0.278 0.383 0.470 0.401 0.304 0.512
V˙A (l/min) 0.975 1.65 1.5 1.875 1.7 2.6 1.56 1.2 3.3 2.88
9.4 Limitations
CO2 production MRCO2 and O2 consumption MRO2 are two important quantities in the
functioning of the respiratory system. These two quantities are equal for the carbohydrate
metabolism but if the patient’s metabolism uses different sources such as fats or proteins,
MRCO2 is smaller thanMRO2 (subsection 2.3.3). Unfortunately, because the total concen-
tration of CO2 in blood depends on 3 chemical species (CO2 dissolved in blood, HCO
–
3
and CO2 complexed with hemoglobin), the identification of the value of MRCO2 from
blood sample analyses has proved to be quite delicate and even impossible in our experi-
ments. For this reason, we have introduced the approximation of equalMRCO2 andMRO2 .
If the long-term purpose of our work is to provide an additional therapeutic tool to
clinicians, other limitations must also be emphasized. First, the status of the pigs used in
experiments does not exactly correspond to that of humans in the ICU. In the experiments,
hypercapnia was induced by protective ventilation and injection of water in the lungs, but
no real ARDS or chronic obstructive pulmonary disease was considered. In addition, even
if the pig cardiopulmonary system is close to that of human, ICU patients could have
different responses to the ECCO2RT. Therefore, the model has been only validated for pig
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experiments and clinical studies have to be carried out in order to validate the model in
the ICU. This aspect will be developed in Chapter 11.
Finally, this mathematical model is validated only for a specific ECLS, which is the
Maquet ECCO2RD (PALP®, Germany). Other and larger ECLS, such as venovenous ex-
tracorporeal membrane oxygenation (vv-ECMO), should also be considered. In particular,
it is worth mentioning that larger ECLS are also used to oxygenate blood and this chapter
does not consider this possibility.
9.5 Summary
The mathematical model of the respiratory system connected to a vv-ECLS has several
subject-specific parameters. These parameters have been estimated with experimental
data and their values are close to the values that can be observed in real patients. When
all the parameters are identified before the ECCO2RT, the mathematical model can cor-
rectly simulate the decrease in PCO2 during the ECCO2RT.
To validate the mathematical model, the PCO2 predictions are compared with exper-
imental results obtained in pigs. First the ECLS model has been tested alone and the
model Mod1 (the most complexed one) have shown the best results. Consequently, this
model was used for all the simulations of the respiratory system connected to a vv-ECLS.
The results show that these simulations are able to reproduce experimental data for quite
long periods of time (up to about 150 minutes for experiments H and up to about 60 min-
utes for experiments A) and until the stabilization of the respiratory system is reached.
The quite good agreement between the theoretical approach and animal data can thus be
considered as a strong argument proving the validity of our model.
Furthermore, the adaptations of the mathematical model to be used in the ICU are
also discussed and analyzed. The results show that the mathematical model without the
transport delays should be preferred since the computation time is smaller and the errors
between the measurements and the simulations are approximatively the same. In the ICU,
various measurements are not always taken and different parameters cannot be estimated.
For the cardiac output, this chapter demonstrates that a weight-based approximation
could be used. On the other hand, a weight approximation for the parameters MRCO2
and MRO2 should be avoided.
Part V
Application in the intensive care unit
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To prepare the use of the mathematical model in the ICU, the validation with pig
experiments is not sufficient and the model must also be tested and validated in the ICU.
Even if the animal experiments were performed with the aim to be similar to clinical appli-
cations, the measuring instruments available in the ICU and the clinical environment are
quite different from the experiments: less data are estimated and all the surgical opera-
tions are safer (less invasive and strict sterility conditions). Moreover, the cardiopulmonary
pathologies simulated for the animals experiments try to simulate the pathologies that are
really observed on patients but these simulations can significantly differ from those really
observed in clinic. Finally, the results can also diverge because the behavior and response
of the human cardio-pulmonary system can be different from that of the pig.
In this last part of the thesis, two chapters are introduced. Chapters 10 and 11 respec-
tively describe, discuss and analyze the results related to the clinical uses of va-ECLS and
vv-ECLS.

Chapter 10
Application for patients assisted by a
va-ECLS
This chapter describes the validation and potential applications of our mathematical model
in the ICU. First, the current clinical protocol used to decide if a patient assisted by a
va-ECLS can be weaned is presented in section 10.1. The final aim of the study is to couple
our mathematical model with this weaning protocol in order to improve the therapeutic
approach in the ICU. Therefore, this chapter analyzes clinical data from several patients to
validate the mathematical model for ICU applications. The main features of each studied
patient are described in section 10.2. With the clinical data of these patients, the values
of the parameters of the model can be estimated and are given in section 10.3. After
the parameter identification, the model can simulate different hemodynamic states of the
cardiovascular system for different extracorporeal blood flows. The comparison between
the simulated values and the clinical data is described in section 10.4. Afterwards, the
discussion of the different results is developed in section 10.5 and the limitations of the
mathematical model are described in section 10.6. Finally, the last section summarizes
the results of this chapter.
10.1 Clinical weaning criteria from va-ECLS
If a patient under a va-ECLS recovers from its major metabolic disturbance (such as septic
shocks), has a pulsatile arterial waveform for at least 24 hours and has a mean arterial
pressure larger than 60 mmHg with low doses of catecholamine (noradrenaline < 5µg/min
and dobutamine < 10µg/min [77]), clinicians can proceed to a weaning test [4]. The
weaning test consists in gradually decreasing the extracorporeal blood flow and checking
the following parameters when the extracorporeal blood flow is decreased to approximately
0.5−1 l/min [4]:
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• VTI > 12 cm (this symbol has been defined in section 6.2, p. 88),
• left ventricular ejection fraction (described in our model by SV /maxT(Vh)) > 20−25 %,
• mean arterial blood pressure (P a) > 60 mmHg.
In addition to these weaning criteria, the pulmonary function should not be severely im-
paired: if PaO2/FiO2 <100 mmHg when FI,O2 of the ECLS gas flow is set at 21 %,
bridging the patient from va- to vv-ECLS should be considered [4].
If all these criteria are respected, the medical team can consider removing the ECLS.
10.2 Clinical trial
With the aim to validate the model in the ICU, clinical data are taken from 6 patients
(labeled Patient1 to Patient6) assisted by a va-ECLS. These patients suffer from distinct
heart pathologies and a patient-specific care is administered to each of them. For each
patient, one or two weaning tests were carried out and their main characteristics are de-
scribed in Table 10.1. Each weaning test was performed by decreasing progressively the
extracorporeal blood flow (Qd) to different values. For each extracorporeal blood flow, the
essential hemodynamic parameters were recorded (diastolic and systolic blood pressure in
the arteries, mean central venous pressure, V TI, φLV OT and the diastolic volume, see sec-
tion 6.2, p. 88). Except for the second weaning test performed on Patient2, each weaning
test will be analyzed in this chapter. For the second weaning test performed on Patient2,
the parameter identification is impossible with our method since Qd was directly decreased
to 0.5 l/min.
Table 10.1 shows that, except for Patient6, the last weaning test for each patient was
conclusive and the va-ECLS was switched off. Unfortunately, 3 of these patients died after
the ECLS removal. For Patient6, a high dose of catecholamine was administered in order
to increase the arterial pressure (P a > 60 mmHg) and this injection should have prevented
the weaning of va-ECLS. However, the arterial hypotention of the patient was due to an
hepatic dysfunction and not to a cardiovascular dysfunction.
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10.3 Value of the parameters
The parameters of the model are estimated with the procedure described in subsection 8.1.2
of Chapter 8. The heart rate (HR) and the extracorporeal blood flow (Qd) are directly
measured and the values of HR in terms of Qd are presented in Figure 10.1 for each wean-
ing test. For Patient4 and Patient5, 2 weaning tests (labeled T1 and T2 respectively) were
carried out. Other patients had only one weaning test which is labeled T1. Remember that
the experimental data depicted by crosses are used for the identification while the experi-
mental data depicted by diamonds are used for testing the predictions of the mathematical
model (see section 8.1). The values of HR represented by diamonds are thus not used as
input data and, in evaluating the prediction of the mathematical model, HR is estimated
using equation 8.1 from section 8.1. The 2 coefficients of the linear development of HR in
terms of Qd are given, for each weaning test, in Table 10.2. Except for the weaning test
Patient1 T1, Figure 10.1 and Table 10.2 demonstrate that HR increases with the decrease
in Qd.
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Figure 10.1 – Heart rate in terms of Qd for the different weaning tests. The crosses correspond
to the experimental data used for the parameter identification and the diamonds correspond to
the experimental data used for testing the predictions of the mathematical model.
As in Chapter 8, the values of the 10 coefficients, defining the linear dependence of the
5 parameters with respect to Qd, are determined by the method presented in section 6.2
and using n = 3. Their values are provided in Table 10.2 for each weaning test. Note
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Table 10.2 – Values of the 2 coefficients of the linear expressions for each parameter (Eh, SBV ,
Ah, Ea and Rs) and the two coefficients of the linear expression of HR.
Patient1 Patient2 Patient3 Patient4 Patient5 Patient6
Data T1 T1 T1 T1 T2 T1 T2 T1 Mean
± σ
Parameter identification
E0,h
(mmHg/ml)
2.81 1.74 1.01 0.90 0.97 1.93 1.93 3.58 1.86
± 0.95
SBV0 (ml) 1159 410 789 1026 820 1108 1276 1305 987
± 300
A0,h (ml−1) 0.050 0.022 0.016 0.025 0.022 0.036 0.034 0.051 0.032
± 0.013
E0,a
(mmHg/ml)
2.03 0.93 1.30 1.12 1.44 1.49 1.96 1.20 1.43
± 0.39
R0,s
(mmHg · s/ml)
1.20 1.29 0.63 0.82 0.83 0.76 0.79 0.35 0.84
± 0.30
ESl,h
(mmHg · s/ml2)
-0.011 0.002 0.002 0.000 -0.005 -0.003 -0.003 -0.014 -0.004
± 0.006
SBVSl (s) -3.97 3.50 -2.61 -2.25 0.92 -7.09 -3.62 -6.78 -2.74
± 3.59
ASl,h (s/ml2) -7·e-5 2·e-4 -4·e-5 -7·e-5 -8·e-5 -1·e-4 -6·e-5 -1·e-4 -5·e-5
± 1·e-4
ESl,a
(mmHg · s/ml2)
-0.003 0.044 0.007 0.004 -0.003 0.019 0.004 0.014 0.011
± 0.015
RSl,s
(mmHg · s2/ml2)
-0.007 -0.008 -0.001 -0.004 -0.004 0.004 -0.003 0.000 -0.003
± 0.004
Heart rate estimation
HR0 (s−1) 1.70 1.46 1.65 1.34 1.35 1.64 1.31 2.46 1.62
± 0.37
HRSl (ml−1) 0.005 -0.002 -0.003 -0.003 -0.007 -0.002 -0.001 -0.005 -0.002
± 0.003
that, like in the pig experiments, the values of the independent terms in equation 6.4 are
of the same order of magnitude for the different weaning tests but the values of the slopes
in equation 6.4 are different for the different patients.
For the identification of the 10 coefficients, the differences between experimental data
(crosses in the different figures) and the simulated values of P a, PPa, P v, maxT(Vh) and
SV are minimized. The corresponding relative errors, ∆P a/P a, ∆PPa/PPa, ∆P v/P v,
∆maxT(Vh)/maxT(Vh) and ∆SV/SV , with and without the absolute values (these sym-
bols have already been introduced in section 8.1), are given in Table 10.3. In addition,
the relative errors of the ejection fraction (EF ) and V TI are also given in this table.
Indeed, these quantities are of paramount importance in the ICU since their values de-
termine the decision of weaning a va-ECLS. V TI is directly proportional to SV and the
proportional factor is the area of the left ventricular outflow tract (equation 6.2). Since
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Table 10.3 – Errors between the simulations and the measurements of P a, PPa, P v, maxT(Vh),
SV , V TI and EF during the parameter identification phase.
Patient1 Patient2 Patient3 Patient4 Patient5 Patient6
Data T1 T1 T1 T1 T2 T1 T2 T1 Mean
± σ
Ψ(p∗) 548 117 262 106 25 371 112 374 239
± 180
|∆PPa/PPa| 0.034 0.020 0.017 0.002 0.009 0.028 0.007 0.037 0.019
± 0.013
|∆P a/P a| 0.040 0.007 0.030 0.023 0.005 0.017 0.005 0.025 0.019
± 0.013
|∆P v/P v| 0.032 0.076 0.024 0.034 0.012 0.054 0.015 0.065 0.039
± 0.024∣∣∣∣∣∆maxT(Vh)maxT(Vh)
∣∣∣∣∣ 0.004 0.009 0.003 0.001 0.009 0.069 0.045 0.006 0.018± 0.025
|∆SV/SV |
or
|∆V TI/V TI|
0.018 0.018 0.010 0.022 0.021 0.052 0.004 0.010 0.019
± 0.015
|∆EF/EF | 0.019 0.017 0.007 0.023 0.029 0.127 0.044 0.009 0.034
± 0.039
∆PPa/PPa 0.010 0.020 0.001 0.000 0.002 0.016 0.007 0.014 0.009
± 0.008
∆P a/P a 0.005 -0.002 0.001 0.000 0.001 0.005 0.005 0.005 0.002
± 0.003
∆P v/P v 0.016 0.023 0.019 0.017 0.012 0.019 0.015 0.019 0.018
± 0.003
∆maxT(Vh)
maxT(Vh)
0.004 0.009 0.001 0.000 0.002 -0.004 0.004 0.006 0.003
± 0.004
∆SV/SV
or
∆V TI/V TI
0.000 0.018 -0.003 -0.006 -0.003 0.008 0.004 0.006 0.003
± 0.008
∆EF/EF -0.004 0.000 -0.004 -0.007 -0.005 0.023 0.002 0.000 0.001
± 0.009
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the experimental value of φLV OT is used as an input data for the parameter identification,
∆SV/SV = ∆V TI/V TI. Table 10.3 shows that the errors between the measurements
and the corresponding values are small: for all the weaning tests, the means |∆P a/P a|,
|∆PPa/PPa|, |∆maxT(Vh)/maxT(Vh)| and |∆SV/SV | (= |∆V TI/V TI|) are all smaller
than 2 % and the means |∆P v/P v| and |∆EF/EF | are both smaller than 4 %. Table 10.3
also shows that the simulated P v and PPa overestimate the corresponding clinical data
(∆P v/P v = 1.8 % and ∆PPa/PPa = 0.9 %) while there is no global overestimation or
underestimation for the other quantities.
10.4 Predicted and clinical values during weaning tests
After estimating all the parameters of the mathematical model, this model can be used
to simulate the cardiovascular system during weaning tests and these simulations can be
compared to available clinical data taken during these tests.
Figure 10.2, Figure 10.3 and Figure 10.4 represent the evolution of simulated and clini-
cal hemodynamic variables for all the weaning tests. The simulated values are depicted by
solid lines while experimental data are depicted by crosses and diamonds (as already men-
tioned, the experimental data depicted by crosses are used for the parameter identification
while the experimental data depicted by diamonds are used to validate the mathematical
model). The simulations and the clinical data demonstrate that all the hemodynamic
criteria to wean a va-ECLS are respected for the weaning test Patient1 T1, Patient 3 T1,
Patient 4 T2, Patient5 T1 and Patient5 T2. After these weaning tests, the ECLS was
actually switched off. For the weaning test Patient2 T1 (Figure 10.2), V TI obtained with
the mathematical model and measured in the ICU are both smaller than 12 cm. The
ECLS was thus not switched off after this weaning test. For the weaning test Patient4 T1
(Figure 10.3), the clinical value of V TI is close to 12 cm for Qd = 0.5 l/min. In addition, it
is worth mentioning that V TI decreases with the decrease in Qd while the other weaning
tests show an apposite trend. This weaning test was thus not totally conclusive and a
second weaning test was carried out the next day. Finally, for the weaning test Patient6
T1 (Figure 10.4), P a obtained with the mathematical model and measured in the ICU
are both smaller than 60 mmHg even if a high dose of noradrenaline was administered.
However, the ECLS was switched off because the arterial hypotention was due to a hepatic
dysfunction and not a cardiovascular dysfunction.
These figures also show that the agreement between the simulations and crosses is
good and this fact has already been discussed in section 10.3. The difference between the
diamonds and the simulations are a bit larger and the quantitative values of these errors
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Figure 10.2 – Evolution of P a, PPa, P v, maxT(Vh) and SV in terms of different Qd for the
3 weaning tests Patient1 T1, Patient2 T1 and Patient3 T1. The solid lines are the simulations
and the crosses and diamonds are the experimental data (the difference between diamonds and
crosses has already been explained in Figure 10.1).
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Figure 10.3 – Evolution of P a, PPa, P v, maxT(Vh) and SV in terms of different Qd for the 2
weaning tests Patient4 T1 and Patient4 T2. The solid lines are the simulations and the crosses
and diamonds are the experimental data (the difference between diamonds and crosses has already
been explained in Figure 10.1).
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Figure 10.4 – Evolution of P a, PPa, P v, maxT(Vh) and SV in terms of different Qd for the
3 weaning tests Patient5 T1, Patient5 T2 and Patient6 T1. The solid lines are the simulations
and the crosses and diamonds are the experimental data (the difference between diamonds and
crosses has already been explained in Figure 10.1).
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are given in Table 10.4. The relative errors ∆maxT(Vh)/maxT(Vh) and ∆SV/SV are also
provided in this table. Note that in this case, ∆SV/SV 6= ∆V TI/V TI since, in testing
the prediction of the model, the values of experimental φLV OT are not used as input data.
To estimate the values of φLV OT , the assumption of a constant value for the different Qd
is taken and the estimated value is equal to the mean of the 3 experimental values used
during the parameter identification phase (crosses)1. Table 10.4 shows that the errors are
small (the mean errors of P a, maxT(Vh), SV and V TI are all smaller than 7 % and the
mean errors of PPa, P v and EF are all smaller than 10 %).
10.5 Discussion
This section discusses the values of the different coefficients estimated in the previous
section and compares these values with the values obtained in the pig experiments (see
Chapter 8). Indeed, this comparison can be considered since the pig’s cardiovascular
system is rather similar than the human’s cardiovascular system and the literature has
provided similar parameter values ([86, 105, 18]). In addition, this section discusses the
ability of our model to predict the essential hemodynamic quantities during weaning tests.
10.5.1 Values of the parameters for Qd = 0
Table 10.2 has shown that the coefficient E0,h, which correspond to the value of parameter
Eh for Qd = 0, has larger values than those obtained with the pig experiments during
ECLST (Table 8.7). This result makes sense since the weaning tests are carried on patients
only when they have almost recovered a healthy cardiac activity while the weaning tests are
carried out only a few minutes after the cardiac arrest for the pig experiments. However,
the values shown in Table 10.2 are smaller than those presented in the literature for a
healthy adult (Eh = 3 mmHg/ml [18]). This difference can be explained by the fact
that the studied patients have not yet fully recovered a normal cardio-vascular activity.
Another important parameter is the systemic resistance Rs and Table 10.2 shows that the
values of R0,s, which correspond to the values of parameter Rs for Qd = 0, are smaller
than those obtained with the pig experiments during ECLST (Table 8.7). However, these
values are of the same order of magnitude than those found in literature for a healthy
adult (Rs = 0.95 mmHg · s/ml [18]). The values of the other coefficients indexed with
"0" are similar to those obtained with the pig experiments (during baseline situation and
ECLST, see Table 8.7).
1The accuracy of φLV OT and the variation of φLV OT with Qd are too small to be estimated
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Table 10.4 – Errors between the predictions of the mathematical model and the measurements
of P a, PPa, P v, maxT(Vh), SV , EF and V TI.
Patient1 Patient2 Patient3 Patient4 Patient5 Patient6
Data T1 T1 T1 T1 T2 T1 T2 T1 Mean
± σ
|∆PPa/PPa| 0.085 0.148 0.007 0.023 0.121 0.098 0.016 0.105 0.075
± 0.053
|∆P a/P a| 0.052 0.037 0.061 0.022 0.032 0.118 0.039 0.050 0.051
± 0.030
|∆P v/P v| 0.058 0.295 0.056 0.060 0.172 0.003 0.024 0.116 0.098
± 0.096∣∣∣∣∣∆maxT(Vh)maxT(Vh)
∣∣∣∣∣ 0.002 0.137 0.001 0.094 0.036 0.152 0.022 0.024 0.058± 0.060
|∆SV/SV | 0.089 0.045 0.130 0.098 0.018 0.044 0.023 0.103 0.069
± 0.042
|∆EF/EF | 0.091 0.081 0.131 0.161 0.056 0.093 0.001 0.130 0.093
± 0.050
∆V TI/V TI 0.024 0.060 0.131 0.098 0.006 0.048 0.056 0.103 0.066
± 0.042
∆PPa/PPa 0.085 -0.148 0.007 0.023 0.121 -0.098 -0.016 -0.105 -0.016
± 0.095
∆P a/P a 0.052 -0.037 -0.061 -0.022 -0.032 -0.118 -0.039 0.050 -0.026
± 0.056
∆P v/P v 0.058 -0.295 -0.056 -0.060 -0.172 0.003 -0.024 0.116 -0.054
± 0.130
∆maxT(Vh)
maxT(Vh)
0.002 0.137 0.001 0.011 -0.036 0.152 -0.022 -0.024 0.028
± 0.074
∆SV/SV -0.089 0.045 -0.130 0.098 0.018 0.044 -0.023 0.103 0.008
± 0.084
∆EF/EF -0.091 -0.081 -0.131 0.102 0.056 -0.093 -0.001 0.130 -0.014
± 0.100
∆V TI/V TI -0.024 0.060 -0.131 0.098 0.006 -0.048 -0.056 0.103 0.001
± 0.082
n 1 1 1 2 1 1 1 3
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10.5.2 Variation of the parameters with Qd
Table 10.2 has provided the slopes of the parameters in terms of Qd and these values allow
us to analyze the variation of the different parameters with respect to Qd. For parameter
HR, this table and Figure 10.1 have shown that HR increases with the decrease in Qd
while the pig experiments have shown an opposite trend (Table 8.2). This difference can be
explained by the fact that the heart of the patients partially recovered its normal activity.
Their heart thus responds differently than the heart of the pigs, which were still in a patho-
logical condition (see also discussion in subsection 8.4.2). For the other parameters, one
calculates the relative variations of the 5 parameters for a change of Qd equal to 3 l/min
(similar relative variations have been calculated in subsection 8.4.2 but for a change of Qd
equal to 1 l/min, see equations 8.7). The symbols ∆3Eh/Eh, ∆3SBV/SBV , ∆3Ah/Ah,
∆3Ea/Ea and ∆3Rs/Rs are introduced to respectively describe the relative variations of
Eh, SBV , Ah, Ea and Rs. Remember that the 5 slopes have been identified with the
measurements related to 3 different Qd. These variations can be estimated with more ex-
perimental data (see section 8.3). Indeed, the 10 coefficients of the linear expression of the
5 parameters can also be identified using the measurements related to all the Qd and the
corresponding values of ∆3Eh/Eh, ∆3SBV/SBV , ∆3Ah/Ah, ∆3Ea/Ea and ∆3Rs/Rs can
also be estimated (the values of the 10 coefficients estimated with this approach are given
in Table B.5 of Appendix B.3 and the errors obtained for this parameter identification are
given in Table B.6 of Appendix B.3).
Figure 10.5 represents the values of ∆3Eh/Eh, ∆3SBV/SBV , ∆3Ah/Ah, ∆3Ea/Ea and
∆3Rs/Rs for the different weaning tests obtained with the two parameter identifications
(the parameter identification using only 3 Qd is represented by the full bars while the
parameter identification using all the Qd is represented by the empty bars).
This figure demonstrates that the values of ∆3Eh/Eh are always negative for the pa-
rameter identification using all the Qd. The patients thus show an opposite trend in
comparison with the pig experiments. Indeed, for the clinical trials, the heart partially re-
covered its normal activity and thus responds differently than the heart of the pigs, which
were still in a pathological condition. In addition, the increase in the heart contractility
with the decrease in Qd is in agreement with the literature. Indeed, several articles claim
that the heart contractility increases with the increase in preload [65] (remember that the
preload increase with the decrease in Qd). Finally, note that the results for the parameter
identification using 3 Qd show a similar general trend but the values of ∆3Eh/Eh obtained
with this method are rather different from those obtained with the parameter identification
using all Qd.
Except for the weaning test Patient2 T1, the values of ∆3SBV/SBV are always nega-
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Figure 10.5 – Values of ∆3Eh/Eh, ∆3SBV/SBV , ∆3Ah/Ah, ∆3Ea/Ea and ∆3Rs/Rs obtained
with the parameter identification using the measurements related to 3 Qd and with the parameter
identification using the measurements related to all Qd for each weaning test.
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tive for the parameter identification using all Qd (remember that for the pig experiments,
∆1SBV/SBV has not shown clear trend but their values were small). Except for Patient4
T2, the results for the parameter identification using 3 Qd present similar values. The
increase in SBV with the decrease in Qd could result from the vasoconstriction of the
small vessels and the increase in heart contractility when Qd decreases.
Figure 10.5 also shows that, except for the weaning test Patient2 T1, the values of
∆3Ah/Ah are always negative for both parameter identifications (remember that for the
pig experiments, ∆1Ah/Ah has not shown clear trend but their values were small). The
increase in Ah with the decrease in Qd could result from an inadequate description of
EDPVR by equation 4.6 (see subsection 4.1.4, p. 57). Indeed, if Qd decreases, the preload
and afterload of the heart change (the preload increases and the afterload decreases) and
the values of pressure and volume in the heart also vary.
While the values of ∆1Ea/Ea have not shown clear trend for the pig experiments,
Figure 10.5 shows that the values of ∆3Ea/Ea are always positive for the parameter iden-
tification using all Qd. Except for the weaning tests Patient1 T1 and Patient4 T2, the
results for the parameter identification using 3 Qd present similar trends. The decrease
in Ea with the decrease in Qd can be explained as follows. The assumption of a linear
relationship between the pressure and the volume was taken for the passive element of the
cardiovascular system whereas, in reality, the pressure volume relationship has a convex
shape. Figure 10.6 illustrates this pressure volume relationship and this figure shows that
the slope of the curve decreases when the pressure decreases. If Qd decreases from Qd,1
to Qd,2, the hemodynamic in the arteries changes; the pressures and the volumes in the
arteries decreases and the slope of the curve decreases from Ea(Qd,1) to Ea(Qd,2).
	
Ah	constant	Ah(Vh)	A c nstantA h)
Chapter 4. Passive Elements: Resistances, Valves and Chambers
Equation 4.4 can also be adapted to take the blood’s inertia into account. Such
a valve model allows to reproduce the fact that the valves "open on pressure and
close on flow" [89,113]. However, adapting Equation 4.4 to include inertances is not
an easy task because the differential Equation 4.3 has to be solved a priori to know
when Q becom s negative, m king simulation more computationally intensive.
4.4 Pressure-Volume Relationships of the Chambers
In lumped models of the CVS, passive elastic chamber elements are used to ac-
count for the deformable properties of the large vessels, namely the arteries and
veins. As its name indicates, the pressure-volume relationship of a chamber de-
scribes the r lationship b tween the blood volume inside the c mber and the
p ssure ex rted by the chambe . The pressure-volum relationship is often de-
scribed using a convex function P(V) [109,114], an example of which is displayed
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Figure 4.4: Left: illustration of P(V) and its first-order Taylor approximation. Right:
illustration of the change of variables in Equation 4.11.
A first-order Taylor approximation of this function around a chosen working
point [109] V = V¯, yields
P(V) ⇡ P(V¯) + dP
dV
    
V=V¯
(V   V¯). (4.5)
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Figure 10.6 – Pressure volume relationship in the cardiovascular system for the passive elements.
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Finally, Figure 10.5 shows that, as it was the case for the pig experiments, the values
of ∆3Rs/Rs are always negative for the parameter identification using 3 Qd (the values
obtained with parameter identification using all the Qd are rather similar). As previously
mentioned in subsection 8.4.2, a possible physiological interpretation could be explained
by the baroreflex.
10.5.3 Prediction of the mathematical model
Table 10.4 has shown small prediction errors (all the relative errors are smaller than 10 %)
but the estimated values of |∆P a/P a|, |∆P v/P v| and |∆maxT(Vh)/maxT(Vh)| are larger
than those obtained with the pig experiments. The larger error on maxT(Vh) could be
due to a worse accuracy with the estimation of this volume by echocardiography. Indeed,
with this method, the clinician has to measure a specific 2D dimension with the electro-
cardiograph and the volume is calculated by assuming that the heart is spherical [98]. The
larger error on P a and P v could be explained by the fact that the breathing of the patient
interferes with the blood pressure signals. Indeed, for the pig experiments, the ventilator
was disconnected to remove the effects of breathing on the cardiovascular system while this
disconnection is, of course, not imposed to the ICU patients. Figure 10.7 illustrates the
time evolution of left ventricle volume, arterial pressure and venous pressure before and
after switching off the ventilator for Pig8. This figure shows that the systolic and diastolic
blood pressures in the arteries are affected by breathing and that the venous pressure is
actually greatly impacted by breathing. This effect could explain the large error on P v
(|∆P v/P v| = 9.8 %) for the clinical trial.
As already mentioned in subsection 8.4.3 of Chapter 8, another important information
is to check that the model allows a better prediction of the physiologically relevant quanti-
ties than a simple interpolation from previous measurements. The quantitative errors for
the predictions obtained with the interpolations can be estimated with the same method
as the prediction errors obtained with the mathematical model. Table 10.5 compares the
mean relative errors obtained using the mathematical model with the corresponding er-
rors obtained with the interpolations. This table shows the same general results as the
pig experiments: the predicted values of P a, P v and SV are a little better with the model
than with the interpolations but the predicted values of PPa is a little worse with the
model than with the interpolations. As far as the values of SV and P a, which are of
paramount importance to check the patient recovery, are concerned, the values obtained
with the mathematical model present relative errors 15 % smaller than those obtained
with the interpolation. This result shows the interest of our modeling approach.
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Figure 10.7 – Time evolution of left ventricle volume, arterial pressure and venous pressure
before and after switching off the ventilator (these experimental data are taken from Pig8).
10.6 Limitations
As already mentioned in Chapter 8, several assumptions were introduced to build the
mathematical model of the cardiovascular system connected to a va-ECLS. A limiting hy-
pothesis is the absence of a description of the cardio-pulmonary controls. For the clinical
trials, another rough hypothesis is that the values of Ri and Ro, describing the resistance of
the input and output valves, are not patient-specific and are taken from literature. Indeed,
some of our patients (Patient1, Patient5 and Patient6) had a replacement of one or two
cardiac valves and the mechanical features of these synthetic valves are certainly different
from real cardiac valves.
Even if the arterial and venous blood pressures are measured continuously in the ICU,
it is impossible, with the current technology used in the CHU of Liège, to extract and
record the complete time evolution of the data. The medical team thus records the hemo-
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Table 10.5 – Comparison between the prediction errors obtained with the mathematical model
and the prediction errors obtained with the interpolations of the measurements.
Global errors Mathematical model Interpolation
|∆PPa/PPa| 0.075 ± 0.053 0.039 ± 0.040
|∆P a/P a| 0.051 ± 0.030 0.060 ± 0.049
|∆P v/P v| 0.098 ± 0.096 0.103 ± 0.096∣∣∣∣∣∆maxT(Vh)maxT(Vh)
∣∣∣∣∣ 0.058 ± 0.060 0.064 ± 0.075
|∆SV/SV | 0.069 ± 0.042 0.081 ± 0.050
|∆EF/EF | 0.093 ± 0.050 0.102 ± 0.052
|∆V TI/V TI| 0.066 ± 0.042 0.073 ± 0.047
∆PPa/PPa -0.016 ± 0.095 0.006 ± 0.057
∆P a/P a -0.026 ± 0.056 -0.016 ± 0.079
∆P v/P v -0.054 ± 0.130 -0.067 ± 0.127
∆maxT(Vh)
maxT(Vh)
0.028 ± 0.074 0.035 ± 0.088
∆SV/SV 0.008 ± 0.084 0.010 ± 0.099
∆EF/EF -0.014 ± 0.100 -0.018 ± 0.108
∆V TI/V TI 0.001 ± 0.082 0.006 ± 0.091
dynamic data by hand and only one value of P a, PPa and P v are taken for each Qd. It
would be useful to investigate a solution in order to extract and record the complete blood
pressure signal since the current method looses a large number of information.
Finally, the number of patients that were considered in our study is rather small and
additional clinical trials should be carried out. Furthermore, the number of different Qd
for each weaning test is also small. The decrease in Qd could be performed with more
intermediate steps and more clinical data would be available with the aim of testing the
predictions of the mathematical model.
10.7 Summary
In this chapter, the clinical application of the cardiovascular model connected to a va-
ECLS has been presented. The current strategy to decide if a patient can be weaned from
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va-ECLS has been described in section 10.1. It consists in estimating several hemody-
namic parameters for a low value of extracorporeal blood flow (Qd ≈ 0.5− 1 l/min). Our
cardiovascular model could be helpful in predicting the hemodynamic parameters for this
low value of Qd. Indeed, with this approach, the clinicians would not need to decrease Qd
until this low value is reached.
To validate the prediction of weaning tests simulated by the mathematical model, the
different parameters of the model have been estimated using clinical data corresponding to
3 different Qd. These estimated parameters are thus patient-specific and their values have
been discussed in subsection 10.5.1 and subsection 10.5.2. After the parameter identifica-
tion, the mathematical model is used to simulate the weaning tests performed on patients
and the simulated values are compared to the clinical data. The relative errors between
the predictions obtained with mathematical model and the clinical data are rather small
(all the relative errors are smaller than 10 %). Like in the pig experiments, the prediction
errors of the mean arterial pressure and of the stroke volume obtained with the mathemat-
ical model are smaller than those obtained with the linear interpolations using the same
measurements as the parameter identification.

Chapter 11
Application for patients assisted by a
vv-ECLS
This chapter describes the methodology to validate our model of the respiratory system
connected to a vv-ECLS with clinical data obtained in the CHU of Liège. The protocol of
the studied clinical trials is described in section 11.1. Using the clinical data, the parame-
ters corresponding to the baseline situation can be estimated with the procedure described
in section 7.2. For the protective ventilation, the method is different and the procedure is
described in section 11.2. The values of the identified parameters are given in section 11.3.
Afterwards, the mathematical model of the respiratory model connected to a vv-ECLS
can be used to simulate the system and the results are presented in section 11.4. Since
the results of the experiments presented in Chapter 9 have shown that the ECLS model
Mod1 is the best ECLS model and that transport delays do not improve the prediction of
the respiratory model connected to a vv-ECLS, the ECLS model used in this chapter is
Mod1 and the transport delays are neglected. As for the pig experiments, the main results
consist in the time evolution of PCO2 estimated by the mathematical model at several
places in the body. Then, the results are discussed and analyzed in section 11.5 and the
limitations of our model are drawn in section 11.6. Finally, section 11.7 summarizes the
results of this chapter.
11.1 Clinical trials
As already mentioned in subsection 7.1.2, two sets of clinical trials are distinguished: clin-
ical trial S, which refers to the European study Supernova [81], and clinical trial R, which
refers to a retrospective study performed on patients assisted by a vv-ECLS in the CHU of
Liège. Clinical trials S should be preferred to test our mathematical model since they fol-
low a stringent protocol (the protocol has already been described in subsection 7.1.2) and
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more clinical data are available. Unfortunately, only one patient (S1) has been recruited
in clinical trial S at the CHU of Liège. Four patients in clinical trial R (R1-R4) are also
analyzed in this chapter. These 4 patients do not follow a unique rigorous protocol: the
main characteristics of each patient are provided in Table 11.1 and the different ventilator
and ECLS settings are summarized in Table 11.2 of section 11.3. Table 11.1 shows that all
patients suffer from severe ARDS (Pa,O2/FI,O2 < 100 mmHg [31]) and, except for patient
R3, the patients also have severe hypercapnia (Pa,CO2 > 70 mmHg). For each patient, the
protective ventilation (or the change of ventilator settings for patient R1) is induced a few
minutes after the ECLS is launched and Table 11.2 provides the values of the ventilator
settings before and after they are changed.
For clinical trial R, the membrane used for the extracorporeal therapy is a Quadrox-iD
Adult® (Maquet, Getinge Group). Blood samples at the inlet and outlet cannulae are
taken several hours after the ECLS initialization.
Table 11.1 – Main characteristics of clinical trial R.
Patient R1 R2 R3 R4
Baseline situation
Severity of ARDS: Pa,O2/FI,O2 (mmHg) 45 41 50 52
Hypercapnia: Pa,CO2 (mmHg) 108 88 41 88
ECLST
Time when blood
samples are drawn
(number of minutes after
the ECLS is switched on)∗
Arterial blood sample 45, 210, 260 30 25, 90 2, 50
Venous blood sample 267 60 1, 2, 25 65
11.2 Estimation of parameters fs and V˙A during the pro-
tective ventilation
Whereas the method to estimate the parameters during baseline situation is the same
as in the pig experiments, the estimation of the parameters fs and V˙A during protective
ventilation (or after the change of the ventilator settings for patient R1) is different (see
∗The number of minutes is approximate
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section 7.2). Indeed, for the patient safety, the protective ventilation is never induced
before the ECLST. In the ICU, the change of the ventilator settings is thus always started
a few minutes after the beginning of the ECLST. Therefore, the goals of the study is not
to predict only the ECLST but it is to predict the ECLST combined with the protective
ventilation. The value of the two parameters fs and V˙A after the change of the ventilator
settings must thus be estimated without any measurements. In such a situation, a first
approximation for these parameters will be obtained from the animal experiments previ-
ously analyzed. In these experiments, one can determined the relative variation of fs and
V˙A in terms of the relative variation of V˙E (V˙E = fr · VT ) and these relations will also be
simply assumed valid for human.
Figure 11.1 shows the relative variation of V˙A with respect to the relative variation of V˙E
for the animal experiments. Since ARDS is also induced in experiments A during protective
ventilation, only experimental data from experiments H are shown in Figure 11.1 and will
be used here (ARDS increases the pulmonary shunt and ARDS could decrease the alveolar
ventilation). In this figure, the diamonds are the experimental data and the dashed line
is the linear interpolation of these data with the natural constraint of passing through
the trivial point (∆V˙E/V˙E = 0, ∆V˙A/V˙A = 0). The interpolation shows that ∆V˙A/V˙A is
almost equal to ∆V˙E/V˙E and the equality ∆V˙A/V˙A = ∆V˙E/V˙E is thus considered valid
for human. Therefore, the estimate
(
V˙A
)
PV
, defining V˙A during protective ventilation (or
after the change of ventilator settings for patient R1), can be obtained as follows:
∆V˙A/V˙A = ∆V˙E/V˙E
⇔
(
V˙A
)
PV
−
(
V˙A
)
Baseline(
V˙A
)
Baseline
=
(
V˙E
)
PV
−
(
V˙E
)
Baseline(
V˙E
)
Baseline
⇔
(
V˙A
)
PV
=
(
V˙A
)
Baseline
·
(
V˙E
)
PV(
V˙E
)
Baseline
, (11.1)
where
(
V˙E
)
PV
is known since this parameter is directly related to the settings fr and VT
of the ventilator that are chosen by the clinicians.
The estimation of parameter fs after a variation of V˙E is more delicate. Indeed, the
left panel of Figure 11.2 shows the relative variation of fs with respect to the relative
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Figure 11.1 – Relative variation of alveolar ventilation ∆V˙A/V˙A in terms of relative variation
of minute ventilation ∆V˙E/V˙E for experiments H.
variation of V˙E for experiments H and no clear relationship between these two quantities
can be established. However, the pig experiments have shown that the ARDS significantly
increases fs (see subsection 9.3.2). These experiments also show that the increase in fs
with the decrease in V˙E is much smaller than the increase in fs related to ARDS induction.
The right panel of Figure 11.2 confirms this statement by comparing the value of ∆fs/fs|∆V˙E/V˙E |
for experiments H with the value of ∆fs/fs|∆V˙E/V˙E | for experiments A and by showing that the
values for experiments A is almost 10 times larger than that of experiments H. Therefore,
the variation of fs with the variation of V˙E is small in comparison with the large changes
of fs for a subject suffering from ARDS. As a first approximation, the variation of fs with
the variation of V˙E will thus be neglected in our mathematical model. This assumption
gives the following estimation of fs during protective ventilation:
(fs)PV = (fs)Baseline . (11.2)
Note that these estimations of the 2 parameters V˙A and fs after the change of the
ventilator settings are first approximations. The estimations of these parameters will be
discussed in subsection 11.5.2 and, using clinical data, a new and better estimation of
(fs)PV will be suggested.
11.3 Values of the parameters
The diffusion coefficients across the membrane of the ECLS are not supposed to be the
same in clinical trial S than in clinical trial R since the membranes are different. Using
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Figure 11.2 – Relative variation of pulmonary shunt ∆fs/fs in terms of relative variation of
minute ventilation ∆V˙E/V˙E (left panel) and mean of the fraction of the relative variation of
pulmonary shunt ∆fs/fs over the absolute value of the relative variation of minute ventilation
∆V˙E/V˙E for experiments H and experiments A (right panel).
the method presented in subsection 7.2.5, the coefficients DCO2 and DO2 can be estimated
for each membrane and the values are given in Table 11.2. The setting of the ECLS are
different for each clinical trials and are also given in Table 11.2. For the extracorporeal
blood flow Qd, it is always larger or equal to 1 l/min and the recirculation is thus taken
into account for the clinical trials (see subsection 5.3.2, p. 74).
The other parameters of the model are also provided in Table 11.2 for all the patients.
Parameter FI,O2 , VT and fr are the ventilator settings. On the other hand, the values
of MRCO2 , MRO2 and kHCO3 are determined by the procedures described in subsections
7.2.1 and 7.2.3. However, for clinical trial R, no venous measurements are taken before the
ECLST and MRCO2 , MRO2 have to be estimated during ECLST. Indeed, some venous
and arterial blood samples are taken during ECLST when the patient reaches a stabilized
state (PO2 and PCO2 are in a time independent situation). Since the mathematical model
assumes constant metabolism for ICU patients, these estimated values are also valid dur-
ing baseline situation.
The values of the parameters describing the pulmonary insufficiencies, fs and V˙A, are
determined by the procedures described in subsections 7.2.4 for the baseline situation and
in section 11.2 for the protective ventilation. The values of these parameters for each
patient are also given in Table 11.2.
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Table 11.2 – Measurements, settings of the ventilator and ECLS, identified parameters and
estimated parameters for clinical trial S (S1) and for Clinical trial R (R1-R4).
Clinical trial S Clinical trial R
Data S1 R1 R2 R3 R4
Baseline situation
Measurements
Weight (kg) 77 80 113 132 71.3
Height (cm) 177 181 186 175 160
Weight base parameters
CO (l/min) 5.84 6 7.25 7.60 5.34
VL,CO2 (l) 3.29 2.99 4.81 5.63 3.04
VL,O2 (l) 2.54 2.31 3.72 4.36 2.35
VT,CO2 (l) 15.5 14.0 22.5 26.4 14.3
VT,O2 (l) 6.2 5.6 9.0 10.6 5.7
Ventilator settings
FI,O2 0.6 1 1 1 1
VT (l) 0.475 0.317 0.329 0.422 0.362
fr (min-1) 25 40 35 22 26
Identified parameters
MRO2 (lO2/min) 0.204 0.300 0.276 0.258 0.258
MRCO2 (lCO2/min) 0.204 0.300 0.276 0.258 0.258
kHCO3 (lCO2/l) 2.6 ·10−5 -0.098 0.300 0.064 0.053
fs 0.319 0.558 0.588 0.573 0.515
V˙A (l/min) 4.04 2.77 3.19 6.97 2.97
Measured parameters
CHb (lHb/l) 0.163 0.125 0.133 0.191 0.147
ECLST combined with protective ventilation (except R1)
Ventilator settings
FI,O2 0.6 1 1 0.8 1
VT (l) 0.375 → 0.330 → 0.300 0.554 0.135 0.270 170
fr (min-1) 25 27 10 12 10
ECLS setting
Qd (l/min) 1 4 4 5 4.1
V˙D (l/min) 6 4 9 9 → 6 ∗ 9
FID,O2 0.21 0.7 1 1 1
Estimated parameters
fs 0.319 0.558 0.588 0.573 0.515
V˙A (l/min) 3.19 → 2.80 → 2.55 3.27 0.37 2.43 0.54
Identified parameters
DCO2 (lCO2/s/mmHg) 8.5 · 10−5 1.6 · 10−4
DO2 (lO2/s/mmHg) 6.4 · 10−6 5.8 · 10−6
∗The decrease in V˙D from 9 to 6 l/min was set approximately 45 minutes after the ECLS was launched
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Finally, parameters VL,CO2 , VL,O2 , VT,CO2 , VT,O2 and VTB are proportional to the body
weight (Table 7.1, p. 99). Cardiac blood flow is not always measured in the ICU before
or after the first hours of ECLST. In our study, CO is assumed to be proportional to the
BSA (see subsection 9.3.4, p. 140). To estimate the BSA, the Mosteller formula [115] is
used and the approximation of CO is thus given by:
CO (l/min) = 3 · BSA = 3 ·
√
Weight ·Height
3600
, (11.3)
where the weight is in kg and the height is in cm. The values of VL,CO2 , VL,O2 , VT,CO2 ,
VT,O2 , VTB and CO for each patient are given in Table 11.2.
11.4 Comparaison between simulations and clinical data
Like in section 9.2 for the pig experiments, the simulations must be compared with clinical
data in order to validate the model in the ICU. In clinical trial R, a traditional ECLS is
used (not a ECCO2RD) and the oxygenation of blood is as essential as the CO2 removal.
Therefore, for this chapter, both the O2 and the CO2 partial pressure simulations are
compared with the experimental data. For both molecules, the mean errors ∆P and the
mean relative errors ∆P/P (see section 11.4), with and without the absolute value, are
used to test the predictions of the model. Since the first minutes of PO2 and PCO2 pre-
dictions are not useful for the goal of this study and since the unstationary description of
the mathematical model is based on rough approximations, the clinical data taken during
the first 10 min of ECLST will not be taken into account to test the prediction of the
simulations.
Remember also that the protocols of clinical trial S and clinical trial R are quite
different and the corresponding results will be thus presented separately, with clinical trial
S considered in subsection 11.4.1 and clinical trial R considered in subsection 11.4.2.
11.4.1 Clinical trial S
Figure 11.3 presents the time evolutions of PCO2 (upper panel) and PO2 (bottom panel)
in the arteries and veins during the different phases of observation (before the ECLST,
when the ECLS is switched on and the tidal volume is reduced to 0.375 l, when the tidal
volume is reduced to 0.330 l and when the tidal volume is reduced to 0.300 l). In this
figure, the full lines describe the numerical simulations while diamonds and crosses de-
scribe the experimental data in the arteries and veins respectively. Before the ECLST,
the agreement is perfect for PCO2 in the arteries since parameters fs and V˙A are iden-
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tified to fit PCO2 in the arteries. On the other hand, as already observed in Figure 9.4
of subsection 9.2.2, the agreement is not perfect for the venous PCO2 because MRCO2
is not estimated with the measurements but with the approximation MRCO2 = MRO2 .
During the ECLST, the simulations correspond quite well with the experimental data and
they both show a significant decrease in PCO2 in the arteries and veins when the ECLS is
switched on, a small increase in PCO2 when the tidal volume is reduced to 0.330 l and when
the tidal volume is reduced to 0.300 l, a small decrease in PO2 when the ECLS is switched
on and almost no change of PO2 when the tidal volume is reduced to 0.330 l and to 0.300 l.
Table 11.3 provides the mean errors ∆P and the mean relative errors ∆P/P , with
and without absolute value, for PCO2 and PO2. The number of PCO2 or PO2 measure-
ments (m) is also given. It can be seen from this table that the PCO2 errors are small
(|∆PCO2|/PCO2| = 0.06 ± 0.04) and we can consider that the simulations do not overesti-
mate or underestimate the experimental data (∆PCO2/PCO2 =0.01± 0.05). The PO2 errors
are larger than the PCO2 errors (|∆PO2/PO2 | =0.14 ± 0.08 compared to |∆PCO2/PCO2 |
= 0.04 ± 0.03) and overestimations are always observed for the PO2 errors (∆PO2/PO2 =
0.14 ± 0.08).
11.4.2 Clinical trial R
Figure 11.4 presents the time evolutions of PCO2 (left panel) and PO2 (right panel) in the
arteries and veins during the different phases of observation (before the ECLST and when
the ECLS is switched on) for patient R2. The results for the other patients have similar
features and are given in Figure B.8 of Appendix B.4. As in Figure 11.3, the full lines
describe the numerical simulations while diamonds and crosses describe the experimental
data in the arteries and veins respectively. The agreement is also perfect for PCO2 in the
arteries before the ECLST. During the ECLST, the PCO2 simulations correspond quite
well with the experimental data but, on the other hand, there is a significant error between
the PO2 simulations and the experimental data. The simulations show a large decrease in
PCO2 in the arteries and veins even after the induction of the protective ventilation. They
also show a large increase in PO2 in the arteries and veins when the ECLS is switched on
and a significant decrease in PO2 when the protective ventilation is induced. The increase
is larger than the decrease and PO2 is thus larger during the ECLST combined with the
protective ventilation than before the ECLST. The experimental data also show an in-
crease in PO2 in the arteries during the ECST combined with the protective ventilation.
Table 11.4 provides the mean errors ∆PCO2 and ∆PO2 and the mean relative errors
∆PCO2/PCO2 and ∆PO2/PO2 , with and without absolute value, for the 4 patients (R1, R2,
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Figure 11.3 – Time evolution of calculated (lines) and measured (crosses and diamonds) CO2
partial pressures in the veins and arteries (upper panel) and O2 partial pressures in the veins and
arteries (bottom panel) for the patient S1. The different phases of observation are delimited by
vertical arrows, with self explaining-labels.
Table 11.3 – PCO2 and PO2 errors between the simulations and the measurements during
ECLST for patient S1. The line m indicates the number of PCO2 or ¶O2 measurements available
during ECLST .
Data CO2 O2
|∆P | (mmHg) 1.43 ± 1.28 7.12 ± 4.48
|∆P/P | 0.04 ± 0.03 0.14 ± 0.08
∆P (mmHg) -1.00 ± 1.97 7.12 ± 4.48
∆P/P 0.01 ± 0.05 0.14 ± 0.08
m 9 9
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Figure 11.4 – Time evolutions of calculated (lines) and measured (crosses and diamonds) CO2
partial pressures in the veins and arteries (left panel) and O2 partial pressures in the veins and
arteries (right panel) for the patient R2. The different phases of observation are delimited by
vertical arrows, with self-explaining labels.
R3 and R4). The number of PCO2 or PO2 measurements (m) is also given. This table
demonstrates that the error is small for PCO2 and the value of |∆PCO2/PCO2 | for all the
patients is of the same order as the one obtained with pig experiments (|∆PCO2/PCO2 |
= 11%, see Table 9.3 p. 136). ∆PCO2/PCO2 for all the patients is positive (∆PCO2/PCO2
= 5%) and this result indicates that the PCO2 simulations frequently overestimate the
experimental data. On the other hand, the error is rather large for PO2 (|∆PO2/PO2 |
for all patients is equal to 28%) and the simulations overestimate the experimental data
(∆PO /PO2 for all patients is equal to 20% and only the patient R1 underestimate the
experimental data).
Table 11.4 – PCO2 and PO2 errors between the simulations and the measurements during
ECLST for clinical trial R. The line m indicates the number of PCO2 or PO2 measurements
available during ECLST (after the change of ventilator settings).
CO2 O2
Data R1 R2 R3 R4 Mean R1 R2 R3 R4 Mean
|∆P | (mmHg) 5.47 4.56 4.52 1.68 4.05 17.24 8.69 11.32 22.34 14.90
|∆P/P | 0.16 0.09 0.16 0.04 0.11 0.19 0.25 0.20 0.50 0.28
∆P (mmHg) 5.47 -4.56 3.64 0.17 1.18 -16.36 8.69 11.32 22.34 6.50
∆P/P 0.16 -0.09 0.13 0.00 0.05 -0.16 0.25 0.20 0.50 0.20
m 4 2 2 2 4 2 2 2
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11.5 Discussion
This section discusses the physiological meaning of important parameters estimated in
this chapter and compares these values with the values obtained with pig experiments (see
Chapter 9). In addition, this section also discusses the ability of our model to predict the
decrease in PCO2 and PO2 during the ECLST.
11.5.1 Values of the parameters
The diffusion coefficients across the membrane of the ECLS, DCO2 and DO2 , are similar
for clinical trial S and clinical trial R (Table 11.2) and, as expected, DCO2 is larger than
DO2 . DCO2 and DO2 for the ECLS used in the ICU are larger than those estimated for the
pig experiments. This difference can be explained by the exchange surface of the ECLS
membrane which is smaller for the pig experiments (the ECLS used in the experiments
is a PALP® (Getinge, Sweden) while the ECLS used in the clinical trials is an HLS Set
Advanced 5.0® (Getinge, Sweden) or a Quadrox-iD Adult® (Getinge, Sweden)).
Table 11.2 shows that the values of the lumped parameter V˙A are in the same range
than the pig experiments (Table 9.1 p. 130). The values of V˙A for humans are a bit larger
since parameter VT is larger because of a larger weight for the patients than that of the
pigs. In this table, the values of fs are in the same range as in experiments A during the
protective ventilation combined with ARDS (Table 9.1 p. 130). fs is larger for clinical trial
R than clinical trial S and this result is in agreement with clinic since patients R suffer
from ARDS while patient S1 suffers from moderate lung pathology. The value of fs for
patients R is larger than in previous studies on humans suffering from ARDS (31±10%
[54]) but in these studies the patients were not assisted with an ECLS and their respiratory
pathologies were certainly less severe than in our study. The values of MRO2 and MRCO2
(0.259±0.035 lO2/min/kg and lCO2/min/kg) are in the same range than previous studies
(MRO2 = 0.26 − 0.31 lO2/min/kg and MRCO2 = 0.21 − 0.26 lCO2/min/kg [9, 10]).
11.5.2 Quality of the PCO2 and the PO2 predictions
For the clinical trial S, the agreement between the PCO2 simulations and experimental
data is excellent and the agreement between the PO2 simulations and experimental data
is rather good for but only one case S1 was recorded in our hospital. However, for this
patient S1, a significant number of experimental data was recorded during the first hours
of ECLST (9 blood samples were taken for this patient). On the other hand, for clinical
trial R, the agreement between the PCO2 simulations and experimental data is good but
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the difference between the PO2 simulations and experimental data is significant.
In order to improve the prediction of PO2, the parameters influencing PO2 and which
were based on rough approximation, are analyzed in more detail in the following para-
graphs. The estimation of V˙A after the change of the ventilator settings is based on the
approximation 11.1. However, Figure 11.3 shows that PO2 undergoes nearly no variation
with the decrease in VT from 0.375 l to 0.300 l while PCO2 increases appreciably. This
phenomena can be explained by the fact that hemoglobin is fully saturated after the pul-
monary capillaries even during protective ventilations. Therefore, the decrease in VT to
achieve a protective ventilation will have a minute influence on PO2 in arteries. Since VT
is directly proportional to V˙A, V˙A influences mainly PCO2. With this information and the
small errors obtained for the simulated PCO2 (Table 11.3 and Table 11.4), the value of
parameter V˙A after the change of the ventilator settings, which is estimated using equation
11.1, can be considered as a good approximation. On the contrary, fs influences PO2 and
the value of this parameter after the change of the ventilator settings, which is estimated
using the approximation 11.2, could be erroneous. Table 11.3 and Table 11.4 show that
the PO2 simulations overestimate the experimental data and the difference between these
simulations and the experimental data could be decreased by increasing fs.
Other parameters also greatly influence PO2. The value of extracorporeal recirculation
Rrecir is based on rough approximation (equation 5.13, p. 74) and an increase in this
parameter will decrease PO2 since the efficacy of the ECLS will be reduced. Finally, the
hemoglobin concentration is changed when ECLS is started since extracorporeal circulation
is filled with water before the ECLST. As a consequence, a dilution of hemoglobin occurs
when the ECLS is switched on and this effect could decrease PO2 since less hemoglobin
molecules will reach the tissues.
The influence of the 2 parameters, fs and Rrecir, and of the dilution of hemoglobin on
PO2 and PCO2 is analyzed below.
Influence of Rrecir
The value of Rrecir, defined by equation 5.13, depends on the parameter krecir which
has been fixed to an empirical value of 0.083 min/l. If krecir is arbitrary increased from
0.083 to 0.15, the recirculation Rrecir for patient R2 is increased from 0.332 to 0.6 and
Figure 11.5 compares the PCO2 and the PO2 simulations in the veins and arteries for
patient R2 when Rrecir = 0.6 with the previous PCO2 and PO2 simulations in the veins
and arteries (Rrecir= 0.332). This figure shows that the increase in Rrecir improves the
agreement between the PO2 simulations and experimental data. However, the increase
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in Rrecir has also a significant influence on PCO2 since the calculated PCO2 considerably
increases when Rrecir increases. Therefore, the increase in Rrecir cannot improve the PO2
description without reducing the quality of the PCO2 predictions.
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Figure 11.5 – Comparison of the PCO2 (left panel) and the PO2 (right panel) simulations in the
veins and arteries when Rrecir = 0.6 (dotted lines) with the previous PCO2 and PO2 simulations
(Rrecir = 0.33, these simulations are described by solid lines). The different phases of observation
are delimited by vertical arrows, with self explaining-labels.
Influence of the dilution
For taking into account the dilution of hemoglobin, a dilution ratio DHb is estimated with
the following formula:
DHb =
VTB
VTB + VIN + VOUT
. (11.4)
where the numerator is the total volume of the cardiovascular system and the denominator
is the total volume of the cardiovascular system complemented by the extracorporeal
circulation (all the symbols have already been defined in subsection 5.5, p. 76). Therefore,
the mathematical model can estimate the hemoglobin concentration when the ECLS is
switched on by the following equation:
(CHb)ECLST = DHb · (CHb)Baseline , (11.5)
and the relative variation of CHb can be deduced from equation 11.5:
∆CHb/CHb =
(CHb)ECLST − (CHb)Baseline
(CHb)Baseline
= DHb − 1 . (11.6)
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Table 11.5 gives the measurements of hemoglobin concentrations during baseline situation
and ECLST situation. This table also provides the relative variation of these measurements
and the value of DHb−1 for each patient. The measurements indicates that ∆CHb ≈ −13%
while the corresponding estimations (DHb− 1) is approximately equal to -8 %. Therefore,
parameter DHb predicts rather nicely the dilution of blood when the ECLS is switched
on. Figure 11.6 compares the PCO2 and the PO2 simulations when dilution is taken into
account (dotted lines) and when dilution is not taken into account (solid lines). There is
almost no difference between the two simulations for PCO2 in the arteries and veins, there
is a tiny difference between the two simulations for PO2 in the arteries and there is a small
difference between the simulations for PO2 in the veins. Consequently, taking into account
the dilution of blood slightly improves the PO2 description without reducing the quality
of the PCO2 predictions (Table B.7 and Table B.8 of Appendix B.4 that show ∆PCO2 ,
∆PO2 , ∆PCO2/PCO2 and ∆PO2/PO2 with and without absolute value for all the patients).
Therefore, the dilution of hemoglobin should be taken into account in the mathematical
model and this effect will be considered in all the subsequent simulations.
Table 11.5 – Hemoglobin concentrations during baseline situation and ECLST situation, relative
variation of these concentrations and the estimation of 1 −DHb for clinical trial S (S1) and for
clinical trial R (R1-R4).
Clinical trial S Clinical trial R
Data S1 R1 R2 R3 R4
Baseline situation
Measured parameters
CHb (lHb/l) 0.163 0.125 0.133 0.191 0.147
ECLST combined with protective ventilation (except R1)
Measurements
CHb (lHb/l) 0.141 0.108 0.109 0.170 0.132
∆CHb/CHb -0.137 -0.137 -0.178 -0.110 -0.107
Estimated parameters
DHb − 1 -0.10 -0.09 -0.07 -0.06 -0.10
Influence of fs
Since V˙A does not influence PO2, the estimation of parameter fs is of paramount impor-
tance to fit the experimental PO2. As in the two previous analysis, it would be useful to
estimate if this parameter influences PCO2. If fs is estimated to fit the experimental PO2
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Figure 11.6 – Effect of dilution on the prediction of PCO2 and PO2. The solid lines represent
the PCO2 (left panel) and the PO2 (right panel) simulations in the veins and arteries when DHb
= 1 while the dotted lines represent the PCO2 (left panel) and the PO2 (right panel) simulations
in the veins and arteries when DHb = 0.93). The different phases of observation are delimited by
vertical arrows, with self-explaining labels.
after the change of the ventilator settings for patient R2, the identified value of fs is equal
to 0.76. Figure 11.7 compares the PCO2 and the PO2 simulations in the veins and arteries
for patient R2 when parameter (fs)PV is increased from 0.588 (previously used value) to
0.76. Note that for these simulations, the dilution of hemoglobin is taken into account.
With the new value of fs, the agreement between simulations and experimental data is
perfect for PO2. The comparison between the PCO2 simulations obtained with the new
value of fs with the previous PCO2 simulations shows that the new predicted values are
almost identical to the previous simulations.
Since Table 11.3 and Table 11.4 have shown that the PO2 simulations overestimate the
experimental data for each patient except patient R1, the increase in parameter fs during
the protective ventilation for patient S1, R2, R3 and R4 and the decrease in fs after
the change of the ventilator settings for patient R1 (for this patient the tidal volume is
increased) would improve the PO2 prediction of our mathematical model. In addition, since
fs has a little influence on PCO2, this variation of fs will not affect the good predictions of
the simulated PCO2. Furthermore, the physiological meaning of the increase in fs with the
decrease in V˙E has already been described in subsection 9.3.2, p. 138 (the lung dynamics
are changed and some alveoli could collapse with the reduction of V˙E). Therefore, the
assumption of no variation of fs with V˙E, which has been established in section 11.2,
should be reconsidered. To build a relationship between ∆fs and ∆V˙E, the values of fs
after the change of ventilator setting is estimated by fitting PO2 in the arteries during this
phase and the variation of fs in terms of ∆V˙E could be established.
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Figure 11.7 – Comparison of the PCO2 (left panel) and the PO2 (right panel) simulations
in the veins and arteries when (fs)PV = 0.75 (dotted lines) with the previous PCO2 and PO2
simulations ((fs)PV = 0.558, these simulations are illustrated by solid lines). The different phases
of observation are delimited by vertical arrows, with self-explaining labels.
Table 11.6 shows the values of fs identified after the change of the ventilator settings
and Figure 11.8 shows ∆fs/fs in terms of ∆V˙E/V˙E for all the patients. In Figure 11.8,
the diamonds represent the clinical data and the dashed line is the linear interpolation of
these data with the natural constraint of passing trough the trivial point (∆V˙E/V˙E = 0,
∆fs/fs = 0). This figure shows that the errors between the clinical data and the interpo-
lation are small and well distributed (3 clinical data underestimate ∆fs/fs and 4 clinical
data overestimate ∆fs/fs). Therefore, the interpolation gives a good approximation of the
relative variation of fs in terms of the relative variation of V˙E and equation 11.2, which
has provided the first approximation of (fs)PV , is thus replaced by the following equation:
∆fs/fs = −0.45 ·∆V˙E/V˙E
⇔ (fs)PV = (fs)Baseline · (−0.45) ·∆V˙E/V˙E + (fs)Baseline . (11.7)
With this new estimation of fs after the variation of the ventilator settings, the
mathematical model is simulated for each patient and ∆PCO2 , ∆PO2 , ∆PCO2/PCO2 and
∆PO2/PO2 , with and without absolute value, are provided in Table 11.7 and Table 11.8.
These tables demonstrate that the PO2 errors is greatly decreased with the new values of
(fs)PV : |∆PO2/PO2| = 0.11 instead of 0.26 for patients R (Table B.7 of Appendix B.4) and
|∆PO2/PO2| = 0.05 instead of 0.10 for patient S1 (Table B.8 of Appendix B.4). The PCO2
errors have still the same values (|∆PCO2/PCO2| = 0.11 for patients R and |∆PCO2/PCO2 |
= 0.04 for patient S1). Therefore, the agreement between the simulations and the experi-
mental data is much better with the new estimations of (fs)PV .
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Table 11.6 – Identified fs during baseline and after the change of ventilator settings for clinical
trial S (S1) and for clinical trial R (R1-R4).
Clinical trial S Clinical trial R
Data S1 R1 R2 R3 R4
Baseline situation
fs 0.319 0.558 0.588 0.573 0.515
ECCO2RT combined with protective ventilation (except R1)
fs 0.388 → 0.389 → 0.397 0.502 0.759 0.705 0.744	
-0,3	-0,2	
-0,1	0	
0,1	0,2	
0,3	0,4	
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Figure 11.8 – Relative variation of pulmonary shunt ∆fs/fs in terms of relative variation of
minute ventilation ∆V˙E/V˙E .
Table 11.7 – PCO2 and PO2 errors between the simulations and the measurements during ECLS
for clinical trial S when the dilution is taken into account and when the estimation of parameter
fs is given by equation 11.7. The line m indicates the number of PCO2 or PO2 measurements
available during ECLST.
Data CO2 O2
|∆P | (mmHg) 1.37 ± 1.23 3.07 ± 2.84
|∆P/P | 0.04 ± 0.03 0.06 ± 0.05
∆P (mmHg) 0.15 ± 1.89 0.85 ± 4.23
∆P/P 0.00 ± 0.05 0.03 ± 0.08
m 9 9
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Table 11.8 – PCO2 and PO2 errors between the simulations and the measurements during ECLS
for clinical trial R when the dilution is taken into account and when the estimation of parameter
fs is given by equation 11.7. The line m indicates the number of PCO2 or PO2 measurements
available during ECLST (after the change of ventilator settings).
CO2 O2
Data R1 R2 R3 R4 Mean R1 R2 R3 R4 Mean
|∆P | (mmHg) 5.16 5.74 4.50 1.37 4.19 12.44 5.80 2.07 2.80 5.78
|∆P/P | 0.15 0.11 0.16 0.03 0.11 0.13 0.17 0.05 0.08 0.11
∆P (mmHg) 5.16 -5.74 4.50 -0.36 0.89 -10.34 -5.80 -2.07 2.80 -3.85
∆P/P 0.15 -0.11 0.16 -0.01 0.05 -0.09 -0.17 -0.05 0.08 -0.06
m 4 2 2 2 4 2 2 2
11.6 Limitations
Table 11.7 and Table 11.8 show that the errors between the simulations and the experi-
mental data are as small as the errors for pig experiments. Nevertheless, one must keep
in mind that several limitations must be emphasized.
Like in the pig experiments, the approximation of equal MRCO2 and MRO2 is taken
(see section 9.4 p. 143). In addition, there is no venous blood sample taken before the
ECLST for clinical trial R and the value of MRCO2 and MRO2 are thus estimated during
ECLST for these patients. Since the goal of this study is to predict the time evolutions of
PCO2 and PO2 when the ECLS is switched on, no measurement should be taken during
ECLST. Therefore, additional clinical trial should be carried out with venous blood sam-
ples taken before the ECLST. These additional data do not requires extra effort from the
medical team since a central venous line is often available for patients with these patho-
logical conditions.
The recirculation cannot be neglected for clinical trial R since the extracorporeal blood
flow is much larger than 1 l/min. However, the value of Rrecir cannot be estimated with
the available clinical data and an empirical relationship is used (see equation 5.13 of sub-
section 5.3.2 p. 74).
For the clinical trials, the protective ventilation is induced just after the ECLST. There-
fore, the goal of the mathematical model is to predict the ECLST but also the protective
ventilation. To achieve that goal, one has tried to find the relationship between the relative
variation of fs (∆fs/fs) in terms of the relative variation of V˙E (∆V˙E/V˙E) and the rela-
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tionship between the relative variation of V˙A (∆V˙A/V˙A) in terms of ∆V˙E/V˙E. While the
relationship between ∆V˙A/V˙A and ∆V˙E/V˙E seems reasonable (∆V˙A/V˙A = ∆V˙E/V˙E) and
this relationship is also valid for the pig experiments, the relationship between ∆fs/fs and
∆V˙E/V˙E is only based on an empirical formula and has been estimated using the clinical
data during ECLST. With the aim to increase the validity of the empirical relationship
between ∆fs/fs and ∆V˙E/V˙E, more clinical data is needed and the additional clinical data
could check the linear interpolation which has been presented in Figure 11.8.
The cardiac output was not estimated before the ECLST and an empirical formula
have been used to provide an approximation of CO. Even if the accuracy of the CO es-
timation by echocardiography is weak, this estimation will be irrefutably better than the
approximation given by equation 11.3. In addition, taking this value will not change the
protocol used in the ICU since an echocardiography is already used to check the localisa-
tion of the cannulae in the cardiovasular system.
Finally, the number of measurements is small for clinical trial R and, in addition to
perform more clinical trials, more blood samples should be drawn during the first hours
of ECLST in order to validate the model.
11.7 Summary
The mathematical model of the respiratory system connected to a vv-ECLS has several
patient-specific parameters and these parameters have been estimated with clinical data.
However, for the clinical trials, the protective ventilation is induced during the ECLST
and the new values of fs and V˙A cannot be estimated before ECLST. The mathematical
model thus estimates these parameters after the change of the ventilator settings without
using clinical data during this situation. When all the parameters are identified, the math-
ematical model can correctly simulate the decrease in PCO2 and PO2 during the ECLST.
To validate the mathematical model, the PCO2 and the PO2 predictions are compared
with clinical data. For the final simulations, the following features are considered:
• the ECLS model is the model Mod 1,
• transport delays are neglected,
• dilution of hemoglobin when the ECLS is switched on is taken into account,
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• the value of V˙A after the change of the ventilator settings is estimated with equation
11.1 and
• the value of fs after the change of the ventilator settings is estimated with equation
11.7.
The final results show that the agreement between the mathematical simulation and the
clinical data is encouraging: the mean relative error |∆PO2/PO2 | and |∆PO2/PO2| of all the
patients of clinical trial R are both equal to 0.11, and |∆PCO2/PCO2| of patient S1 is equal
to 0.04 and |∆PO2/PO2 | of patient S1 is equal to 0.05. These results could even be better
if all the clinical trials followed a stringent protocol such as clinical trial S. However, the
number of patients and the number of measurements are small and more clinical trials
should be carried out to confirm the validation of our mathematical model.
Chapter 12
Conclusion and future work
Extracorporeal life support (ECLS) is already largely used for helping patients suffering
from acute heart and/or lung pathologies. When this technology is used in venovenous
configuration (vv-ECLS), it ensures vital functions of the lung and, when this device is
set up in venoarterial configuration (va-ECLS), it ensures both vital functions of the heart
and the lungs. However, clinicians still face several issues with the use of ECLS and new
therapeutic approaches could improve the medical care given in the intensive care unit
(ICU).
Mathematical models of human physiology become increasingly used to develop unique
tools to personalise care in the ICU [22]. These models are elaborated to be subject-specific
since the parameters of the model are estimated using clinical data. After a proper valida-
tion, the models can be solved in silico to test different clinical approaches or can be used
in real-time to provide therapeutic solutions at the patient’s bedside [22]. In the present
study, such mathematical models have been developed to provide tools which could help
clinicians to improve the use of ECLS.
In this final chapter, the content of this thesis is summarized in section 12.1 and the
main findings are recalled in section 12.2. The methodology for developing and validating
the mathematical models contains of course some limitations, which are summarized in
section 12.3. Finally, the long-term prospect of this study, which consists in developing
medical tools to improve the therapeutic strategy of patient assisted by ECLS, is presented
in section 12.4.
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12.1 Summary
This thesis aims to find a solution to overcome two of the main issues related to the use
of ECLS. The first one concerns the weaning of va-ECLS. Indeed, the clinicians cannot
easily estimate the heart activity when the device is working since, with the venoarterial
configuration, the extracorporeal blood flow Qd decreases the preload and increases the
afterload of the heart. Therefore, the medical team decreases progressively Qd until a
value of approximately 0.5 l/min is reached. For this small value, the interaction of the
ECLS on the cardiovascular system is minimized and clinicians can estimate the hemo-
dynamics of this system. This approach is called a weaning test. In the present study, a
mathematical model has been developed to allow the prediction of the hemodynamics of
the cardiovascular system for lower values of Qd. With this method, an estimation of the
essential hemodynamic variables for Qd = 0 l/min can be calculated and the weaning test
can thus be performed without reducing Qd until a value of approximately 0.5 l/min is
reached. The second issue concerns the settings of vv-ECLS. Indeed, for a given patient,
the clinicians do not know the optimal ventilator and ECLS settings before switching on
the vv-ECLS. Therefore, a mathematical model of the respiratory system connected to a
vv-ECLS has been developed to allow the predictions of PCO2 and PO2 time evolutions.
These predictions can be estimated for different ventilator and ECLS settings and, with
these results, the optimal ventilator and ECLS settings could be chosen. To provide a
potential solution of these two issues, this thesis has been elaborated into 5 main parts
and each are summarized below.
Chapter 2 of Part I has introduced a basic description of the cardiovascular and respi-
ratory systems. This chapter has highlighted the important parameters of these systems
such as the elastance and the resistance of the cardiovascular system and the alveolar
ventilation and the capillary perfusion. The next chapter has introduced the different
components and the applications of ECLS. As the previous chapter, Chapter 3 has also
highlighted the important parameters of this extracorporeal device such as O2 and CO2
diffusion coefficients across the synthetic membrane and the extracorporeal blood flow.
Part II has presented a simple way of modeling the respiratory and cardiovascular sys-
tems and ECLS. Chapter 4 has described the relations between pressures and volumes for
the passive elements (veins and arteries) and the active element (the heart) of the cardio-
vascular system. The modeling of va-ECLS hemodynamics has been extremely simplified.
The interaction between ECLS and the cardiovascular model is simply modeled as a pa-
rameter input. This parameter is the extracorporeal blood flow. Chapter 5 has presented
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the equations defining the gas exchanges in the lungs, in the tissues and in the vv-ECLS.
Part III has described the parameter identifications of the cardiovascular and respira-
tory models and of the ECLS model. Chapter 6 has presented which parameters of the
cardiovascular model connected to va-ECLS can be identified with the available measure-
ments in our lab and in the ICU. These parameters are the elastance in the arteries, the
stress blood volume, the systemic cardiovascular resistance and two parameters describing
the relation between pressures and volumes in the heart (one for the end-diastolic pressure
volume relationship and one for the end-systolic pressure volume relationship). These 5
parameters are assumed to vary linearly with Qd and 10 coefficients describing these lin-
ear relationships are estimated with the measurements. The measurements are the mean
blood pressure and the pulse blood pressure in the arteries, the mean blood pressure in
the veins, the maximum blood volume in the heart and the stroke volume for 3 different
Qd. The 10 coefficients are thus subject-specific. The heart rate is also a parameter of
the cardiovascular model and it is directly measured in our lab and in the ICU. The other
parameters of the model are considered constant and are taken in the literature. Chapter 7
has presented a simple way to estimate the parameters for the lungs, tissues and vv-ECLS.
For the lung, the parameters are the pulmonary shunt and the alveolar ventilation. They
are estimated using PO2 and PCO2 in arteries. For the tissues, the parameters are MRO2
andMRCO2 defining the consumption of O2 and the production of CO2 by the metabolism.
The assumption that MRO2 = MRCO2 is taken and MRO2 is estimated using the mea-
surements of O2 concentrations in arteries and in veins and of cardiac output. For the
vv-ECLS, the parameters are the O2 and CO2 diffusion coefficients across the synthetic
membrane. These coefficients are estimated using the measurements of PO2 and PCO2 at
the inlet and outlet cannulae. Some parameters do not need to be estimated since they are
directly measured. These parameters are the hemoglobin concentration and the cardiac
output. Except for the parameter kHCO3 describing the variations between individuals in
standard HCO3 concentration, the parameters related to blood chemistry are considered
constant and taken in the literature. The other parameters of the respiratory model are
assumed to be proportional to the body weight.
Using the mathematical models with the corresponding parameter identification, the
simulations of the cardiovascular system connected to a va-ECLS and of the respiratory
system connected to a vv-ECLS can be carried out. Chapter 8 of Part IV discusses the
validation of the cardiovascular model during weaning tests from a va-ECLS. This chapter
compares the values simulated by the mathematical model with the experimental data
related to different Qd (smaller than the Qd used for the parameter identification). The
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result of this comparison demonstrates that the model is able to reproduce the experimen-
tal data. Chapter 9 of Part IV discusses the validation of the respiratory model during
the first hours of vv-ECLS therapy. This chapter shows that the PCO2 values simulated
by the mathematical model correspond nicely with the experimental data.
Part V is similar to Part IV except that the simulations are compared to clinical data
taken in the ICU. Chapter 10 demonstrates that the model is able to reproduced the
clinical data during weaning tests from a va-ECLS. Chapter 11 shows that the PCO2 and
PO2 values simulated by the mathematical model correspond nicely to the clinical data.
12.2 Main findings
This thesis has presented two new minimal models that can be identifiable using clinical
data. Previous models of the cardiovascular system [18, 107, 86, 105, 67, 21, 47, 95, 97, 17]
and of the respiratory system [37, 113, 9, 54, 93, 14, 116, 74, 72] have already been pub-
lished, but this study presents the first subject-specific models describing extracorporeal
life support therapies [42, 45, 44]. The two models developed in this thesis are simple
enough to be solved with a small computation time and to be used at the patient’s bed-
side. One model describes the cardiovascular system connected to a va-ECLS and the
other one describes the respiratory system connected to a vv-ECLS.
The cardiovascular model has been used to predict hemodynamic quantities during the
weaning tests from a va-ECLS. The present study has shown that these simulated values
are in agreement with experimental data carried out in our lab. In addition, similar anal-
yses have been carried out with clinical data and a similar good agreement was obtained.
The respiratory model has been used to predict PO2 and PCO2 values during the first
hours of vv-ECLS therapy. For the animal experiments, a new kind of vv-ECLS was
used: the extracorporeal CO2 removal device (ECCO2RD). This device is characterized
by a small extracorporeal blood flow and the blood oxygenation is very low with this
technology. This thesis has shown that the simulated values of PCO2 are in agreement with
experimental data. In addition, clinical data taken from patients assisted by traditional vv-
ECLS and assisted by ECCO2RD have also been analyzed. The results have demonstrated
that the simulated values of PO2 and PCO2 are in agreement with the clinical data.
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12.3 Limitations
A first validation of both models has been performed and has shown encouraging results.
However, experimental and mainly clinical data present several limitations and additional
trials should be performed to improve the model validation. These limitations are de-
scribed in subsection 12.3.1. In addition, with the aim to be simple and identifiable with
the available clinical data, the mathematical models are based on several assumptions and
some parameters cannot be identified and are taken from literature. These approxima-
tions, described in subsection 12.3.2, are also part of the limitations of our work.
12.3.1 Experimental and clinical data
The access to the different measurements is rather delicate in the ICU and even in our
lab. Indeed, several experimental and clinical data have weak accuracy and some mea-
surements are not taken continuously such as PCO2 and PO2 in arteries and veins. In
addition, for the clinical cases, the blood pressures and the left ventricle volumes are not
estimated continuously.
The number of pig experiments that were carried out is small: 8 pigs suffering from
cardiogenic shock assisted by a va-ECLS, 4 "healthy" pigs assisted by an ECCO2R therapy
and 6 pigs suffering from ARDS assisted by an ECCO2R therapy. For the experiments us-
ing va-ECLS, the weaning tests were performed with only 3 different Qd for the 3 first pigs.
Since the parameter identification needs 3 different Qd, the prediction of the mathematical
model cannot have been analyzed for those pigs. Only the weaning tests carried out on
the last pig were performed with more than 8 different Qd. Additional pig experiments
should be considered using a protocol defining weaning tests with as many Qd as for this
pig. In addition, with our experiments, Qd could not exceed 1.2 l/min. Additional exper-
iments should thus be performed with larger cannulae, which implies larger pigs, in order
to increase the highest limit of Qd (similar experiments have already been presented in
the article of Ostadal et al. [82]). Concerning the experiments using ECCO2RD, only the
first pig suffering from ARDS was subject to different Qd. For the 5 other pigs of this set
of experiments, the ECLS was fixed to only one Qd during the CO2 removal therapy. Ad-
ditional experiments should be carried out with different ECLS and ventilator settings in
order to improve the validation of the mathematical model. In addition, only ECCO2RD
was used for the pig experiments and it would be beneficial to carry out also experiments
with a traditional vv-ECLS.
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Finally, the clinical data that we have considered are taken from retrospective data and
additional limitations have been observed. Except for patient S1 (see subsection 7.1.2),
the clinical trials did not follow a stringent protocol. Therefore, the exact time of the
variations of ECLS and ventilator settings were not available. In addition, the values of
these settings were not directly fixed. These values are changed several times and only the
final fixed values are recorded. As a result, few clinical trials are analyzed in this study.
Additional clinical trials with a stringent protocol should thus be carried out.
12.3.2 Model
One of the most limiting hypotheses of our approach is the absence of a description of
the cardio-pulmonary controls and regulations. Indeed, for the cardiovascular model, Qd
sharply decreases during weaning tests and the hemodynamics is greatly changed. For
the respiratory model, PO2 increases and PCO2 steeply decreases when the vv-ECLS is
switched on. The variations of PO2 and PCO2 have an influence on the cardiovascular
system. For instance, hypercapnia and hypoxia induce a reduction of the vascular diam-
eters in the pulmonary circulation [108, 78]. The pulmonary vascular resistance is thus
increased and the cardiac output and the pulmonary perfusion can be modified. The vari-
ations of PO2 and PCO2 can also provoke pulmonary responses by decreasing or increasing
the diameters of bronchioles [46] and by decreasing or increasing the tidal volume (if the
patient breaths spontaneously, see Section 2.4).
Several parameters are considered constant and are taken from literature. However,
some of these parameters could vary between individuals but their estimations are impos-
sible with the available clinical data. For instance, the input and output cardiac valves
resistances are considered constant in our model whereas some patients had a replacement
of one or two cardiac valves. This could represent a rough approximation since these syn-
thetic valves probably present different hemodynamic properties.
Equally, the models developed in this study could be too simplified. Indeed, lumped
models significantly simplify the studied systems and the model elaborated in this study
could neglect essential information. For example, the cardiovascular model omits the de-
scription of the pulmonary circulation. Our model considers that the heart is only one
pump extracting the blood in the vena cava and ejecting the blood in the aorta. This
description of the cardiovascular system is a rough approximation since the pulmonary
circulation can have a significant influence over the whole circulation. An other example
is that the respiratory model omits the mechanics of ventilation. The ventilation is de-
scribed in our model by only one lumped parameter: the alveolar ventilation V˙A. This
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simplification reduces the possible applications of our model in order to improve the ther-
apeutic strategies in the ICU. For instance, the positive end-expiratory pressure (PEEP)
is an important ventilator setting and it can increase or decrease V˙A. However, PEEP is
not explicitly described in our model but is included in the lumped parameter V˙A. The
influence of PEEP on the respiratory system cannot thus be analyzed and optimized using
our model.
Finally, the respiratory and cardiovascular systems are modeled separately and no
coupling between them is taken into account. Yet, in certain cases, it would be helpful
to have a cardio-pulmonary model. For instance, a patient assisted with a va-ECLS
can recover a normal cardiac activity without recovering a normal respiratory activity.
Therefore, the respiratory model should be added to the cardiovascular model in order
to predict the evolution of PO2 and PCO2 during weaning tests from va-ECLS. This
information could help the clinician with the decision of bridging the patient from va- to
vv-ECLS.
12.4 Future work
As already mentioned in the previous section, a first interesting extension of our work
would be to perform additional clinical trials with patients assisted with vv- and va-
ECLST.
Regarding va-ECLS, the weaning tests should be performed by decreasing Qd with
more intermediate steps. In particular, Qd used for the parameter identification are not
much larger than those used for testing the prediction of the mathematical model. The
validation of the cardiovascular model during weaning tests would be stronger if the dif-
ference between the 2 sets of Qd was larger. Another interesting approach would be to
perform more than 2 weaning tests for a given patient. With these additional trials, the
evolution of the patient’s cardiovascular system could be studied and the evolution of the
estimated parameters of the model could be analyzed.
After performing additional clinical trials to validate the cardiovascular model con-
nected to a va-ECLS in the ICU, a medical tool could be developed in order to improve
the therapeutic strategy used in the ICU. This final goal of the present study is illustrated
in Figure 12.1. This figure shows the first version of our computer software estimating
different hemodynamic quantities for Qd = 0 l/min. In order to start this va-ECLS simu-
lator, clinicians have to enter the diastolic and systolic blood pressures in the arteries, the
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central venous pressure (CVP), the heart rate (HR), the V TI, the diastolic volume in the
left ventricle and the diameter of the left ventricular outflow tract (LVOT) related to 3
different Qd. The upper panel shows the graphic interface before starting the simulation
while the bottom panel shows the solution.
Regarding vv-ECLS, the ventilator and ECLS settings are recorded continuously and
these data should be saved during the first hours of ECLS therapy. A stringent protocol,
like the one already used for the clinical trial S1 (see subsection 7.1.2), should be per-
formed to ensure that all the clinical conditions would be respected.
After performing additional clinical trials to validate the respiratory model in the ICU,
a medical tool could be developed in order to estimate the adequate ECLS and ventilator
settings for a given patient. Figure 12.2 illustrates this final goal with the clinical data of
patient S1 (see section 11.3). This figure shows the first version of our computer software
estimating the stabilized PO2 and PCO2 in arteries for different ECLS and ventilator
settings. In order to start this va-ECLS simulator, clinicians have to enter the ventilator
settings before switching on the ECLS, the features of the gas flow entering the ECLS
(FID,O2 and V˙D), the synthetic membrane used (HLS Set Advanced 5.0 or Quadrox-iD
Adult) and several patient parameters (weight, height, cardiac output, PO2, PCO2, pH,
hemoglobin concentration and hemoglobin saturation in arteries and PO2 and hemoglobin
saturation in veins). The upper panel of Figure 12.2 shows the results for the patient S1.
These results demonstrate that an extracorporeal blood flow smaller or equal to 1 l/min is
enough for the CO2 removal of this patient, even for an hyper protective ventilation defined
by a tidal volume of 3 ml/kg. This panel also shows that there is no oxygenation of blood
when the extracorporeal blood flow increases (note that the irregularity for the isoline PO2
= 82 mmHg is due to the fact that only 5 different values of tidal volumes and 40 values of
extracorporeal blood flow are used to plot the graph). This result is due to the fact that
the arterial blood of the patient was already oxygenated and the gas entering the ECLS
is atmospheric air. This graph also shows that PO2 slightly decreases with the increase
in tidal volume. This observation is due to the Bohr effect. Indeed, the large decrease
in PCO2 when tidal volume increases induces an alkalosis which modifies the hemoglobin
saturation curve. The bottom panel of Figure 12.2 also provides the stabilized PO2 and
PCO2 in arteries for different ECLS and ventilator settings administered to patient S1 but
the gas entering the ECLS is enriched with O2 (FID,O2 = 0.9). The PCO2 in arteries is
almost identical to the previous simulation. For the PO2 in arteries, the estimated values
are larger and the PO2 increases with the increase in the extracorporeal blood flow.
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Figure 12.1 – Patient-specific va-ECLS simulator. The clinical data are taken from the weaning
test Patient6 T1 (see section 10.4). The upper panel shows the graphic interface before starting
the simulation while the bottom panel shows the solution.
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CO2 (upper graph) and O2 (bottom graph) partial pressures in the arteries (mmHg)  
for different extracorporeal blood flows and different protective ventilations 
	
CO2 (upper graph) and O2 (bottom graph) partial pressures in the arteries (mmHg)  
for different extracorporeal blood flows and different protective ventilations 
Figure 12.2 – Patient-specific vv-ECLS simulator. The upper panel shows the results for the
patient S1 (see section 11.3) and the bottom panel shows the results for patient S1 if the gas
entering the ECLS is enriched with O2 (FID,O2 = 0.9)
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Appendix A
Decrease in MRO2 and MRCO2 with
temperature
The detailed analysis of the temperature dependence of metabolism is not the purpose of
the present paper since the final goal of our approach is to develop a model to be used
in the ICU, where temperature is controlled and kept constant. However, in the animal
experiments to which the model was compared, the temperature of the animals was de-
creasing. It was thus necessary to take this effect into account to obtain a good validation
of the model, but given our final purpose, a rather rough description of the temperature
changes is sufficient.
The decrease in temperature in the experiments during the ECCO2RT is illustrated
in Figure A.1 for 3 pigs (for the other pigs, the temperature has not been recorded).
Unfortunately it was not possible to estimate the corresponding decrease in parameters
MRO2 and MRCO2 . Indeed, the estimation of these parameters requires stabilized (i.e.
time independent) data (see subsection 7.2.3), which were not available in the experiments
during the ECCO2RT.
To study the metabolism changes with temperature, we made a retrospective analysis
of other experiments carried out in our lab (see [88]), for which appropriate data were
available. The composition of the gas expired out the ventilator has been recorded con-
tinuously for two pigs (pig 1 and pig 2). In a stabilized situation, the CO2 production by
metabolism is equal to the CO2 extraction by the ventilator and we can write the following
equation:
MRCO2 = V˙A · FE,CO2 , (A.1)
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where FE,CO2 is the end tidal CO2 volume fraction and V˙A is estimated from the tidal
volume and the respiratory frequency given by the ventilator and an assumed dead space
fixed equal to 30% of the tidal volume [49]. The O2 consumption (MRO2) can be estimated
similarly. Figure A.2 and Figure A.3 show the time evolutions of MRCO2 and MRO2 and
the time evolution of temperature for the two pigs. We observe on these figures that the
temperature,MRO2 andMRCO2 decrease linearly. The decrease inMRO2 andMRCO2 are
similar (a little bit larger forMRO2). Therefore, we use the slope of the linear interpolation
of MRCO2 , MRO2 and that of the linear interpolation of the temperature to estimate the
decrease in the metabolism production rates with temperature. For pig 1, the rates found
are of 0.0138 l/min/°C and 0.0213 l/min/°C for MRCO2 and MRO2 respectively and,
for pig 2, the rates found are of 0.0125 l/min/°C and 0.0275 l/min/°C for MRCO2 and
MRO2 respectively. The mean value is taken (0.0188 l/min/°C). Then from Figure A.1,
we can calculate a mean time rate of change for the temperature of the animals used in
the experiments, and we found the value 0.0255°C/min. Finally, from this value and from
the value of the metabolism rate of change with temperature, we deduce the following
estimation of the time rate of change of metabolism production rates in the experiments:
4.78× 10−4 l/min2. This value was used in our simulations for all animals. 	
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Figure A.1 – Decrease in temperature for 3 pigs (H2, H3 and H4) when the ECCO2RD is
switched on.
Appendix A. Decrease in MRO2 and MRCO2 with temperature 215
Time	(min)
0 50 100 150 200 250 300
Te
m
pe
ra
tu
re
	(°
C)
25
30
35
y = -3.4e-04 t + 0.20
y = -2.2e-04 t + 0.17
y = -1.6e-02 t + 34.04
M
et
ab
ol
ism
:	M
RO
2	
(lO
2/
m
in
)	a
nd
	M
RC
O
2	
(lC
O
2/
m
in
)
0
0.2
0.4
Temperature
Temperature	(linear)
MRO2
MRO2	(linear)
MRCO2
MRCO2	(linear)
Figure A.2 – Time evolution ofMRCO2 andMRO2 and time evolution of temperature for pig 1.
Time	(min)
0 20 40 60 80 100 120 140
Te
m
pe
ra
tu
re
	(°
C)
31
32
33
34
35
36
y = -4.4e-04 t + 0.23
y = -2.0e-04 t + 0.18
y = -1.6e-02 t + 35.51
M
et
ab
ol
ism
:	M
RO
2	
(lO
2/
m
in
)	a
nd
	M
RC
O
2	
(lC
O
2/
m
in
)
0.1
0.15
0.2
0.25
0.3
0.35
Temperature
Temperature	(linear)
MRO2
MRO2	(linear)
MRCO2
MRCO2	(linear)
Figure A.3 – Time evolution ofMRCO2 andMRO2 and time evolution of temperature for pig 2.

Appendix B
Additional tables and figures
B.1 Pig experiments with a va-ECLS
217
218 B.1. Pig experiments with a va-ECLS
Qd (l/min)
0 0.5 1
Ve
nt
ric
le 
vo
lum
e 
(m
l)
40
60
80
100
120
140
MaxVh
MaxVh exp.
MaxVh exp.
SV
SV exp.
SV exp.
Qd (l/min)
0 0.5 1
Ao
rti
c p
re
ss
ur
e 
(m
m
Hg
)
45
50
55
60
65
70
75
Mean
Mean exp.
Mean exp.
∆
∆ exp.
∆ exp.
Qd (l/min)
0 0.5 1
Ve
ins
 p
re
ss
ur
e 
(m
m
Hg
)
0
5
10
15
20
25
Mean
Mean exp.
Mean exp.
maxT(Vh) exp.
maxT(Vh)
SV
SV exp.
PPa
PPa exp.
Pa exp.
Pa
Pv
Pv exp.
Pig4 T1 
Qd (l/min)
0 0.5 1
Ve
nt
ric
le 
vo
lum
e 
(m
l)
40
60
80
100
120
140
MaxVh
MaxVh exp.
MaxVh exp.
SV
SV exp.
SV exp.
Qd (l/min)
0 0.5 1
Ao
rti
c p
re
ss
ur
e 
(m
m
Hg
)
60
70
80
90
Mean
Mean exp.
Mean exp.
∆
∆ exp.
∆ exp.
Qd (l/min)
0 0.5 1
Ve
ins
 p
re
ss
ur
e 
(m
m
Hg
)
0
5
10
15
20
Mean
Mean exp.
Mean exp.
maxT(Vh) exp.
maxT(Vh)
SV
SV exp.
PPa
PPa exp.
Pa exp.
Pa
Pv
Pv exp.
Pig4 T2 
Qd (l/min)
0 0.5 1
Ve
nt
ric
le 
vo
lum
e 
(m
l)
20
40
60
80 MaxVh
MaxVh exp.
MaxVh exp.
SV
SV exp.
SV exp.
Qd (l/min)
0 0.5 1
Ao
rti
c p
re
ss
ur
e 
(m
m
Hg
)
40
50
60
70
Mean
Mean exp.
Mean exp.
∆
∆ exp.
∆ exp.
Qd (l/min)
0 0.5 1
Ve
ins
 p
re
ss
ur
e 
(m
m
Hg
)
0
5
10
15
20
Mean
Mean exp.
Mean exp.
maxT(Vh) exp.
maxT(Vh)
SV
SV exp.
PPa
PPa exp.
Pa exp.
Pa
Pv
Pv exp.
Pig5 T1 
Qd (l/min)
0 0.5 1
Ve
nt
ric
le 
vo
lum
e 
(m
l)
30
40
50
60
70
80
90
MaxVh
MaxVh exp.
MaxVh exp.
SV
SV exp.
SV exp.
Qd (l/min)
0 0.5 1
Ao
rti
c p
re
ss
ur
e 
(m
m
Hg
)
30
40
50
60
70
80
Mean
Mean exp.
Mean exp.
∆
∆ exp.
∆ exp.
Qd (l/min)
0 0.5 1
Ve
ins
 p
re
ss
ur
e 
(m
m
Hg
)
0
5
10
15
Mean
Mean exp.
Mean exp.
maxT(Vh) exp.
maxT(Vh)
SV
SV exp.
PPa
PPa exp.
Pa exp.
Pa
Pv
Pv exp.
Pig5 T2 
Ve
nt
ric
ula
r v
olu
m
e 
(m
l) 
Ve
nt
ric
ula
r v
olu
m
e 
(m
l) 
Ve
nt
ric
ula
r v
olu
m
e 
(m
l) 
Ve
nt
ric
ula
r v
olu
m
e 
(m
l) 
Ve
no
us
 p
re
ss
ur
e 
(m
m
Hg
) 
Ve
no
us
 p
re
ss
ur
e 
(m
m
Hg
) 
Ve
no
us
 p
re
ss
ur
e 
(m
m
Hg
) 
Ve
no
us
 p
re
ss
ur
e 
(m
m
Hg
) 
Figure B.1 – Evolution of P a, PPa, P v, maxT(Vh) and SV in terms of different Qd for the
weaning tests Pig4 T1, Pig4 T2, Pig5 T1 and Pig5 T2. The solid lines are the simulations and
the crosses and diamonds are the experimental data (the difference between diamonds and crosses
has already been explained in Figure 8.1.)
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Figure B.2 – Evolution of P a, PPa, P v, maxT(Vh) and SV in terms of different Qd for the
weaning tests Pig6 T1, Pig6 T2, Pig7 T1 and Pig7 T2. The solid lines are the simulations and
the crosses and diamonds are the experimental data (the difference between diamonds and crosses
has already been explained in Figure 8.1.)
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Figure B.3 – Evolution of P a, PPa, P v, maxT(Vh) and SV in terms of different Qd for the
weaning tests Pig4 T1, Pig4 T2, Pig5 T1 and Pig5 T2. The solid lines are the simulations
obtained with the parameter identification using the measurements related to all Qd and the
crosses are the experimental data.
Appendix B. Additional tables and figures 221
Qd (l/min)
0 0.5 1
Ve
nt
ric
le 
vo
lum
e 
(m
l)
40
60
80
MaxVh
MaxVh exp.
SV
SV exp.
Qd (l/min)
0 0.5 1A
or
tic
 p
re
ss
ur
e 
(m
m
Hg
)
40
50
60
70
80
Mean
Mean exp.
∆
∆ exp.
Qd (l/min)
0 0.5 1V
ein
s p
re
ss
ur
e 
(m
m
Hg
)
0
5
10
15
Mean
Mean exp.
Qd (l/min)
0 0.5 1
Ve
nt
ric
le 
vo
lum
e 
(m
l)
40
60
80
100
MaxVh
MaxVh exp.
SV
SV exp.
Qd (l/min)
0 0.5 1A
or
tic
 p
re
ss
ur
e 
(m
m
Hg
)
40
50
60
70
Mean
Mean exp.
∆
∆ exp.
Qd (l/min)
0 0.5 1V
ein
s p
re
ss
ur
e 
(m
m
Hg
)
0
5
10
Mean
Mean exp.
Qd (l/min)
0 0.5 1
Ve
nt
ric
le 
vo
lum
e 
(m
l)
40
60
80
100
120
MaxVh
MaxVh exp.
SV
SV exp.
Qd (l/min)
0 0.5 1A
or
tic
 p
re
ss
ur
e 
(m
m
Hg
)
30
40
50
60
70
Mean
Mean exp.
∆
∆ exp.
Qd (l/min)
0 0.5 1V
ein
s p
re
ss
ur
e 
(m
m
Hg
)
0
2
4
6
8
10
Mean
Mean exp.
Qd (l/min)
0 0.5 1
Ve
nt
ric
le 
vo
lum
e 
(m
l)
20
40
60
80
100
MaxVh
MaxVh exp.
SV
SV exp.
Qd (l/min)
0 0.5 1A
or
tic
 p
re
ss
ur
e 
(m
m
Hg
)
30
40
50
60
Mean
Mean exp.
∆
∆ exp.
Qd (l/min)
0 0.5 1V
ein
s p
re
ss
ur
e 
(m
m
Hg
)
0
2
4
6
8
10
Mean
Mean exp.
Pig6 T1 
Pig6 T2 
Pig7 T1 
Pig7 T2 
maxT(Vh) exp.
maxT(Vh)
SV
SV exp. PPa
PPa exp.
Pa exp.
Pa
Ve
no
us
 p
re
ss
ur
e 
(m
m
Hg
) 
Pv
Pv exp.
maxT(Vh) exp.
maxT(Vh)
SV
SV exp.
PPa
PPa exp.
Pa exp.
Pa
Pv
Pv exp.
Ve
no
us
 p
re
ss
ur
e 
(m
m
Hg
) 
Ve
nt
ric
ula
r v
olu
m
e 
(m
l) 
Ve
nt
ric
ula
r v
olu
m
e 
(m
l) 
maxT(Vh) exp.
maxT(Vh)
SV
SV exp.
PPa
PPa exp.
Pa exp.
Pa
Pv
Pv exp.
Ve
no
us
 p
re
ss
ur
e 
(m
m
Hg
) 
Ve
nt
ric
ula
r v
olu
m
e 
(m
l) 
maxT(Vh) exp.
maxT(Vh)
SV
SV exp.
PPa
PPa exp.
Pa exp.
Pa
Pv
Pv exp.
Ve
nt
ric
ula
r v
olu
m
e 
(m
l) 
Pv
Pv exp.
Ve
no
us
 p
re
ss
ur
e 
(m
m
Hg
) 
Ve
nt
ric
ula
r v
olu
m
e 
(m
l) 
Figure B.4 – Evolution of P a, PPa, P v, maxT(Vh) and SV in terms of different Qd for the
weaning tests Pig6 T1, Pig6 T2, Pig7 T1 and Pig7 T2. The solid lines are the simulations
obtained with the parameter identification using the measurements related to all Qd and the
crosses are the experimental data.
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Figure B.5 – Evolution of P a, PPa, P v, maxT(Vh) and SV in terms of different Qd for the
weaning tests Pig8 T1 and Pig8 T2. The solid lines are the simulations obtained with the param-
eter identification using the measurements related to all Qd and the crosses are the experimental
data.
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B.2 Pig experiments with a vv-ECLS	
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Figure B.6 – Time evolution of calculated (lines) and measured (crosses, circles and diamonds)
CO2 partial pressures in the veins, in the right ventricle and in the arteries for pigs H1, H3
and H4. The labels PV, QD 200, QD 400 and QD 600 mean respectively the start of protective
ventilation and blood flow through the ECCO2RD set to 200, 400 and 600 ml/min.
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Figure B.7 – Time evolution of calculated (lines) and measured (crosses and diamonds) CO2
partial pressures in the veins and arteries for pigs A1, A2, A3, A4 and A5. The labels PV, QD
200, QD 400, QD 600 and QD 800 mean respectively the start of protective ventilation and blood
flow through the ECCO2RD set to 200, 400, 600 and 800 ml/min.
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B.3 Clinical trials with a va-ECLS
Table B.5 – Values of the 2 coefficients of the linear expressions for each parameter (Eh, SBV ,
Ah, Ea and Rs) obtained with the parameter identification using the measurements related to all
the Qd.
Patient1 Patient2 Patient3 Patient4 Patient5 Patient6
Data T1 T1 T1 T1 T2 T1 T2 T1 Mean
± σ
Parameter identification
E0,h
(mmHg/ml)
2.84 2.10 1.13 0.91 0.91 2.76 1.94 2.82 1.93
±0.85
SBV0 (ml) 1130 493 834 1092 953 1026 1309 1168 1001
±250
A0,h (ml−1) 0.050 0.030 0.016 0.027 0.022 0.040 0.034 0.047 0.033
±0.012
E0,a
(mmHg/ml)
1.80 1.17 1.14 1.18 1.24 1.64 1.94 1.65 1.47
±0.32
R0,s
(mmHg · s/ml)
1.08 1.37 0.59 0.87 0.81 0.80 0.79 0.43 0.84
±0.29
ESl,h
(mmHg · s/ml2)
-0.012 -0.007 0.000 0.000 -0.003 -0.023 -0.003 -0.002 -0.006
±0.008
SBVSl (s) -3.540 1.521 -3.597 -4.215 -3.546 -4.334 -4.383 -4.647 -3.343
±2.012
ASl,h (s/ml2) -6E-5 2E-5 -5E-5 -1E-4 -1E-4 -2E-4 -6E-5 -8E-5 -8E-5
±6E-5
ESl,a
(mmHg · s/ml2)
0.000 0.038 0.010 0.003 0.004 0.014 0.004 0.007 0.010
±0.012
RSl,s
(mmHg · s2/ml2)
-0.005 -0.009 0.000 -0.005 -0.003 0.002 -0.003 -0.002 -0.003
±0.004
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Table B.6 – Errors between the predictions of the mathematical model and the measurements
of P a, PPa, P v, maxT(Vh), SV , EF and V TI using the measurements related to all Qd.
Patient1 Patient2 Patient3 Patient4 Patient5 Patient6
Data T1 T1 T1 T1 T2 T1 T2 T1 Mean
± σ
Ψ(p∗) 910 368 458 526 230 1273 178 453 549
± 367
|∆PPa/PPa| 0.035 0.039 0.018 0.012 0.031 0.044 0.009 0.020 0.026
± 0.013
|∆P a/P a| 0.039 0.007 0.024 0.022 0.012 0.024 0.011 0.019 0.020
± 0.010
|∆P v/P v| 0.037 0.127 0.025 0.032 0.061 0.043 0.016 0.050 0.049
± 0.035∣∣∣∣∣∆maxT(Vh)maxT(Vh)
∣∣∣∣∣ 0.003 0.052 0.009 0.042 0.015 0.071 0.036 0.006 0.029± 0.025
|∆SV/SV |
or
|∆V TI/V TI|
0.064 0.033 0.052 0.041 0.022 0.048 0.010 0.030 0.037
± 0.017
|∆EF/EF | 0.062 0.028 0.048 0.079 0.029 0.112 0.034 0.032 0.053
± 0.030
∆PPa/PPa 0.009 0.021 0.015 0.011 0.003 0.019 0.006 0.012 0.012
± 0.006
∆P a/P a 0.006 0.002 0.009 0.008 0.000 0.011 0.005 0.006 0,006
± 0,004
∆P v/P v 0,016 0,032 0,016 0,017 0,007 0,018 0,015 0,018 0,017
± 0,007
∆maxT(Vh)
maxT(Vh)
0.004 0.011 0.009 0.004 0.003 0.006 0.004 0.005 0.006
± 0.003
∆SV/SV
or
∆V TI/V TI
-0.001 0.019 0.010 0.006 0.006 0.012 0.004 0.006 0.008
± 0.006
∆EF/EF -0.011 0.004 0.001 0.007 0.000 0.017 0.001 0.001 0.003
± 0.008
n 4 4 4 5 4 4 4 6
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Figure B.8 – Time evolution of calculated (lines) and measured (crosses and diamonds) CO2
partial pressures in the veins and arteries (left panels) and O2 partial pressures in the veins
and arteries (right panels) for patients R1, R3 and R4. The different phases of observation are
delimited by vertical arrows, with the self explaining labels.
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Table B.7 – PCO2 and PO2 errors between the simulations and the measurements during ECLS
for clinical trial R and when the dilution is taken into account in our mathematical model. The
line m indicates the number of PCO2 or PO2 measurements available during ECLST (after the
change of ventilator settings).
CO2 O2
Data R1 R2 R3 R4 Mean R1 R2 R3 R4 Mean
|∆P | (mmHg) 5.37 4.75 4.25 1.44 3.95 18.33 7.50 10.37 20.55 14.19
|∆P/P | 0.16 0.09 0.15 0.04 0.11 0.20 0.21 0.18 0.44 0.26
∆P (mmHg) 5.37 -4.75 4.25 -0.04 1.21 -18.33 7.50 10.37 20.55 5.02
∆P/P 0.16 -0.09 0.15 0.00 0.05 -0.20 0.21 0.18 0.44 0.16
m 4 2 2 2 4 2 2 2
Table B.8 – PCO2 and PO2 errors between the simulations and the measurements during ECLS
for clinical trial S and when the dilution is taken into account in our mathematical model. The
line m indicates the number of PCO2 or PO2 measurements available during ECLST.
Data CO2 O2
|∆P | (mmHg) 1.35 ± 1.24 5.33 ± 4.72
|∆P/P | 0.04 ± 0.03 0.10 ± 0.08
∆P (mmHg) 0.11 ± 1.89 5.33 ± 4.72
∆P/P 0.00 ± 0.05 0.10 ± 0.08
m 9 9
